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Résumé 
 
 Le syndrome de Joubert  est une maladie récessive caractérisée par une malformation 
congénitale distincte du tronc cérébral et du cervelet, associée à une anomalie des mouvements 
oculaires (apraxie oculomotrice), une respiration irrégulière, un retard de développement, et 
une ataxie à la démarche. Au cours de la dernière décennie, plus de 20 gènes responsables ont 
été identifiés, tous ayant un rôle important dans la structure et la fonction des cils primaires. 
Ainsi, le syndrome de Joubert est considéré une ciliopathie. Bien que le Syndrome de Joubert 
ait été décrit pour la première fois dans une famille  canadienne-française en 1969,  le(s) 
gène(s) causal demeurait inconnu dans presque tous les cas de syndrome de Joubert recensés 
en 2010 dans la population canadienne-française, soit début de mon projet doctoral.  
  
 Nous avons identifié un total de 43 individus canadiens-français (35 familles) atteints 
du  syndrome de Joubert. Il y avait un regroupement de familles dans la région du Bas-Saint-
Laurent de la province de Québec, suggérant la présence d'un effet fondateur. L’objectif de ce 
projet était de caractériser la génétique du syndrome de Joubert dans la population canadienne-
française.  Notre hypothèse était qu’il existait un effet fondateur impliquant au moins un 
nouveau gène JBTS.  
 
 Ainsi, dans un premier temps, nous avons utilisé une approche de cartographie par 
homozygotie. Cependant, nous n’avons pas identifié de région d’homozygotie partagée parmi 
les individus atteints, suggérant la présence d’une hétérogénéité génétique ou allélique. Nous 
avons donc utilisé le séquençage exomique chez nos patients, ce qui représente une approche 
plus puissante pour l’étude de conditions génétiquement hétérogènes.  
 
 Nos travaux ont permis l’identification de deux nouveaux gènes responsables du 
syndrome de Joubert: C5orf42 et TMEM231.  Bien que la localisation cellulaire et la fonction 
de C5orf42 soient inconnus au moment de cette découverte, nos résultats génétiques combinés 
avec des études ultérieures ont établi un rôle important de C5orf42 dans la structure et la 
fonction ciliaire, en particulier dans la zone de transition, qui est une zone de transition entre le 
cil et le reste de la cellule. TMEM231 avait déjà un rôle établi dans la zone de transition 
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ciliaire et son interaction avec d’autres protéines impliquées dans le syndrome de Joubert était 
connu. Nos études ont également identifié des variants rares délétères chez un patient JBTS 
dans le gène ciliaire CEP104.  Nous proposons donc CEP104 comme un gène candidat JBTS.   
Nous avons identifié des mutations causales dans 10 gènes, y compris des mutations dans 
CC2D2A dans 9 familles et NPHP1 dans 3 familles. Au total, nous avons identifié les 
mutations causales définitives chez 32 des 35 familles étudiées (91% des cas). Nous avons 
documenté un effet fondateur complexe dans la population canadienne-française avec de 
multiples mutations récurrentes dans quatre gènes différents (C5orf42, CC2D2A, TMEM231, 
NPHP1).  
 
 Au début de ce projet de recherche, l’étiologie génétique était inconnue chez les 35 
familles touchées du syndrome de Joubert. Maintenant, un diagnostique moléculaire définitif 
est identifié chez 32 familles, et probable chez les 3 autres. Nos travaux ont abouti à la 
caractérisation génétique du syndrome de Joubert dans la population canadienne-française 
grâce au séquençage exomique, et révèlent la présence d'un effet fondateur complexe avec une 
l'hétérogénéité allélique et intralocus importante. Ces découvertes ont éclairé la physiologie de 
cette maladie. Finalement, l’identification des gènes responsables ouvre de nouvelles 
perspectives diagnostiques ante-natales, et de conseils génétique, très précieuses pour les 
familles. 
 
Mots-clés: Syndrome de Joubert, Cil, Ciliopathie, Zone de transition ciliaire, Séquençage 
exomique, Effet fondateur, Signe de la dent molaire, Canadiens-français, C5orf42, TMEM231, 
CEP104 
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Abstract 
 
Joubert syndrome (JBTS) is a primarily autosomal recessive disorder characterized by 
a distinctive mid-hindbrain/cerebellum malformation, eye movement abnormalities 
(oculomotor apraxia), irregular breathing, developmental delay, and ataxia. Over the past 
decade, over 20 causal genes have been identified, all of which have an important role in the 
structure and function of the primary cilia.  Thus, JBTS joins an expanding category of 
diseases termed “ciliopathies”.  Though JBTS was first described in affected siblings of a 
French Canadian (FC) family in 1969, the underlying genesis basis of the disorder was 
unknown in the overwhelming majority of FC cases at the onset of this doctoral project in 
2010.  
 
We identified a total of 43 FC individuals with JBTS from 35 families.  We observed a 
clustering of the affected families in the Lower Saint-Lawrence region of the province of 
Quebec, suggesting the presence of a founder effect. The aim of this doctoral project was to 
characterize the genetic landscape of JBTS in the FC population, and we hypothesized the 
presence of a founder effect in novel JBTS gene(s).  Therefore, we initially used a 
homozygosity mapping approach.  However, we did not identify any shared regions of 
homozygosity amongst affected individuals, suggesting the presence of genetic and/or allelic 
heterogeneity. We therefore primarily used a whole exome sequencing approach in our JBTS 
patients, a strategy that is better suited for the study of genetically heterogeneous conditions.  
 
Our work has resulted in the identification of two novel JBTS genes: C5orf42 and 
TMEM231. In total, we have identified causal mutations in C5orf42 in 14 families (including 
the original JBTS family described in 1969), and TMEM231 in 2 families.  Though the 
function and cellular localization of C5orf42 was not known at the time of the publication of 
our manuscript, our genetic findings combined with subsequent animal and cellular work 
establish the important role of C5orf42 in ciliary structure and function, particularly at the 
ciliary transition zone.  TMEM231 had been previously shown to localize to the ciliary 
transition zone and interact with several JBTS gene products. We also identified deleterious 
rare variants in one JBTS patient in the ciliary gene CEP104, implicating CEP104 as a strong 
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candidate JBTS gene. We identified causal mutations in 10 JBTS genes, including CC2D2A in 
9 families and NPHP1 in 3 families. Definite causal mutations were identified in 32 of 35 
families (91% of cases). We documented a complex founder effect in the FC population with 
multiple recurrent mutations in 4 different genes (C5orf42, CC2D2A, TMEM231, NPHP1).  
 
Prior to the start of this research endeavor, the underlying genetic etiology of Joubert 
syndrome was unknown in all 35 families.  Now, a definite molecular diagnosis has been 
identified in 32 families, and a probable molecular diagnosis in the remaining 3. Therefore, 
our work has resulted in the unraveling of the genetic basis of JBTS in the French-Canadian 
population using WES, and reveals the presence of a complex founder effect with substantial 
locus and allelic heterogeneity.  
 
 
Keywords: Joubert syndrome, Cilia, Ciliopathy, Ciliary transition zone, Whole exome 
sequencing, Founder effect, Molar tooth sign, French Canadians, C5orf42, TMEM231, 
CEP1041 
 
  
	  	   v	  
 
Table of Contents 
Résumé…………………………………………………………………………...……………..i 
Summary.....................................................................................................................................iii 
List of Figures ...........................................................................................................................vii 
List of Tables............................................................................................................................viii 
List of Abbreviations ................................................................................................................ ix 
Acknowledgements .................................................................................................................... x 
 
Chapter 1: Introduction………………………………………………………………………1 
Clinical features associated with JBTS.………………………………….……………..4 
Pathogenesis: JBTS is a prototypical ciliopathy……………………..…………………6 
The primary cilium- basic biology………….…………………………………………..7 
Key role of the cilia in neurodevelopment……………………….……………………..9 
  Cilia and Sonic HedgeHog Signaling…………….…..……….……...……….11 
Cilia and the WNT pathway…………………………………………..……….14 
Founder effect underlies many autosomal recessive disorders in French 
Canadians…………………………………………………..……….……………...….16 
Landscape of Joubert syndrome in Quebec…………………………………….……..18 
Hypothesis, aims and objectives………………………………………………...…….21 
 
Chapter 2: Mutations in C5orf 42 are responsible for Joubert syndrome in French 
Canadians (Manuscript 1)……………………………………………………………………23 
Abstract………………………………………………………………………………………..25 
Body of manuscript……………………………………………………………………………26 
Supplemental Data and figures………………………………………………………………..39 
 
Chapter 3: Mutations in TMEM231 cause Joubert syndrome in French Canadians 
(Manuscript 2)…………………………………………………………………………………44 
Abstract………………………………………………………………………………………..47 
Body of manuscript……………………………………………………………………………48 
Supplemental Figures and Tables……………………………………………………………..58 
 
Chapter 4: Genetics of Joubert Syndrome in French Canadians (Manuscript 3)………..62 
Abstract………………………………………………………………………………………..64 
Introduction……………………………………………………………………………………65 
Methods………………………………………………………………………………………..66 
Resullts………………………………………………………………………………………...67 
Discussion……………………………………………………………………………………..73 
 
	  	   vi	  
Chapter 5: General Discussion…….……………………….……………………………….83 
Mutations in C5orf42 are the most common cause of JBTS in French Canadians and 
worldwide………………………………………………………………………….…..84 
Mutations in TMEM231 cause JBTS………………………………………………….86 
JBTS- a ciliary transition zone-opathy…………………………………………….….87 
Variability of JBTS phenotype………………………………………………………..88 
The landscape of JBTS is French Canadians is largely unraveled………………..…..89 
Role of WES in JBTS gene discovery………………………………………………...90 
 
References…………………………………………………………………………………….92 
 
ANNEX 1. Recessive	  and	  dominant	  mutations	  in	  retinoic	  acid	  receptor	  beta	  in	  cases	  with	  microphthalmia	  and	  diaphragmatic	  hernia……………………………………………………………….100 
  
	  	   vii	  
List of Figures  
 
Figure 1: Molar Tooth Sign on MRI (p. 2) 
Figure 2. Schematic representation of the primary cilia (p. 10) 
Figure 3: SHH signaling pathway schematic (p. 13) 
Figure 4: WNT signaling pathway schematic (p. 15) 
Figures 5 and 6. Distribution of individuals with Joubert syndrome in the Lower St-Lawrence 
region. (p. 20 and 27) 
Figure 7: Segregation of C5orf42 mutations in families affected with JBTS (p. 32) 
Figure 8.  C5orf42 mutations identified in individuals with Joubert Syndrome (p. 36) 
Figure 9: TMEM231 mutations identified in individuals with JBTS (p. 51) 
Figure 10: Segregation of mutations in candidate JBTS genes. (p. 69) 
Figure 11: Locus and allelic heterogeneity of JBTS in French Canadians. (p. 74) 
Figure 12. Map of Quebec showing the geographic distribution and the genetic heterogeneity 
of FC families with JBTS. (p. 76) 
  
	  	   viii	  
List of Tables 
 
Table 1: Classification of JBTS based on clinical features (p. 3) 
Table 2: Genes associated with JBTS (p. 8) 
Table 3: Variant prioritization Steps in the analysis of combined exome sequences from 13 
individuals with JBTS (p. 29) 
Table 4: Genes with rare homozygous or multiple heterozygous variants from the combined 
exome sequences from 13 individuals with JBTS (p. 30) 
Table 5: Clinical description of JBTS individuals with C5orf42 mutations (p. 34) 
Table 6: Genotypes and phenotypes of French Canadian individuals with JBTS (p. 53) 
Table 7: Clinical characteristics of new additional JBTS patients to this study  (p. 72) 
Table 8: Summary of the clinical features of 43 FC patients with JBTS (p. 79) 
 
  
	  	   ix	  
List of abbreviations 
ARSACS: autosomal recessive spastic ataxia of Charlevoix-Saguenay 
CGNP: cerebellar granular neuronal precursors 
COACH: Coloboma, Oligophrenia/developmental delay, Ataxia, Cerebellar vermis 
hypoplasia, Hepatic fibrosis syndrome 
IFT: intraflagellar transport 
JBTS: Joubert syndrome 
JS: Joubert syndrome 
MKS: Meckel syndrome 
MRI: magnetic resonance imaging 
MTS: molar tooth sign 
OMA: oculomotor apraxia 
OFD: orofacio-digital syndrome 
PCP: planar cell polarity 
SHH: Sonic Hedgehog 
SNP: single nucleotide polymorphism 
TZ: transition zone 
WES: whole exome sequencing  
 
  
	  	   x	  
 
Acknowledgments 
 
When I started my clinical Neurogenetics Fellowship in 2007, I could not have anticipated  
that I would embark in this exciting journey in the world of genetic research, such that I would 
eventually pursue a PhD in molecular biology. 
 
I wish to thank Jacques Michaud, my Phd supervisor, for introducing me to these fascinating 
projects.  In particular, I am grateful that he taught me how to always have a critical eye, and 
encouraged me to continually push the project further.  He is the model of the clinician-
scientist, a role that I wish to follow for the remainder of my career. 
 
I would like to thank Bernard Brais, who encouraged me to start my Masters degree at the start 
of my fellowship, and started the entire process.  He showed me how to engage science with 
enthusiasm and curiosity, and how to think ‘outside the box’ with patients. 
 
I would like to thank Guy Rouleau, whose Neurogenetics clinics at the Montreal General 
Hospital during my residency first made me interested in this field, and for pointing me 
towards many compelling projects. 
 
Thank you to Fadi Hamdan for all that he has taught me, for his advice, patience, support and 
friendship. I am eternally grateful. 
 
Thank you to all the students in Jacques and Bernard’s Lab, who have made this journey so 
enjoyable and stimulating. 
 
And of course thank you to my wonderful husband Ron who is always my pillar of support 
and encouragement, and to my parents, my unconditional cheerleaders.
	  	   1	  
 
 
 
 
Chapter 1: 
Introduction 
  
	  	   2	  
Joubert syndrome [JBTS, MIM 213300] is one of the most frequent forms of inherited 
congenital cerebellar ataxias. It was first described in 1969 by Dr. Marie Joubert.  Dr Joubert 
described 4 French-Canadian siblings with agenesis of the cerebellar vermis, episodic 
breathing abnormalities (hypopnea/hyperpnea), abnormal eye movements (particularly 
oculomotor apraxia), gait ataxia and variable severities of intellectual disability (1). Following 
this seminal description, similarly affected individuals were reported throughout the world, 
and this constellation of clinical symptoms became characterized as “Joubert syndrome”. 
 
 Neuropathologic examination and advances in brain imaging have revealed that all 
JBTS patients have a distinctive midbrain and hindbrain malformation characterized by 
hypoplasia of the cerebellar vermis, thickened abnormally orientated superior cerebellar 
peduncles, and a deep inter-peduncular fossa. These features result in the hallmark “molar 
tooth sign” on axial brain magnetic resonance imaging (see Figure 1) first described by Maria 
Figure 1. Molar Tooth Sign on MRI. Axial T2 brain MRI of a control individual (a) and 
patient with JBTS (b). Note the molar tooth sign (red circle), with deepened 
interpeduncular fossa (black arrow), and thickened and abnormally oriented superior 
cerebellar peduncles (yellow arrows).  
Joubert)syndrome!related!disorders!
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et al. in 1997(2).   
 
JBTS is a clinically heterogeneous condition.  It combines hallmark neurologic signs 
with variable multi-organ involvement, mainly of the eyes, kidneys, skeleton and liver(3).  
The wide and variable clinical spectrum associated with JBTS is reflected by the large and 
confusing list of previously used syndromic designations associated with the various forms of 
JBTS.  For example, the cerebello-oculo-renal syndrome designates individuals with ocular 
and renal involvement; Senior-Löken syndrome designates individuals with kidney and ocular 
disease; the acronym COACH refers to Coloboma, Oligophrenia/developmental delay, 
Ataxia, Cerebellar vermis hypoplasia, Hepatic fibrosis.  These designations are no longer 
commonly used. The term “Joubert syndrome and related disorders” was coined to group all 
conditions sharing the molar tooth sign. Currently, a diagnosis of JBTS is made based on the 
mandatory presence of the molar tooth sign on imaging associated with the variable clinical 
features of hypotonia, ataxia, developmental delay, and oculomotor apraxia. Subtypes of 
JBTS are classified based on the extra-neural organ system involvement (see Table 1). 
 
 
Table 1: Classification of JBTS based on clinical features 
Clinical Subtype Mandatory features Preferentially 
associated features 
Previously used nosology 
Pure Joubert syndrome (JS) MTS  JS 
JS with ocular defects (JS-O) MTS 
Retinal dystrophy 
 JS 
JS with renal defects (JS-R) MTS 
Nephronophthesis 
  
JS with oculorenal defacts 
(JS-OR) 
MTS 
Retinal dystrophy 
Nephronophthesis 
 Cerebellooculorenal syndrome 
Senior-Löken syndrome 
JS with hepatic defects (JS-H) MTS 
Congenital hepatic fibrosis 
Colobomas 
Nephronophthesis 
COACH syndrome 
Gentile syndrome 
JS with orofaciodigital defects 
(JS-OFD) 
MTS 
Lobulated/bifid tongue 
(incl. hamartomas) 
Polydactyly 
Cleft lip/palate Orofaciodigital VI syndrome 
Varadi-Papp syndrome 
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Clinical features associated with JBTS 
 
Neurologic features 
The cardinal features of JBTS are hypotonia, evolving into ataxia and developmental 
delay, often associated with intellectual disability, abnormal eye movements and altered 
respiratory pattern in the neonatal period. Hypotonia is observed in nearly all affected 
patients, and is generally the first sign observed on examination. Motor and language 
development is usually delayed in children with JBTS. In one series, the average age of sitting 
was 19 months, and of walking was 4 years in those who were able to develop these skills(4). 
Patients have ataxia, oromotor dyspraxia, and speech dyspraxia.  Some children require 
assistive devices or need to use sign language for communication (5). Cognitive impairment 
is highly variable in JBTS(6). Intellectual disability, ranging widely from mild to very severe 
is common, with many patients retaining the capacity to attend special schools, learn specific 
job skills and work in protected conditions. It is important to note however that intellectual 
deficit is not inevitable, and that several individuals with borderline or even normal 
intelligence have been reported. Seizures have been reported, although they are not common. 
Behavioral problems, such as impulsivity, autism, perseveration and temper tantrums 
commonly occur (6).  
 
Patients with JBTS can have other central nervous system abnormalities.  These 
include occipital meningomyelocele, heterotopias, polymicrogyria, hydrocephalus, 
hypothalamic hamartoma and corpus callosal abnormalities (7).  
 
Characteristic abnormal eye movements are almost always present(4, 6). Oculomotor 
apraxia is present in the large majority, and manifests as an inability to visually track objects, 
initiate saccades (high velocity large amplitude eye movements).  This results in the 
compensatory head-thrust movement that is the hallmark of oculomotor apraxia.  Oculomotor 
apraxia  likely reflects abnormalities of axonal decussation.  These abnormalities have been 
documented with diffusion tensor magnetic resonance imaging.  As part of the axonal 
decussation abnormality, mirror movements (voluntary movements in a limb are coupled with 
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involuntary ‘mirror’ movements of the contralateral limb) are occasionally observable. 
Nystagmus is also common. Both oculomotor apraxia and nystagmus improve with age.  
 
The respiratory abnormalities consist of short alternating episodes of apnea and 
hyperpnea, or isolated episodic hyperpnea.  These tend to start shortly after birth, intensify 
with emotional stress, and improve with age.  They generally disappear around 6 months of 
age. 
 
Neuropathological examination of the midbrain-hindbrain in patients with JBTS 
reveals a characteristic association of abnormalities.  The cerebellar vermis is invariably 
hypoplastic or absent, the cerebellar nuclei are often hypoplastic or fragmented, and there is 
heterotopia of Purkinje-like neurons.   Pontine and medullary structures, such as the basis 
pontis, reticular formation, inferior olivary nucleus and dorsal column, are dysplastic (8, 9).  
There is typically failure of the decussation of the superior cerebellar peduncles and 
corticospinal tracts, as seen both on histological examination and imaging of fiber tracts on 
MRI(10).   
 
Ocular features 
 
The retina is among the organs the most frequently involved in JBTS. Overall, 
clinically-significant retinal involvement occurs in approximately one third of subjects.  
Retinal involvement can range from extremely severe Leber Congenital amaurosis to 
pigmentary retinopathies evident on fundus exam.  In some cases milder forms of retinal 
dystrophy can be detected only on electroretinogram.  There are two main forms of retinal 
disease,: severe congenital blindness with a flat electroretinogram (known as congenital 
amaurosis), and a later-onset pigmentary retinopathy that manifests with night-blindness and 
has a variable course. Colobomas can be unilateral or bilateral, and mostly affect the posterior 
segment of the eye.  Colobamas are frequent in patients with liver abnormalities, occurring in 
up to 30%, as part of the COACH syndrome(11).  
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Renal involvement 
 
Renal involvement is present in approximately 25% of JBTS patients (12).  It is 
usually in the form of nephronophthesis, a progressive condition characterized by 
tubulointerstitial nephritis and cysts concentrated at the corticomedullary junction.  Most 
patients present around the age of 9 years, with defects in urinary concentration, and progress 
to end stage renal disease late in the second decade(13).  
 
Skeletal defects 
 
Polydactyly is reported in approximately 8 to 16% of cases(12). The most common 
form is post axial affecting hands and feet. Mesoaxial polydactyly is associated with orofacial 
digital syndrome type 6, a subtype of JBTS characterized by the presence of oral frenulae, 
lingual tumors or hamartomas, and craniofacial abnormalities that include wide-spaced eyes 
and a midline lip groove. 
 
Pathogenesis:  JBTS is a prototypical ciliopathy 
 
Over the past decade, advances in genetic research have revealed that JBTS is not only 
a clinically heterogeneous, but also a genetically heterogeneous disorder.  Indeed, 24  causal 
genes have been identified to date.  The first known causal gene, AHI1 (MIM# 608894), was 
identified in 2004 (14), and the second gene NPHP1 (MIM# 6071000) identified in 2005 
(15). An updated list of JBTS genes is provided in Table 2. All these genes encode proteins 
that localize to the cilia, and all have an important role in ciliary structure or function.  JBTS 
is thus considered a ciliopathy, and joins an expanding groups of disorders characterized by 
dysfunction of the cilia. To date, more than 30 human diseases are classified as ciliopathies, 
Examples of other ciliopathies include Meckel syndrome (MIM# 249000), Bardet-Biedl 
syndrome (MIM# 209900), Nephronophthisis (MIM# 256100), Orofacial digital syndrome 
(MIM# 311200), Alstrom syndrome (MIM# 203800) and Jeune Asphyxiating Thoracic 
Dysplasia (or Short-rib thoracic dysplasia, MIM# 208500).  Overall, at least 80 ciliopathy 
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genes have been implicated so far. Ciliopathy disorders in general share overlapping features.  
All typically have multi-organ involvement, because cilia are present on almost all cell types.  
Defects in the primary cilium can affect the kidneys, retina, liver, brain and bones.  The 
phenotype is a varying combination of cystic kidneys, polydactyly, retinopathy, liver fibrosis, 
developmental delay, intellectual disability and central nervous system abnormalities. Though 
ciliopathies may involve any of these organs and the significant clinical overlap between 
them, each disorder has a classical clinical presentation, such that most patients can be 
diagnosed in the clinical setting. For examples, Bardet-Biedl syndrome is characterized by 
intellectual disability, anosmia, obesity, polydactyly, hypogonadism, and retinal degeneration; 
Meckel syndrome is an early lethal disorder characterized by occipital encephalocele, cystic 
kidney and polydactyly; Alstrom syndrome is associated with obesity and retinopathy, but 
unlike JBTS or Bardet-Biedl syndrome, intellectual disability, polydactyly and hypogonadism 
are not a feature. Although individually rare, ciliopathy disorders may collectively have a 
prevalence as high as 1 in 2000 (based on the prevalence of the three common disease traits: 
renal cysts 1 in 500, retinal degeneration 1 in 3000 and polydactyly 1 in 500)(16).  
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Table 2: Genes associated with JBTS. (MKS- Meckel syndrome, LCA- leber congenital 
amaurosis , ATD- asphyxiating thoracic dystrophy, ACLS- acrocallosal syndrome, HLS-
hydrolethalus syndrome) 
 
Gene/Protein	   JBTS	   Other	  ciliopathes	   MIM	  numbers	  
INPP5E	   JBTS1	   	   *613037	  
TMEM216	   JBTS2	   MKS	   *613277	  
AHI1/Jouberin	   JBTS3	   	   *608894	  
TMEM67/Mecklin	   JBTS4	   MKS,	  NPHP	   *609884	  
NPHP1/nephrocystin	  1	   JBTS5	   NPHP	   *607100	  
CEP290	   JBTS6	   MKS,	  LCA	   *610142	  
ARL13B	   JBTS7	   	   *608922	  
RPGRIP1L	   JBTS8	   MKS	   *610937	  
CC2D2A	   JBTS9	   MKS	   *612013	  
OFD1	   JBTS10	   OFD	   *300170	  
TTC21B	   JBTS11	   NPHP,	  ATD	   *612014	  
KIF7	   JBTS12	   ACLS,	  HLS	   *611254	  
TCTN1	   JBTS13	   	   *609863	  
TMEM237	   JBTS14	   	   *614423	  
CEP41	   JBTS15	   	   *610523	  
TMEM138	   JBTS16	   	   *614459	  
C5orf42	   JBTS17	   OFD6	   *614571	  
TCTN3	   JBTS18	   OFD4	   *613847	  
ZNF423	   JBTS19	   NPHP	   *604557	  
TMEM231	   JBTS20	   MKS	   *614949	  
CSPP1	   JBTS21	   	   *611654	  
PDE6D	   JBTS22	   	   *602676	  
TCTN2	   JBTS23	   MKS	   *613846	  
B9D1	   Unassigned	   MKS	   *614144	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The primary cilium – basic biology 
 
The primary cilium is a hair-like organelle protruding from the cell membrane, and is 
present in almost all cell-types. Each cell contains only one non-motile cilium, which is 
remarkably conserved throughout evolution. In the brain, motile cilia are restricted to the 
ependymal cells lining the ventricle and some of the choroid plexus cells, whereas primary 
cilia are present on all brain cells, including neural progenitors and mature neurons, glial cells 
and astrocytes(17).  
 
 The axoneme is the microtubule-based core of the cilia (Figure 2). In the non-motile 
cilia, it is formed by nine doublet microtubules (9+0), whereas in the motile cilia, it contains 
nine doublet microtubules and an extra pair of tubules (9+2) that are attached to a dynein 
motor to generate movement. The proximal end of the axoneme is anchored to the cell by the 
basal body, a modified centriole. The region between the basal body and the base of the 
axoneme is the transition zone. The main body of the transition zone is characterized by 
multiple rows of Y-shaped linkers projecting from the outer doublets of the axoneme and 
attaching to the ciliary membrane, as well as transitional fibers attaching the basal body to the 
peri-ciliary membrane. The transition zone isolates the cytoplasm of the cilia from the rest of 
the cell by acting as a selective barrier to protein diffusion.  It also functions as a loading-
unloading zone for transport into and out of the cilium. Cilia lack the necessary machinery for 
protein synthesis. Thus both soluble and membrane-bound ciliary proteins need to be 
trafficked to the basal body and taken up into the cilium.  Proteins that enter the cilia from its 
base are carried along the axoneme via a microtubule-based transport system called 
intraflagellar transport (IFT). Anterograde transport toward the ciliary tip is regulated by 
complex B, consisting of at least 14 proteins (IFT172, IFT88, IFT81, IFT80, IFT74, IFT70, 
IFT57, IFT54, IFT52, IFT46, IFT27, IFT25, IFT22 and   IFT20), in association with kinesin 
motors (KIF3A, KIF3B, and KAP3). The retrograde transport (i.e. from the tip of the cilia 
towards the base) is provided by complex A, which is composed of six IFT proteins (IFT144, 
IFT140, IFT139, IFT122, IFT121, and IFT43), in association with a dynein motor 
(DYNC2H1 and DYNC2L1)(18).  
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The antennae-like shape of the cilia (typically 5-10um in length) extending into the 
surrounding extracellular environment makes its ideally positioned to detect changes in 
chemical factors, morphogens or growth factors present in the extracellular medium. 
Additionally, the fact that the ciliary compartment is distinct from the remainder of the 
cellular compartment (both at the level of the intracellular compartment and the membrane) 
allows the partitioning of the sensory and signaling proteins away from the main body of the 
cell, and fine-tuning of biological responses to various stimuli. For example, the passive 
bending of the cilia present on renal tubular epithelial cells by fluid flow mediate the 
mechanosensation of extracellular urine flow; bending of the cilia within the kidney tubules 
leads to calcium influx through the polycystin-1 (PC-1)/polycystin-2 (PC-2) calcium channel.  
Mutations in both PC-1 and PC-2 are responsible for polycystic kidney disease. Retinal 
photoreceptors have specialized primary cilium that connects the inner segments which 
contains the cellular nucleus, to the outer nucleus which contains the photo-transducing 
pigments such as rhodopsin (19).  
Axoneme'
Transi-on'Zone'
Basal'Body'
Ciliary'necklace'
Y7shaped'linkers'
Transi-onal'ﬁbers'
External'cellular''
membrane'
IFTA'(dynein'motor)'
IFTB'(kinesin'motor)'
Figure 2. Schematic representation of the primary cilia. IFT: 
intraflagellar transport 
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Key role of the cilia in neurodevelopment 
Primary cilia sense and transduce extracellular signals that influence a wide range of 
processes such as cell proliferation and polarity, developmental processes and neuronal 
growth. As exemplified with JBTS, perturbation in cilium formation or function can lead to 
profound defects in embryogenesis, with involvement of various organs including brain, 
retina, kidneys, liver, skeleton and heart. The primary cilium’s role in brain and organ 
patterning is mediated by morphogen signaling and its central role in the regulation of the 
sonic hedgehog (Shh), canonical and non-canonical Wnt pathways. The primary cilium also 
plays a pivotal role in a number of major growth factor-regulated signaling pathways, 
including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and Notch 
pathways, with receptors for these ligands concentrated on the ciliary membranes(17). 
 
Cilia and Sonic HedgeHog Signaling (Shh) 
 
Shh signaling is essential for embryonic development, acting as a morphogen that is 
involved in patterning of multiple tissues, notably the central nervous system and limbs(20). 
In the central nervous sytem, Shh and the cilia have critical roles in neural tube/spinal cord 
patterning, telencephalic patterning, migration and placement of interneurons in the 
developing cortex, hippocampal neurogenesis, and formation of adult neural stem cells.  
The cilium is required for amplification of the Shh signal when the Shh ligand is 
present. In the absence of Shh, its transmembrane receptor Patched (Ptc) localizes to the base 
of the cilium.  There, Ptc represses the activity of Smo, a transmembrane protein with a 
structure reminiscent of G-protein-coupled receptors, by preventing its localization to the 
cilium. Upon binding of Shh to Ptc, Ptc is translocated outside the compartment allowing 
Smo to enter it, in a process that depends on the anterograde IFT machinery. The ciliary 
accumulation of Smo in turn facilitates the activation of Smo, which ultimately results in the 
accumulation of the active forms of three Gli (Gli-A) transcription molecules (Gli1, Gli2 and 
Gli3) (21). In the absence of Shh, Gli1, Gli2 and Gli3 are proteolytically processed into 
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repressor forms (Gli-R) by the removal of their carboxy tails. The activation of Smo inhibits 
Gli protein processing and results in the accumulation of the full Gli proteins containing the 
transactivator domain, which can enter the nucleus and activate target genes (Figure 3).  Shh-
related tissue patterning stems from the regulation of the balance between Gli transcriptional 
activators and repressors in the developing tissues. In the absence of Shh, Gli2 and Gli3 are 
cleaved to repressor forms (Gli2R, Gli3R), whereas in its presence, proteolysis is inhibited 
and Gli2 and Gli3 function as activators (Gli2A, Gli3A). Gli2A is the primary activator of 
Shh target genes, Gli3R the main repressor. 
Shh signaling and activation of the Gli pathway are particularly important in cerebellar 
development (which is highly abnormal in patients with JBTS(22)). Most cell types of the 
cerebellum arise from the ventricular zone progenitors that are migrating through the forming 
cortex during embryogenesis. The cerebellar granule cells originate from a secondary 
germinal zone in the rostral rhombic lip. In the mouse, progenitors called cerebellar granular 
neuronal precursors (CGNP) undergo a first wave of proliferation at Embyonic day13.5. 
Then, from E17.5 on, they migrate over the nascent cerebellum to form the external granule 
layer where their population massively expands. This expansion is mediated by Shh, which is 
secreted by the Purkinje cells and diffuses up to the outer External Granule Layer where the 
CGNPs are located. The CGNPs highly express Gli1, the readout of the Shh pathway(23). 
Among the identified mitogens in the cerebellum (e.g. FGF-2, IGF-1 and EGF), Shh is the 
most potent mitogenic factor, able to trigger up to a 100-fold increase of CGNP proliferation 
in vitro (24). The proliferation phase of the CGNPs peaks at P5-8 and declines thereafter to 
stop at around P15. From P8, CGNPs start extending processes and initiate their onwards 
migration. The duration and intensity of the proliferation phase generating the pool of CGNPs 
is critical for the final shape and function of the cerebellum. Conditional removal of ciliary 
genes in CGNPs gives rise to striking dysgenesis and abnormal foliation of the cerebellum, as 
well as decreased target genes of and proliferation of CGNPS during cerebellar 
development(23).  
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 Shh signaling is also essential for spinal cord and neural tube patterning.  Disruption 
of Shh signaling leads to dorso-ventral patterning defects of the spinal cord, and neural tube 
defects such as failed closure of the neural tube (occipital encephalocele or exencephaly) and 
midline defects (colobomas, corpus callosum defects, defects of decussation of the 
corticospinal tracts)(17). Shh protein is produced from the ventral pole of the neural tube and 
forms a ventral-to-dorsal concentration gradient.  This gradient establishes the differential 
spatial patterns of gene expression in neural progenitor cells.  High levels of Shh signaling 
induce the expression of the homeodomain protein Nkx2.2; consequently, Nkx2.2 is most 
strongly expressed ventrally. Low levels of Shh are sufficient to induce the expression of the 
transcription factor Olig2, which is expressed more dorsally than Nkx2.2.(25-27). Regulation 
of the balance between activated and repressor forms of Gli is critical in Shh-mediated 
patterning, and is regulated in part by the cilia.  This explains why disruption of ciliary 
function can lead to different patterning abnormalities that reflect overactivity of either Gli-R 
or Gli-A. 
Ptc$ Smo$
Gli$R& Repressor&
Gli$R&
SHH&target&genes&OFF$
Ptc$ Smo$
Gli$A& Ac4vator&
Gli$A&
SHH&target&genes&ON$
SHH$
Figure 3: SHH signaling pathway schematic. In the absence of SHH, the receptor Ptc is 
located in the cilium and suppresses Smoothened (Smo).  Full-length Gli transcription 
factors are truncated into their repressor forms (Gli-R). The binding of SHH to Ptc facilitates 
the activation of Smo, which ultimately results in the accumulation of the active forms of Gli 
(Gli-A) which can enter the nucleus and activate target genes. (Modified from Goetz and 
Anderson, Nature Reviews Genetics, 2010) 
	  	   14	  
Disruption of Shh signaling also accounts for the limb patterning defects associated 
with ciliopathies, as Shh plays an important role in anteroposterior patterning of the limbs. 
Shh initially acts as morphogen and originates from posterior margin of the limb bud in a 
region called the zone of polarizing activity. Subsequently, it has mitogenic activity, which 
ensures the production of a sufficient number of cells to promote the normal complement of 
digits. Together, these two activities of Shh are responsible for specifying the identity of each 
digit and, as the limb bud expands, the position within the limb bud in which each digit forms. 
Loss-of-function mutations to Shh results in a loss of digits, whereas mutations in Gli3 cause 
polydactyly (28). Though the exact mechanism underlying polydactyly in ciliopathies has not 
been elucidated, disruption of Shh transduction signalling and abnormal Gli3 processing are 
key central processes (29) .  
 
Cilia and the WNT pathway 
 
The canonical and non-canonical (planar cell polarity, PCP) Wnt pathways are other 
important signaling pathways also regulated in part by the cilia. The Wnts are a family of 
secreted factors that bind Frizzled (Fzl) receptors to activate distinct signaling cascades, 
depending on the specific Wnt ligand, Wnt receptor, and the activity of Disheveled (Dvl), 
which acts as a molecular switch between signaling cascades (Figure 4).  Canonical β-
catenin-dependent Wnt signaling regulates proliferation, cell cycle progression and 
differentiation in the nervous system(30).  The PCP Wnt signaling pathway provides cells 
with the positional clues required for concerted multicellular actions, such as the convergent 
extension cell movements that lead to neural tube closure (31).  The PCP pathway is 
increasingly implicated in neuronal migration and axon guidance, in particular in the orderly 
development of large axon tracts. In absence of Wnt ligand, cytoplasmic β-catenin is 
constitutively phosphorylated by several kinases and targeted for proteosomal 
degradation(32). In canonical Wnt signaling, the binding of Wnt ligands to Fzl and LRP5 or 
LRP6 coreceptors transduces a signal across the plasma membrane that results in the 
activation of the Dvl.  Activated Dvl inhibits the degradation and leads to the stabilization and 
accumulation of β-catenin in the cytoplasm. β-catenin then migrates into the nucleus where it 
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can act as a co-activator for TCF/LEF- mediated transcription of neurodevelopmental genes.  
Several JBTS genes, such as AHI, which encodes jouberin, regulate canonical Wnt signaling 
by facilitating β-catenin translocation to the nucleus. It has been shown that the primary 
cilium serves to modulate Wnt pathway responsiveness by sequestering β-catenin and 
jouberin within the cilium, thus limiting their nuclear entry. Similarly, other studies 
investigating the roles of the ciliary and basal body genes Kif3a, Ift88, and Ofd1 have 
revealed an inhibitory role of the primary cilium on canonical Wnt signaling, suggesting that 
loss of ciliary or basal body components leads to hyper-responsiveness to external canonical 
Wnt stimuli (33, 34). Loss of Kif3a in mice leads to enhanced β-catenin-dependent 
transcriptional activation. Embryonic fibroblasts from both Kif3a and Ofd1 mutant mice, as 
well as Ofd1-deficient embryonic stem cells have a hyper-responsive canonical Wnt response.  
 
Figure 4: WNT signaling pathway schematic. The extracellular signalling molecule WNT 
activates the canonical pathway (right) and the planar cell polarity (PCP) pathway (left). In the 
canonical pathway, interaction of WNT with the transmembrane receptor frizzled (FZ) activates 
dishevelled (DVL), which induces the disassembly of a complex (axin, APC and GSK3β),  and 
results in the accumulation of β-catenin in the cyctoplasm. β-catenin then translocates where it 
can activate the transcription of target genes. In the PCP pathway, FZ functions through G-
proteins to activate DVL, which thereupon signals to Rho GTPases (Rho or Rac or both). 
Activated Ras signals through the c-Jun amino (N)-terminal kinase (JNK). Activation of Rho-
GTPases induces changes in the cytoskeleton. (Modified from Moon et al, Nature Reviews 
Genetics, 2004) 
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 The non-canonical PCP pathway is also activated via the binding of Wnt to Fzl and 
its co-receptor, however, it does not result in the downstream accumulation of β-catenin. Fzl 
recruits Dvl to form a complex with the Dvl-associated activator of morphogenesis 1 
(DAAM) which then activates the small G-protein Rho. In turn, Rho activates Rho-associated 
kinase  (ROCK), which is one of the major regulators of the cytoskeleton. Mutations in 
several ciliopathy-related genes, such as TMEM237, TMEM216 or TMEM67, result in 
abnormal PCP cascade activity, and conversely, mutations in key PCP pathway proteins such 
as inturned (intu), fuzzy (fuz) or dvl, were found to result in abnormal ciliogenesis.  
 
 In conditions of normal ciliary signaling, the PCP pathway is favored over the 
canonical pathway by inhibition of Dvl and activation of B-catenin destruction complex. With 
disruption of normal the basal body or ciliary function, there is decreased PCP signaling and 
upregulation of canonical Wnt signaling. Dysregulation of the Wnt pathway plays a critical 
role in the formation of renal cysts associated with ciliopathies.  The Wnt pathway is required 
for the induction of the metanephric mesenchyme to develop the proximal portions of the 
nephron and for regulation of cell proliferation.  Both PCP defects and hyperactivity of the 
canonical wnt signaling in transgenic mice overexpressiving B-catenin can result in the 
formation of cysts.  The underlying mechanism is thought to be related to the fact that normal 
diving cells in the renal tubules orient their mitotic spindles parallel to the lumen, resulting in 
tubular elongation, whereas mis-orientated mitotic spindles, as observed in animal models of 
cystic kidney disease, result in tubular dilation(35). 
  
Founder effect underlies many autosomal recessive disorders in French Canadians 
 
There are a large number of genetic disorders that have a markedly increased 
incidence in the French-Canadian population. These include Autosomal recessive spastic 
ataxia of Charlevois-Saguenay (ARSACS, MIM# 270550), Agenesis of corpus callosum and 
peripheral neuropathy (ACCPN, Andermann syndrome (MIM# 218000), Leigh syndrome 
French-Canadian type (MIM# 220111), Oculopharyngeal muscular dystrophy (OPMD, 
MIM# 164300), Hereditary sensory and autonomic neuropathy type II (HSAN II, MIM# 
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201300), Myotonic dystrophy (MIM# 160900) and many others.  The increased incidence of 
these hereditary disorders in the FC population reflects the presence of founder effects.  A 
founder effect refers to the reduction in genetic variation that results when a small population 
establishes a new colony. The gene pool of the first generation of settlers (which may not 
represent the gene pool of the entire population it is derived from) contributes 
disproportionately to the ensuing population structure.  Thus, if the founding settlers carry 
rare gene mutations, these will be passed on to future generations.  Alleles that may have been 
rare in the original population will occur with a higher frequency in the settlers and their 
descendants.   
 
The French-Canadian population arose following successive recent immigration 
waves. Of Quebec’s current >7 million inhabitants, 6 million are descendants from French 
Settlers. The French Colony of Nouvelle-France was first settled in 1608, with the foundation 
of the City of Quebec.  From 1608 till the time it passed into British rule, approximately 
8,500 permanent settlers arrived in Quebec, including only 1,600 women. The 2600 settlers 
who arrived before 1680 have contributed two thirds of the gene pool of the current French-
Canadian population. Though settlers came from regions throughout France, the major source 
of immigrants to Nouvelle-France were the Atlantic seaports and the regions around Paris. 
French settlement in North America occurred in two main regions along the Saint Lawrence 
River and Acadia (now New Brunswick and Nova Scotia). In the 17th century, the population 
groups had limited social and geographical mobility; therefore there were limited marriages 
between families from different regions or social groups.  By the English conquest in 1759, 
most of the French-Canadian population lived in farming settlements along the Saint 
Lawrence River and, because of language and religious barriers, intermixed minimally with 
the Protestant English-speaking newcomers.  The French-Canadian population has had a high 
fertility rate, attributed to the encouragement by the clergy, and frequently referred to as “la 
revanche des berceaux” (the revenge of the cradles). The high fecundity rate, early marriage 
and overall low infant mortality rate resulted in a rapid expansion of the French-Canadian 
population. Thus, the founding of the French-Canadian population by a limited number of 
settlers, combined with the relative isolation of the population and the higher fecundity rate, 
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explains the presence of a number of founder effects.  This has resulted in the increased 
incidence of these rare genetic disorders in the French-Canadian population (36, 37). 
 
For the recessive disorders with a higher incidence in the French-Canadian population, 
a single common founder mutation is usually observed, present at a higher carrier frequency 
amongst French-Canadian individuals.  This explains the increased incidence of disease 
despite very low rates of consanguineous marriages. For example, ARSACS affects 1 in 1519 
individuals in Charlevoix and 1 in 1952 individuals in the Saguenay, where the estimated 
carrier frequency is 1/22.  One mutation (c.6594delT) in the causal gene SACS represents 94% 
of mutated alleles.  Similarly, Leigh syndrome affects 1/2916 live births in the Saguenay-Lac-
Saint-Jean region.  Again, in Leigh syndrome only one allele, A354V, represents 98% of 
mutant alleles in the causal gene LRPPRC (36). 
 
Landscape of Joubert syndrome in Quebec 
 
Despite the fact that JBTS was first described in Quebec, the overwhelming majority 
of French-Canadian patients with JBTS did not have causal mutations identified at the onset 
of my doctoral project in 2010.  In fact, in 2010, only 8 JBTS genes were known. 
Determining the precise underlying genetic etiology of JBTS is of great importance for 
several reasons.  For the patients and their families, it facilitates genetic counseling and 
prenatal testing.  It also concludes the diagnostic process (providing closure for families), 
improves the accuracy of prognostication and allows tailored medical management. Critically, 
determining causal genes expands our knowledge of the pathophysiology of JBTS and allows 
improved understanding of mechanisms underlying normal brain development.  Ultimately, 
the understanding of the pathophysiology of these disorders will enable the development of 
targeted treatments in the future.   
 
The precise incidence of JBTS is not known, but is estimated to be between 1/80,000 
and 1/100,000 live births(38). Our preliminary observation suggested that there is a high 
prevalence of JBTS in the French-Canadian population living in the Lower St-Lawrence 
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(“Bas-du-Fleuve” in French) region of the province of Quebec (Figure 5). In particular, there 
is a striking cluster of families from the east end of the region (Matapedia region), including 
one family from Mont-Joli (population of 6,568), 3 families from Amqui (population 6,261) 
and 3 other families from Sayabec (population 1,877). This distribution strongly suggested 
the presence of a founder effect for JBTS. 
 
The population of the Lower St-Lawrence region was initially established as the result 
of the immigration of a limited number of settlers (6,000 individuals) from Quebec City and 
its surroundings in the late 17th and early 18th century followed by a rapid increase of the 
population due to a high fertility rate(39). The establishment of settlers in the region followed 
a west-to-east pattern, with later settlers migrating to regions further east. A small number of 
Acadians also contributed to the early population of the Matapedia region(40). Thus, the 
demographic growth of this population appears to be characterized by a series of bottlenecks 
that may have resulted in regional founder effects. We hypothesized that a founder effect 
could underlie the clustering of individuals with JBTS in the Lower St-Lawrence region.  If 
this were true, a single common homozygous mutation might explain a large proportion of 
them. 
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It was initially established that the population of the
Lower St. Lawrence region was a result of both the immi-
gration of a limited number of settlers (6,000 individuals)
from Quebec City and its surrounding areas in the late
17th century and beginning of the 18th century and a rapid
increase in settlers resulting from a high fertility rate.22
The establishment of settlers in the region followed a
west-to-east pattern, and settlers later migrated to regions
farther east. A small number of Acadians also contributed
to the early population of the Matapedia region.23 The
demographic growth of this population thus appears to
be characterized by a series of bottlenecks that might
have resulted in regional founder effects. We hypothesized
that a founder effect could underlie the clustering of
individuals with JBTS in the Lower St. Lawrence region,
raising the possibility that a common homozygous muta-
tion explains a large portion of them. We performed
whole-genome SNP genotyping in all 15 individuals with
JBTS by using the Illumina Human 610 Genotyping
BeadChip panel, which interrogates 620,901 SNPs, and
we used PLINK24 to search for homozygosity regions con-
taining >30 consecutive SNPs and extending over >1Mb.
We identified several overlapping regions of shared
homozygosity, but these regions were not found in more
than five families, were small (1 megabase or less), and
contained genes that are unlikely to play a role in cilia
development and/or function (Table S1, available online).
Altogether, the genotyping data suggest the presence of
allelic and/or genetic heterogeneity within our cohort.
Given the lack of hints from genotype-based mapping,
we decided to sequence the protein-coding exomes of all
our JBTS-affected subjects in the hopes of identifying a
unique candidate gene harboring private pathogenic vari-
ants in a large fraction of the samples. Genomic DNA from
each sample was captured with the Agilent SureSelect
Figure 1. Distribution of Individuals with JBTS
in the Lower St. Lawrence Region
Numbers refer to families (pedigrees in Figure 2).
Note the cluster of families along Route 132,
which follows the Matapedia River.
50 Mb oligonucleotide library, and the
captured DNA was sequenced with paired-
end 100 bp reads on Illumina HiSeq2000.
The result was an average of 14.7 Gb of
raw sequence for each sample. Data were
analyzed as previously described.25 After
we used Picard (v. 1.48) to remove putative
PCR-generated duplicate reads, we aligned
the reads to human genome assembly
hg19 by using a Burroughs-Wheeler algo-
rithm (BWA v. 0.5.9). The median read
depth of the bases in CCDS (consensus
coding sequence) exons was 115 (deter-
mined with Broad Institute Genome
Analysis Toolkit v. 1.0.4418).26 On average,
88% (52.9%) of the bases in CCDS exons were covered
by at least 20 reads. We called sequence variants by
using custom scripts for Samtools (v. 0.1.17), Pileup, and
varFilter, and we required at least three variant reads as
well as >20% variant reads for each called position.
Single-nucleotide variants (SNVs) had Phred-like quality
scores of at least 20, and small insertions or deletions
(indels) had scores of at least 50. We used Annovar to
annotate variants according to the type of mutation,
occurrence in dbSNP, SIFT score, and 1,000 Genomes allele
frequency.27 To identify potentially pathogenic variants,
we filtered out (1) synonymous variants or intronic vari-
ants other than those affecting the consensus splice sites,
(2) variants seen in more than one of 261 exomes from
individuals with rare, monogenic diseases unrelated to
JBTS (these individuals were sequenced at the McGill
University and Genome Quebec Innovation Centre), and
(3) variants with a frequency greater than 0.5% in the
1,000 Genomes Browser (Tables 1 and 2).
We first examined the exome datasets to look for rare
variants in the 15 genes already associated with JBTS (these
genes are INPP5E [MIM 613037], TMEM216 [MIM 613277],
AHI1 [MIM 608894], NPHP1 [MIM 607100], CEP290
[MIM 610142], TMEM67 [MIM 609884], RPGRIP1L
[MIM 610937], ARL13B [MIM 608922], CC2D2A [MIM
612013], CXORF5 [MIM 300170], KIF7 [MIM 611254],
TCTN1 [MIM 609863], TCTN2 [MIM 613885], TMEM237
[MIM 614424], and CEP41)2–19 as well as in the JBTS
candidate gene, TTC21B (MIM 612014).28 Two individuals
(II-1 from family 484 and II-2 from family 473, Figure S2)
that are not known to be related were each found to be
carrying two heterozygous missense variants (c.4667A>T
[p.Asp1556Val] and c.3376G>A [p.Glu1126Lys]) in
CC2D2A (RefSeq accession number NM_001080522.2).13,14
These amino acids are highly conserved, and both
694 The American Journal of Human Genetics 90, 693–700, April 6, 2012
Figure 5. Distribution of individuals with Joubert syndrome in the Lower St-
Lawrence region. Note the cluster of families along Route 132, which follows the 
Matapedia river. 
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Hypotheses and objectives 
 
JBTS remains largely unexplained in French Canadians. Given the documented 
presence of multiple founder effects in the French-Canadian population, and our preliminary 
observation that multiple affected families clustered in the Lower Saint Lawrence and 
Matapedia regions, we hypothesized that there existed a founder effect with a recurrent 
mutation in one gene that explains the majority of cases.  In addition, given the fact that 
causal mutations in known JBTS genes were rarely identified in French-Canadian JBTS 
families on a clinical basis, we hypothesized the presence of a recurrent founder mutation in a 
novel JBTS gene. Therefore, our initial objective was to study these French-Canadian 
families using single nucleotide polymorphism (SNP) genotyping and homozygosity 
mapping, a strategy that is well suited for the study of families with an autosomal recessive 
disorder in which a founder effect is suspected.  
Because JBTS is known to be a very genetically heterogeneous condition, we also 
hypothesized that, though a founder mutation likely existed and explained the majority of FC 
JBTS families, mutations in more than one gene probably accounted for the genetic etiology 
in Quebec.  Thus, we anticipated using WES to study all JBTS families that remained 
unexplained following our initial SNP genotyping and homozygosity approach. Indeed, WES 
is an extremely powerful strategy to study disorders that are clinically and genetically 
heterogeneous, such as JBTS.  
 
The specific objectives of this project were: 
 
1) To recruit a cohort of French-Canadian families with JBTS and assess their 
geographic distribution throughout Quebec 
2) To clinically characterize the affected JBTS individuals by extensive phenotypic 
evaluation of all JBTS patients when possible, supplemented by review of medical 
records and radiographic imaging. 
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3) To identify the causal genes underlying JBTS in the French-Canadian population 
using (a) a homozygosity mapping approach and/or (b) whole exome sequencing 
(WES).  
4) To evaluate for the presence of a genetic founder effect in the French-Canadian 
population. 
5) To look for genotype-phenotype correlations. 
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Chapter 2: 
 
 
Mutations in C5ORF42 cause Joubert 
syndrome in the French Canadian 
Population 
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Manuscript 1: 
Mutations in C5ORF42 cause Joubert syndrome in the French 
Canadian Population. 
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ABSTRACT 
 
Joubert syndrome (JBTS) is an autosomal recessive disorder characterized by a 
distinctive mid-hindbrain malformation, developmental delay with hypotonia, ocular-motor 
apraxia and breathing abnormalities. Although JBTS was first described more than 40 years 
ago in French Canadian siblings, the causal mutations have not yet been identified in this 
family, nor in most French Canadian individuals subsequently described. We ascertained a 
cluster of 15 individuals with JBTS from 11 families living in the Lower St-Lawrence region. 
SNP genotyping excluded the presence of a common homozygous mutation that would 
explain the clustering of these individuals. Exome sequencing performed in all the 15 subjects 
showed that 9 affected individuals from 7 families (including the original JBTS family) 
carried rare compound heterozygous mutations in C5ORF42. Two missense variants 
(c.4006C>T [p.Arg1336Trp], c.4690G>A [p.Ala1564Thr]) and a splicing mutation 
(c.7400+1G>A), which causes exon skipping, were found in multiple subjects, not known to 
be related, whereas three other mutations, all truncating (c.6407delC [p.Pro2136Hisfs*31], 
c.4804C>T [p.Arg1602X], c.7477C>T [p.Arg2493X]), were identified in single individuals. 
None of the unaffected first-degree relatives were compound heterozygotes for these 
mutations. Moreover, none of the 6 putative mutations was detected among 477 French 
Canadian controls. Our data suggests that mutations in C5ORF42 explain a large fraction of 
French Canadian individuals with JBTS. 
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Joubert syndrome (JBTS; MIM 213300) is an autosomal recessive disorder 
characterized by the presence of hypotonia, apnea or hyperpnea in infancy, oculomotor 
apraxia, and variable developmental delay or intellectual impairment (reviewed in1). The 
diagnostic hallmark of JBTS is the presence of a complex malformation of the midbrain-
hindbrain junction that comprises cerebellar vermis hypoplasia or aplasia, deepened 
interpeduncular fossa, and elongated superior cerebellar peduncles. This malformation takes 
the appearance of a molar tooth on axial brain MRI. In a subset of individuals, JBTS also 
involves other organs, resulting in cystic kidneys, retinopathy, or polydactyly. JBTS is a 
genetically heterogeneous condition with 15 genes described to date(41-58). All of these 
genes appear to play a role in the development and/or function of non-motile cilia. Although 
JBTS was first described in French Canadian siblings more than 40 years ago by Marie 
Joubert and colleagues, until now the causal mutations have not yet been identified in the 
original family nor in most French Canadians subjects(1).  
 
There is a high prevalence of JBTS in the French Canadian population living in the 
Lower St-Lawrence (“Bas-du-Fleuve” in French) region of the province of Quebec (Fig. 6). 
In total, we identified 16 living affected individuals (from 11 unrelated families) with at least 
one grandparent originating from that region. Informed consent was obtained from all 
individuals or their legal guardians. This project was approved by our institutional ethics 
committee. We were initially able to collect blood-derived DNA from 15 of these individuals, 
including an affected individual (II-1 in family 394; individual BD in(1)) from the original 
JBTS family described by Marie Joubert and colleagues in 1969. There was a striking cluster 
of 7 families from the east end of the region (Matapedia region), including one family from 
Mont-Joli (population of 6,568), 3 families from Amqui (population 6,261) and 3 other 
families from Sayabec (population 1,877). Individual II-1 from family 394 did not undergo 
brain imaging studies but an MRI scan performed in her brother (II-2) showed the molar tooth 
sign (MTS)(59, 60). All the other affected individuals showed the MTS and variable 
expression of the classical JBTS features. The cohort included three families with two 
affected siblings, and in no case were parents affected, consistent with a recessive mode of 
transmission. 
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 The population of the Lower St-Lawrence region was initially established as the result 
of the immigration of a limited number of settlers (6,000 individuals) from Quebec City and 
its surroundings in the late 17th century and beginning of the 18th century followed by a rapid 
increase due to a high fertility rate(39). The establishment of settlers in the region followed a 
west-to-east pattern, with later settlers migrating to regions further east. A small number of 
Acadians also contributed to the early population of the Matapedia region(40). The 
demographic growth of this population thus appears to be characterized by a series of 
bottlenecks that may have resulted in regional founder effects. We hypothesized that a 
founder effect could underlie the clustering of individuals with JBTS in the Lower St-
It was initially established that the population of the
Lower St. Lawrence region was a result of both the immi-
gration of a limited number of settlers (6,000 individuals)
from Quebec City and its surrounding areas in the late
17th century and beginning of the 18th century and a rapid
increase in settlers resulting from a high fertility rate.22
The establi hment of settlers i the region followed a
west-to-east pattern, and settlers later migrated to regions
farther east. A small number of Acadians also contributed
to the early population of the Matapedia region.23 The
demographic growth of this population thus appears to
be chara terized by a series f bottlen cks that might
have resulted in regional founder effects. We hypothesized
that a founder effect could underlie the clustering of
individuals with JBTS in the Lower St. Lawrence region,
raising the possibility that a common homozygous muta-
tion explains a large portion of them. We performed
whole-genome SNP genotyping in all 15 individuals with
JBTS by using the Illumina Human 610 Genotyping
BeadChip panel, which interrogates 620,901 SNPs, and
we used PLINK24 to search for homozygosity regions con-
taining >30 consecutive SNPs and extending over >1Mb.
We identified several overlapping regions of shared
homozygosity, but these regions were not found in more
than five families, were small (1 megabase or less), and
contained genes that are unlikely to play a role in cilia
development and/or function (Table S1, available online).
Altogether, the genotyping data suggest the presence of
allelic and/or genetic heterogeneity within our cohort.
Given the lack of hints from genotype-based mapping,
we decided to sequence the protein-coding exomes of all
our JBTS-affected subjects in the hopes of identifying a
unique candidate gene harboring private pathogenic vari-
ants in a large fraction of the samples. Genomic DNA from
each sample was captured with the Agilent SureSelect
Figure 1. Distribution of Individuals with JBTS
in the Lower St. Lawrence Region
Numbers refer to families (pedigrees in Figure 2).
Note the cluster of families along Route 132,
which follows the Matapedia River.
50 Mb oligonucleotide library, and the
captured DNA was sequenced with paired-
end 100 bp reads on Illumina HiSeq2000.
The result was an average of 14.7 Gb of
raw sequence for each sample. Data were
analyzed as previously described.25 After
we used Picard (v. 1.48) to remove putative
PCR-generated duplicate reads, we aligned
the reads to human genome assembly
hg19 by using a Burroughs-Wheeler algo-
rithm (BWA v. 0.5.9). The median read
depth of the bases in CCDS (consensus
coding sequence) exons was 115 (deter-
mined with Broad Institute Genome
Analysis Toolkit v. 1.0.4418).26 On average,
88% (52.9%) of the bases in CCDS exons were covered
by at least 20 reads. We called sequence variants by
using custom scripts for Samtools (v. 0.1.17), Pileup, and
varFilter, and we required at least three variant reads as
well as >20% variant reads for each called position.
Single-nucleotide variants (SNVs) had Phred-like quality
sc r s of at least 20, and small insertions or deletions
(indels) had scores of at least 50. We used Annovar to
annotate variants according to the type of mutation,
occurrence in dbSNP, SIFT score, and 1,000 Genomes allele
frequency.27 To identify potentially pathogenic variants,
we filter d out (1) synonymous variants or intronic vari-
ants other than those affecting the consensus splice sites,
(2) variants seen in more than one of 261 exomes from
individuals with rare, monogenic diseases unrelated to
JBTS (these individuals were sequenced at the McGill
University and Genome Quebec Innovation Centre), and
(3) variants with a frequency greater than 0.5% in the
1,000 Genomes Browser (Tables 1 and 2).
We first examined the exome datasets to look for rare
variants in the 15 genes already associated with JBTS (these
genes are INPP5E [MIM 613037], TMEM216 [MIM 613277],
AHI1 [MIM 608894], NPHP1 [MIM 607100], CEP290
[MIM 610142], TMEM67 [MIM 609884], RPGRIP1L
[MIM 610937], ARL13B [MIM 608922], CC2D2A [MIM
612013], CXORF5 [MIM 300170], KIF7 [MIM 611254],
TCTN1 [MIM 609863], TCTN2 [MIM 613885], TMEM237
[MIM 614424], and CEP41)2–19 as well as in the JBTS
candidate gene, TTC21B (MIM 612014).28 Two individuals
(II-1 from family 484 and II-2 from family 473, Figure S2)
that are not known to be related were each found to be
carrying two heterozygous missense variants (c.4667A>T
[p.Asp1556Val] and c.3376G>A [p.Glu1126Lys]) in
CC2D2A (RefSeq accession number NM_001080522.2).13,14
These amino acids are highly conserved, and both
694 The American Journal of Human Genetics 90, 693–700, April 6, 2012
Figure 6. Distribution of indivi uals wit  Joubert syndrome in the Lower St-
Lawrence region. Numbers refer to families (pedigrees in Figure 7). Note the cluster 
of families along Route 132, which follows the Matapedia river. 
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Lawrence region, raising the possibility that a common homozygous mutation explains a large 
fraction of them. We performed whole-genome SNP genotyping in all 15 individuals with 
JBTS using the Illumina Human 610 Genotyping BeadChip panel, which interrogates 620,901 
SNPs, and searched for regions of homozygosity containing >30 consecutive SNPs and 
extending over >1Mb with PLINK(61). We identified several overlapping regions of shared 
homozygosity, but these regions were not found in more than 5 families, were small (1 
megabase or less), and contained genes that are unlikely to play a role in cilia development 
and/or function (supplementary data; Table S1, p. 35). Altogether, the genotyping data 
suggest the presence of allelic and/or genetic heterogeneity within our cohort.  
 
 Given the lack of hints from genotype-based mapping, we decided to sequence the 
protein-coding exomes of all our subjects with JBTS in the hope of identifying a unique 
candidate gene harboring private pathogenic variants in a large fraction of the samples. 
Genomic DNA from each sample was captured with the Agilent SureSelect 50 Mb 
oligonucleotide library, and the captured DNA was sequenced with paired-end 100 bp reads 
on Illumina HiSeq2000 resulting in an average of 14.7 gigabases (Gb) of raw sequence for 
each sample. Data were analyzed as previously described(62). After removing putative PCR-
generated duplicate reads using Picard (v. 1.48), we aligned reads to human genome assembly 
hg19 using a Burroughs-Wheeler algorithm (BWA v. 0.5.9). Median read depth of bases in 
consensus coding sequence (CCDS) exons was 115 (determined with Broad Institute Genome 
Analysis Toolkit v. 1.0.4418)(63). On average 88% (±2.9%) of bases in CCDS exons were 
covered by at least 20 reads. We called sequence variants using Samtools (v. 0.1.17), Pileup, 
and varFilter using custom scripts, requiring at least 3 variant reads as well as >20% variant 
reads for each called position, with Phred-like quality scores of at least 20 for single 
nucleotide variants (SNVs) and at least 50 for small insertions or deletions (indels). Annovar 
was used to annotate variants according to the type of mutation, occurrence in dbSNP, SIFT 
score, and 1000 Genomes allele frequency(64). To identify potentially pathogenic variants we 
filtered out: 1) synonymous variants or intronic variants other than those affecting the 
consensus splice sites; 2) variants seen in more than one of 261 exomes from individuals with 
rare, monogenic diseases unrelated to JBTS that were sequenced at the McGill University and 
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Genome Quebec Innovation Centre; and 3) variants with a frequency greater than 0.5% in the 
1000 genomes dataset (Table 3).  
We first examined the exome datasets to look for rare variants in the 15 genes already 
associated with JBTS (INPP5E [MIM 613037], TMEM216 [MIM 613277], AHI1 [MIM 
608894], NPHP1 [MIM 607100], CEP290 [MIM 610142], TMEM67 [MIM 609884], 
RPGRIP1L [MIM 610937], ARL13B [MIM 608922], CC2D2A [MIM 612013], CXORF5 
[MIM 300170], KIF7 [MIM 611254], TCTN1 [MIM 609863], TCTN2 [MIM 613885], 
TMEM237 [MIM 614424], CEP41)(41-58), as well as in the JBTS candidate gene TTC21B 
(MIM 612014)(65)28. Two individuals (II-1 from family 484 and II-2 from family 473, Figure 
S2. p. 37), not known to be related, were each found to be carrying two heterozygous 
missense variants (c.4667A>T [p.Asp1556Val] and c.3376G>A [p.Glu1126Lys]) in CC2D2A 
(RefSeq NM_001080522.2)(51, 52). These amino acids are highly conserved and both 
mutations are predicted to be deleterious according to SIFT (scores <0.05)(66) and Polyphen-
2 (scores >0.90)(67) (supplementary data; Fig. S1, p 42). The c.4667A>T (p.Asp1556Val) 
mutation has already been reported in individuals with JBTS(68). Segregation studies 
indicated that the affected individuals, but none of their unaffected first-degree relatives, were 
was detected in 261 in-house control exomes, which were
derived from other projects including some French Cana-
dian subjects, and in the 1,000 Genomes Browser. RT-PCR
performed on RNA extracted from the blood of individuals
II-2 (from family 394) and III-4 (from family 406/301), who
both carry the c.7400þ1G>A splicing mutation, showed
that this mutation causes skipping of exon 35 in C5ORF42
(NM_023073.3) and results in the creation of a premature
stop codon (Figure S3). The p.Arg1336Trp amino acid
substitution is predicted to be damaging (SIFT¼ 0.00; Poly-
phen-2 ¼ 0.99) and to affect a residue that is conserved
across vertebrate species (Figure 3B).
On the basis of the exome-sequencing data, four
additional JBTS-affected individuals from three families
(301, 468, and 489) were each carrying a single heterozy-
gous C5ORF42 mutation, including the already described
c.4006C>T (p.Arg1336Trp) and c.7400þ1G>A mutations
and the truncating mutation c.7477C>T (p.Arg2493*)
(NM_023073.3) (Figure 2 and Table 3). The c.7477C>T
(p.Arg2493*) mutation was absent from our 261 control
exomes and the 1,000 Genomes Browser. Our SNP geno-
typing data suggest that these four individuals—but not
the other individuals with JBTS in our cohort—are hetero-
zygous for a unique 5 Mb haplotype that encompasses
C5ORF42 (Figure S4). It seemed unlikely that this haplo-
type would be carrying three different rare mutations;
therefore, this observation suggests that the four individ-
uals might carry a second mutation linked to this haplo-
type. Upon further inspection of the exome data, we
discovered that all four individuals are also heterozygous
for another missense variant, c.4690G>A (p.Ala1564Thr)
(based on the ENST00000388739 transcript annotated by
the Ensemble Genome Browser). This allele was not
included in our original filtered dataset because it is located
in an internal coding exon (chr5: 37,157,522–37,157,415)
not annotated by RefSeq for the longest isoform of the
gene (NM_023073.3). Sanger sequencing confirmed the
presence of the various mutations in the four affected
individuals. Segregation studies showed that the four
affected individuals but none of their unaffected first-
degree relatives were compound heterozygous for
c.4690G>A (p.Ala1564Thr) and for one of the three other
mutations (c.4006C>T [p.Arg1336Trp], c.7400þ1G>A,
and c.7477C>T [p.Arg2493*]) (Figure 2). The additional,
alternative exon (which we designate exon 40a) with the
c.4690G>A (p.Ala1564Thr) mutation occurs between
RefSeq annotated exons 40 and 41 (NM_023073.3), is
present in brain expressed sequence tag (EST) clones with
GenBank accession numbers AK096581 and BC144070,
and retains the large open reading frame of the gene. Using
RNA-sequencing data made publicly available by Illumi-
na’s Body Map 2.0 (see Web Resources), we were able to
confirm the expression of the exon. The assembly of raw
data from 16 different tissues identified a large number of
reads that mapped to that exon in both brain and testes
samples; significantly fewer reads mapped to other tissues
(Figure S5). Reads that covered both ends of the exon and
spliced correctly to neighboring exons were found in either
brain or testes samples. The c.4690G>A (p.Ala1564Thr)
mutation was also absent from our 261 control exomes
and from the 1,000 Genomes Browser. It was not possible
to get accurate SIFT or Polyphen-2 predictions for this
mutation because the corresponding exon was not anno-
tated across species.
We further addressed the frequency of the six putative
C5ORF42 mutations identified in our JBTS individuals in
the French Canadian population. Genotyping 477 French
Canadian controls, including 96 Acadians subjects and 96
subjects from the Gaspe´sie region located immediately east
of Matapedia, did not identify a carrier of any of the six
C5ORF42 mutations. However, some of these mutations
are reported in the heterozygous state at very low frequen-
cies in the National Heart, Lung, and Blood Institute
(NHLBI) Go Exome Sequencing Project (ESP) dataset; these
mutations are c.4006C>T (p.Arg1336Trp) (2/10,754;
minor allele frequency [MAF] ¼ 0.0186%), c.7477C>T
(p.Arg2493*) (1/10,755; MAF ¼ 0.009%; rs139675596),
and c.4690G>A (p.Ala1564Thr) (12/4,574; MAF ¼
0.262%; rs111294855). It should be noted that
c.4006C>T and c.7477C>T correspond to CpG sites,
Table 2. Genes with Rare Homozygous or Multiple Heterozygous
Variants from the Combined Exome Sequences from 13 Individuals
with JBTS
Number of Families
with Mutations
in the Same Gene
Number
of Genes Gene Identity
1 family 528 C5ORF42,.
2 families 16 C5ORF42, ACAN, ADAMTS18,
C10orf68, FSIP2, LRP1B,
MUC12, MUC16, MUC4,
MYO16, PKD1L2, PKHD1L1,
RGPD4, SHROOM4,
TMEM231, ZNF717
3 families 7 C5ORF42, MUC5B, PLEC,
FAT3, FLG, TTN, LAMA5
4 families 1 C5ORF42
5 families 1 C5ORF42
>5 families 0 -
Table 1. Variant Prioritization Steps in the Analysis of Combined
Exome Sequences from 13 Individuals with JBTS
Filters Applied (Sequentially)
Number of
Variants Retained
Nonsynonymous, splicing, and coding indel
variants
34,157a
After excluding variants present in >1
in-house exome
7,075
After excluding variants reported in 1,000
Genomes Browser (frequency > 0.5%)
6,911
aTotal number of variants identified in the combined 13 exomes; redundant
variants were counted only once.
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Table 3. Variant prioritization steps in the analysis of combined sequences from 
13 individuals with JBTS 
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compound heterozygotes for these mutations (supplementary data; Fig. S2, p. 42). We 
conclude that these mutations are likely pathogenic. Both individuals have a mild phenotype. 
They have  oculomotor apraxia and only mild motor delay (they walked at 18 and 19 months 
and do not have gait ataxia). The individual who is school-aged performs well in a regular 
classroom. Four additional individuals were singly heterozygous for rare variants in the other 
known JBTS genes (c.265C>T [p.Leu89Phe] in TMEM216 [NM_001173991.2], c.3257A>G 
[p.Glu1086Gly] in AHI1 [NM_001134831], c.1600G>A [p.Glu534Lys] in CEP290 
[NM_025114.3], c.3032T>C [p.Met1011Thr] in TTC21B [NM_024753.4]). As each of these 
genes has previously been associated with recessive JBTS, these heterozygous variants are 
unlikely to fully explain the disorder for these persons.  
We next looked at the whole exome data for other protein-coding genes containing 
homozygous or multiple heterozygous variants in the 13 affected individuals not explained by 
CC2D2A (Table 4). Strikingly, five subjects, including a member of the initial JBTS family, 
carried two different 
heterozygous variants in 
an unstudied anonymous 
gene, C5ORF42 (Refseq 
# NM_023073.3). 
Mutations in 6 other 
genes were found in 
affected individuals 
among sets of three 
families (Table 4). 
Because these latter genes 
(MUC5B, PLEC, FAT3, 
FLG, TTN, LAMA5) are 
known to accumulate 
mutations at a high rate, 
they are unlikely to be 
linked to the disease 
was detected in 261 in-house control exomes, which were
derived from other projects including some French Cana-
dian subjects, and in the 1,000 Genomes Browser. RT-PCR
performed on RNA extracted from the blood of individuals
II-2 (from family 394) and III-4 (from fa ily 406/301), who
both carry the c.7400þ1G>A splicing mutatio , showed
that this mutation causes skipping of exon 35 in C5ORF42
(NM_023073.3) and results in the creation of a premature
stop codon (Figure S3). The p.Arg1336Trp amino acid
substitution is predicted to be damaging (SIFT¼ 0.00; Poly-
phen-2 ¼ 0.99) and to affect a residue that is conserved
across vertebrate species (Figure 3B).
On the basis of the exome-sequencing data, four
additional JBTS-affected individuals from three families
(301, 468, and 489) were each carrying a single heterozy-
gous C5ORF42 mutation, including the already described
c.4006C>T (p.Arg1336Trp) and c.7400þ1G>A mutations
and the truncating mutation c.7477C>T (p.Arg2493*)
(NM_023073.3) (Figure 2 and Table 3). The c.7477C>T
(p.Arg2493*) mutation was absent from our 261 control
exomes and the 1,000 Genomes Browser. Our SNP geno-
typing data suggest that these four individuals—but not
the other individuals with JBTS in our cohort—are hetero-
zygous for a unique 5 Mb haplotype that encompasses
C5ORF42 (Figure S4). It seemed unlikely that this haplo-
type would be carrying three different rare mutations;
therefore, this observation suggests that the four individ-
uals might carry a second mutation linked to this haplo-
type. Upon further inspection of the exome data, we
discovered that all four individuals are also heterozygous
for another missense variant, c.4690G>A (p.Ala1564Thr)
(based on the ENST00000388739 transcript annotated by
the Ensemble Genome Browser). This allele was not
included in our original filtered dataset because it is located
in an internal coding exon (chr5: 37,157,522–37,157,415)
not annotated by RefSeq for the longest isoform of the
gene (NM_023073.3). Sanger sequencing confirmed the
presence of the various mutations in the four affected
individuals. Segregation studies showed that the four
affected individuals but none of their unaffected first-
degree relatives were compound heterozygous for
c.4690G>A (p.Ala1564Thr) and for one of the three other
mutations (c.4006C>T [p.Arg1336Trp], c.7400þ1G>A,
and c.7477C>T [p.Arg2493*]) (Figure 2). The additional,
alternative exon (which we designate exon 40a) with the
c.4690G>A (p.Ala1564Thr) mutation occurs between
RefSeq annotated exons 40 and 41 (NM_023073.3), is
present in brain expressed sequence tag (EST) clones with
GenBank accession numbers AK096581 and BC144070,
and retains the large open reading frame of the gene. Using
RNA-sequencing data made publicly available by Illumi-
na’s Body Map 2.0 (see Web Resources), we were able to
confirm the expression of the exon. The assembly of raw
data from 16 different tissues identified a large number of
reads that mapped to that exon in both brain and testes
samples; significantly fewer reads mapped to other tissues
(Figure S5). Reads that covered both ends of the exon and
spliced correctly to neighboring exons were found in either
brain or testes samples. The c.4690G>A (p.Ala1564Thr)
mutation was also absent from our 261 control exomes
and from the 1,000 Genomes Browser. It was not possible
to get accurate SIFT or Polyphen-2 predictions for this
mutation because the corresponding exon was not anno-
tated across species.
We further addressed the frequency of the six putative
C5ORF42 mutations identified in our JBTS individuals in
the French Canadian population. Genotyping 477 French
Canadian controls, including 96 Acadians subjects and 96
subjects from the Gaspe´sie region located immediately east
of Matapedia, did not identify a carrier of any of the six
C5ORF42 mutations. However, some of these mutations
are reported in the heterozygous state at very low frequen-
cies in the National Heart, Lung, and Blood Institute
(NHLBI) Go Exome Sequencing Project (ESP) dataset; these
mutations are c.4006C>T (p.Arg1336Trp) (2/10,754;
minor allele frequency [MAF] ¼ 0.0186%), c.7477C>T
(p.Arg2493*) (1/10,755; MAF ¼ 0.009%; rs139675596),
and c.4690G>A (p.Ala1564Thr) (12/4,574; MAF ¼
0.262%; rs111294855). It should be noted that
c.4006C>T and c.7477C>T correspond to CpG sites,
Table 2. Genes with Rare Homozygous or Multiple Heterozygous
Variants from the Combined Exome Sequences from 13 Individuals
with JBTS
Number of Families
with Mutations
in the Same Gene
Number
of Genes Gene Identity
1 family 528 C5ORF42,.
2 families 16 C5ORF42, ACAN, ADAMTS18,
C10orf68, FSIP2, LRP1B,
MUC12, MUC16, MUC4,
MYO16, PKD1L2, PKHD1L1,
RGPD4, SHROOM4,
TMEM231, ZNF717
3 families 7 C5ORF42, MUC5B, PLEC,
FAT3, FLG, TTN, LAMA5
4 families 1 C5ORF42
5 families 1 C5ORF42
>5 families 0 -
Table 1. Variant Prioritization Steps in the Analysis of Combined
Exome Sequences from 13 Individuals with JBTS
Filters Applied (Sequentially)
Number of
Va iants Retained
Nonsynonymous, splicing, and coding indel
variants
34,157a
After excluding variants present in >1
in-house exome
7,075
After excluding variants reported in 1,000
Genomes Browser (frequency > 0.5%)
6,911
aTotal number of variants identified in the combined 13 exomes; redundant
variants were counted only once.
696 The American Journal of Human Genetics 90, 693–700, April 6, 2012
Table 4. Genes with rare homozygous or multiple heterozygous 
variants from the combined exome sequences from 13 individuals with 
JBTS 
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(supplementary Table S2, p. 40). All 5 affected individuals with changes in C5ORF42 carried 
the same missense mutation (c.4006C>T [p.Arg1336Trp]; NM_023073.3) as well as one of 
three different mutations: one mutation that affects a consensus donor splice site 
(c.7400+1G>A; NM_023073.3) and two truncating mutations (c.6407delC  
[p.Pro2136Hisfs*31] and c.4804C>T [p.Arg1602X]; NM_023073.3) (Fig. 7-8; Table 5). 
Sanger sequencing in the five affected individuals confirmed the presence of these variants. 
Segregation studies indicated that the affected individuals, but not their unaffected first-
degree relatives, were compound heterozygotes for these variants (Fig. 7; Table 5). 
Subsequently, we were able to collect DNA from individual II-2 (individual M.D. in refs (1, 
60)), the affected brother of II-1 in the initial JBTS family (family 394), and found that he 
was a compound heterozygote for the same C5ORF42 mutations as those identified in his 
affected sister (Fig 7B; Table 5). None of these 4 variants was detected in 261 in-house 
control exomes, which were derived from other projects including some French Canadian 
subjects, and in the 1000 genomes dataset. RT-PCR done on RNA extracted from the blood of 
individuals II-2/family 394 and III-4/family 406-301 carrying the c.7400+1G>A splicing 
mutation, showed that this mutation causes skipping of exon 35 in C5ORF42 
(NM_023073.3), resulting in the creation of a premature stop codon (supplementary data; Fig. 
S2. p. 41). The p.Arg1336Trp amino acid substitution is predicted to be damaging (SIFT = 
0.00; Polyphen-2 = 0.99), affecting a residue that is conserved across vertebrate species (Fig. 
8B).  
Based on the exome sequencing data, four additional individuals with JBTS from three 
families (301, 468, 489) were each carrying a single heterozygous mutation in C5ORF42, 
including the already described mutations c.4006C>T (p.Arg1336Trp) and c.7400+1G>A as 
well the truncating mutation c.7477C>T (p.Arg2493X) (NM_023073.3) (Fig. 7, Table 5). The 
c.7477C>T (p.Arg2493X) mutation was absent from our 261 control exomes and the 1000 
genomes dataset. Our SNP genotyping data suggested that these four individuals, but not the 
other individuals with JBTS in our cohort, are heterozygous for a unique 5 Mb haplotype that 
encompasses C5ORF42 (supplementary data; Fig. S3, p. 42). It seemed unlikely that this 
haplotype would be carrying three different rare mutations, hence this observation suggested 
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that the four individuals might carry a second mutation linked to this haplotype. Upon fur ther 
inspection of the exome data, we discovered that all four individuals are also heterozygous for  
  
mutations are predicted to be deleterious according to
SIFT (scores < 0.05)29 and Polyphen-2 (scores > 0.90)30
(Figure S1). The c.4667A>T (p.Asp1556Val) mutation has
already been reported in individuals with JBTS.31 Segrega-
tion studies have indicated that the affected individuals
but none of their unaffected first-degree relatives were
compound heterozygous for these mutations (Figure S2).
We conclude that these mutations are probably patho-
genic. Both individuals have a mild phenotype. They
have oculomotor apraxia and only mild motor delay
(they walked at 18 [II-1 from family 484] and 19 [II-2 from
family 473] months of age and do not have gait ataxia).
The individual who is of school age performs well in
a regular classroom. Four additional individuals were sin-
gly heterozygous for rare variants in the other known
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c.6407del
c.4006C>T
WT
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c.4690G>A
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Figure 2. Segregation of C5ORF42Muta-
tions in Families Affected by JBTS
JBTS-associated genes; such variants
are c.265C>T (p.Leu89Phe) in
TMEM216 (M_001173991.2),
c.3257A>G (p.Glu1086Gly) in
AHI1 (NM_001134831), c.1600G>A
(p.Glu534Lys) in CEP290 (NM_
025114.3), and c.3032T>C
(p.Met1011Thr) in TTC21B (NM_
024753.4). Because each of these
genes has previously been associated
with recessive JBTS, these heterozy-
gous variants are unlikely to fully
explain the disorder that these indi-
viduals have.
We next looked at the whole-exome
data for the other protein-coding
genes containing homozygous or
multiple heterozygous variants in the
13 affected individuals who did not
have mutations in CC2D2A (Tables 1
and 2). Strikingly, five subjects,
including a member of the initial
JBTS family, carried two different
heterozygous variants in an un-
studied anonymous gene, C5ORF42
(NM_023073.3). Mutations in six
other genes were found in affected
individuals among sets of three
families (Tables 1 and2). Because these
latter genes (MUC5B, PLEC, FAT3, FLG,
TTN, and LAMA5) are known to accu-
mulate mutations at a high rate, they
are unlikely to be linked to the disease
(Table S2). All five affected individuals
with changes in C5ORF42 carried the
same missense mutation, c.4006C>T
(p.Arg1336Trp) (NM_023073.3), as
well as one of three different mutations: one mutation
that affects a consensus donor splice site, c.7400þ1G>A
(NM_023073.3), and two truncating mutations, c.6407del
(p.Pro2136Hisfs*31) and c.4804C>T (p.Arg1602*) (NM_
023073.3) (Figures 2 and 3 and Table 3). Sanger sequencing
in the five affected individuals confirmed the presence of
these variants. Segregation studies indicated that the
affected individuals, but not their unaffected first-degree
relatives, were compound heterozygotes for these variants
(Figure 2 and Table 3). Subsequently, wewere able to collect
DNA from individual II-2 (individual M.D.19-20), the
affected brother of II-1 in the initial JBTS family (family
394), and we found that he was compound heterozygous
for the same C5ORF42mutations identified in his affected
sister (Figure 2B and Table 3). None of these four variants
The American Journal of Human Genetics 90, 693–700, April 6, 2012 695
Figure 7. Segregation of C5orf42 mutations in families affected with JBTS 
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 another missense variant, c.4690G>A (p.Ala1564Thr) (based on the 
ENST00000388739 transcript annotated by the Ensemble Genome Browser). This allele was 
not included in our original filtered dataset because it is located in an internal coding exon 
(chr5:37157522-37157415) not annotated by RefSeq for the longest isoform of the gene 
(NM_023073.3). Sanger sequencing confirmed the presence of the various mutations in the 
four affected individuals. Segregation studies showed that the four affected individuals, but 
none of their unaffected first-degree relatives, were compound heterozygous for the mutation 
c.4690G>A (p.Ala1564Thr) and for one of the 3 other mutations (c.4006C>T 
[p.Arg1336Trp], c.7400+1G>A, c.7477C>T [p.Arg2493X]) (Fig. 7). The additional, 
alternative exon with the c.4690G>A (p.Ala1564Thr) mutation, which we designate exon 40a, 
occurs between RefSeq (NM_023073.3) annotated exons 40 and 41, is present in brain EST 
clones with accession numbers AK096581 and BC144070, and retains the large open reading 
frame of the gene. Using RNA-sequencing data made publicly available by Illumina's Body 
Map 2.0 (see URL below), we were able to confirm the expression of the exon. The assembly 
of raw data from 16 different tissues identified a large number of reads mapping to that exon 
in both brain and testes samples with significantly fewer reads in other tissues (supplementary 
data; Fig. S4, p. 43). Reads covering both ends of the exon, splicing correctly to neighboring 
exons, were found in either brain or testes samples. c.4690G>A (p.Ala1564Thr) was also 
absent from our 261 control exomes, and in the 1000 genomes dataset. It was not possible to 
get accurate SIFT or Polyphen-2 predictions on this mutation due to the lack of annotation of 
the corresponding exon across species. 
 
We further addressed the frequency of the six putative C5ORF42 mutations identified 
in our JBTS individuals, in the French Canadian population. Genotyping 477 French 
Canadian controls, including 96 Acadians subjects and 96 subjects from the Gaspésie region 
located immediately east of Matapedia, did not identify any of the six C5ORF42 mutations. 
However, some of these mutations are reported in the heterozygous state at very low 
frequencies in the NHLBI Go Exome Sequencing Project (ESP) dataset, including c.4006C>T 
(p.Arg1336Trp) (2/10754; MAF = 0.0186%), c.7477C>T (p.Arg2493X) (1/10755; MAF = 
0.009%; rs139675596), and c.7957+288G>A (p.Ala1564Thr) (12/4574; MAF = 0.262%; 
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rs111294855). It should be noted that c.4006C>T and c.7477C>T correspond to CpG sites, 
which are associated with a higher mutation rate, possibly explaining the recurrence of these  
nonetheless rare mutations in different populations.  
 
The presence of 5 potentially deleterious mutations in C5ORF42, segregating with the 
disease in 7 presumably unrelated (though all French-Canadian) families, strongly suggests 
that disruption of this gene causes JBTS in our subjects. It remains uncertain whether the 
mutation c.4690G>A (p.Ala1564Thr) is pathogenic, considering that it is not clearly 
deleterious, and that it is found at a higher frequency (0.26%) in the ESP dataset than the 
other mutations. It is possible that this variant is linked to another mutation on the same 
haplotype that was not identified by our exome sequencing approach. 
 
walking ranged between 30 months and 8 years of age
(Table 3). Cognitive impairment was present in all individ-
uals but was variable, ranging from borderline intelligence
to mild intellectual disability. The majority of individuals
also showed oculomotor apraxia and breathing abnormal-
ities mainly characterized by episodes of hyperventilation.
Two individuals showed limb abnormalities; one had
preaxial and postaxial polydactyly, and another had
syndactyly of the third and fourth finger on one hand.
There was no evidence of retinal or kidney involvement.
There was no clear correlation between the type of
C5ORF42 mutation and the associated phenotype.
Surprisingly, we found that three mutations (c.4006C>T
[p.Arg1336Trp], c.7400þ1G>A, and c.4690G>A
[p.Ala1564Thr]) in C5ORF42 were present in multiple
individuals in our cohort. Haplotype studies indicate that
each of these mutations is linked to a distinct haplotype
in these families despite the lack of documented genealog-
ical relationships among them (Figure S4). The higher
frequency of these mutations in the population of the
Lower St. Lawrence region could be explained by a founder
effect with the coincidental occurrence of the three muta-
tions in the same group of settlers or by multiple regional
founder effects corresponding to sequential pioneer fronts.
Although founder effects are typically associated with an
increase in the frequency of a specific allele,33 which is
often accompanied by other alleles that remain at their
usual background frequency, they can also involve
multiple common mutations.36,37
In summary, after the initial description of JBTS in a
French Canadian family 40 years ago, we have shown
that mutations in C5ORF42 explain this neurodevelop-
mental disorder in many affected individuals from the
French Canadian population. We have also found that
C5ORF42 is associated with a complex founder effect in
this population. Although the function of C5ORF42
remains unknown, future studies will likely elucidate its
role in cilia development and/or function.
Supplemental Data
Supplemental Data include five figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.
Acknowledgments
Foremost, we thank the families who generously contributed their
time and materials to this research study. This work was selected
for study by the FORGE Canada Steering Committee, consisting
of K. Boycott (University of Ottawa), J. Friedman (University of
British Columbia), J. Michaud (Universite´ de Montre´al), F. Bernier
(University of Calgary), M. Brudno (University Toronto), B. Fer-
nandez (Memorial University), B. Knoppers (McGill University),
Table 3. Clinical Description of JBTS Individuals with C5ORF42 Mutations
Genotype
Family 406/301 Family 394 Family 474 Family 480 Family 489 Family 479 Family 468
IV-1 IV-2 IV-3 II-1 II-2 II-1 II-1 II-1 II-1 II-1
c.4006C>T (p.Arg1336Trp) þ " " þ þ þ þ " þ þ
c.7400þ1G>A þ þ þ þ þ " þ " " "
c.6407del (p.Pro2136Hisfs*31) " " " " " þ " " " "
c.7477C>T (p.Arg2493*) " " " " " " " þ " "
c.4804C>T (p.Arg1602*) " " " " " " " " þ "
c.7957þ288G>A
(c.4690G>A [p.Ala1564Thr])
" þ þ " " " " þ " þ
Age (years) 8 1.5 3 52 45 4 10 7 13 31
Sex F M F F M F M M F F
Developmental delay þ þ þ þ þ þ þ þ þ þ
Oculomotor apraxia " þ þ þ þ þ þ þ þ þ
Breathing abnormality þ þ þ þ þ þ þ þ " "
Limb abnormalitya " þ " " " þ " " " "
Brain MRI MTS MTS MTS ND MTS MTS MTS MTS MTS MTS
Retinal involvementb " (f) " (e) " (e) " (h) " (h) " (f) " (e) " (e) " (f) " (h)
Renal involvementc " (us) " (us) " (us) " (h) " (h) " (us) " (us) " (us) " (us) " (h)
The nucleotide and amino acid positions are based on reference sequence NM_023073.3 except for c.4690G>A (p.Ala1564Thr), which is based on Ensembl tran-
script ENST00000509849. The following abbreviations are used: F, female; M, male; MRI, magnetic resonance imaging; MTS, molar tooth sign; ND, not done; f,
fundoscopy; e, electroretinogram; h, history; and us, ultrasound.
aIndividual IV-2 from family 406/301 has a 3/4 syndactyly in the left hand and individual II.1 from family 474 has preaxial and postaxial polydactyly of the four
limbs. Individual II-1 from family 394 did not undergo an MRI, but the MRI of her brother (individual II-2 from family 394) documented a MTS.
bLack of retinal involvement was determined by electroretinogram, fundoscopy, or history.
cLack of renal involvement was determined by renal ultrasound or history.
698 The American Journal of Human Genetics 90, 693–700, April 6, 2012
Table 5: Clinical description of JBTS individuals with C5orf42 mutations  
	  	   35	  
Very little is known about C5ORF42 function. The RefSeq version of the full-length 
transcript (NM_023073.3; Ensemble ENST00000425232) apparently derives from virtual 
assembly of overlapping mRNA and EST clones. The predicted major mRNA isoform  
comprises 11,199 bp and contains 52 exons; the putative encoded protein is similarly large, 
comprising 3198 amino acids. With the exception of c.4690G>A (p.Ala1564Thr), all 
mutations reported herein are common to all annotated protein coding transcripts (Fig 8A). 
The predicted protein sequence is well conserved across much of the gene length in other 
vertebrates. It does not appear to contain any specific known functional domains, although 
Gene Ontology suggests it may be a transmembrane protein and ProtoNet predicts a coiled-
coil structure within the protein. Proteomic studies reported interactions between C5ORF42 
and the p21-activating kinase 1 (PAK1) and the small ubiquitin-like modifier 1 (SUMO1)(69, 
70). Although the significance of these interactions remains to be validated and further 
investigated, it is noteworthy that these latter genes play a role in neural development(71, 72). 
EST-expression (Unigene data), microarray profiling (Allen Brain Atlas) and BioGPS, 
indicate that C5ORF42 is widely expressed in a variety of tissues, including the brain.  
 
 In terms of genotype-phenotype correlation, all JBTS individuals with mutations in 
C5ORF42 showed global developmental delay with onset of independent walking between 30 
months and 8 years of age (Table 5). Cognitive impairment was present in all individuals but 
was variable, ranging from borderline intelligence to mild intellectual disability. The majority 
of individuals also showed oculo-motor apraxia and breathing abnormalities mainly 
characterized by episodes of hyperventilation. Two individuals showed limb abnormalities: 
pre- and post-axial polydactyly in one person and syndactyly of the third and fourth finger of 
a hand in another. There was no evidence of retinal or kidney involvement. There was no 
clear correlation between the type of C5ORF42 mutation and the associated phenotype. 
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  Surprisingly, we found that three mutations (c.4006C>T [p.Arg1336Trp], 
c.7400+1G>A, and c.4690G>A [p.Ala1564Thr]) in C5ORF42 were present in multiple 
individuals in our cohort. Haplotyping studies indicate that each of these mutations is linked 
to a distinct haplotype in these families, despite the lack of documented genealogical 
relationships among them (supplementary data; Fig. S3, p.43). The higher frequency of these 
mutations in the population of the Lower St-Lawrence region could be explained by a founder 
effect with the coincidental occurrence of the three mutations in the same group of settlers or 
by multiple regional founder effects corresponding to sequential pioneer fronts. Although 
founder effects are typically associated with an increase in the frequency of a specific 
which are associated with a higher mutation rate, possibly
explaining the recurrence of these nonetheless rare muta-
tions in different populations.
The presence of five potentially deleterious C5ORF42
mutations that segregate with the disease in seven presum-
ably unrelated (though all French Canadian) families
strongly suggests that disruption of this gene causes JBTS
in our subjects. It remains uncertain whether c.4690G>A
(p.Ala1564Thr) is pathogenic, considering that it is not
clearly deleterious and that it is found at a higher
frequency (0.26%) in the ESP dataset than are the other
mutations. It is possible that this variant is linked to
another mutation—not identified by our exome-
sequencing approach—o the same haplotype.
Very little is known about C5ORF42 function. The Ref-
Seq version of the full-length transcript (NM_023073.3;
Ensemble accession number ENST00000425232) appar-
ently derives from vir ual assembly of overl pping mRNA
and EST clones. The predicted major mRNA isoform
comprises 11,199 bp and contains 52 exons; the putative
encoded protein is similarly large and comprises 3,198
amino acids. With the exception of c.4690G>A
(p.Ala1564Thr), all mutations reported herein are common
to all annotated protein-coding transcripts (Figure 3A). The
predicted protein sequence is well conserved across much
of the gene length in other vertebrates. It does not appear
to contain any specific known functional domains,
although the Gene Ontology project suggests that it might
be a transmembrane protein and ProtoNet predicts a
coiled-coil structure within the protein. Proteomic studies
have reported interactions among C5ORF42, the p21-
activating kinase 1 (PAK1), and the small ubiquitin-like
modifier 1 (SUMO1).32,33 Although the significance of
these interactions remains to be validated and further
investigated, it is noteworthy that these latter genes play
a role in neural development.34,35 EST-expression (Unig-
e e data), microarray profiling (Allen Brain Atlas), and
BioGPS indicate that C5ORF42 is widely expressed in
a variety of tissues, including the brain.
In terms of genotype-phenotype correlation, all JBTS
individuals with mutations in C5ORF42 showed global
developmental delay, and the onset of independent
Figure 3. C5ORF42 Mutations Identified in Individuals with JBTS
(A) Scheme showing the positions of the mutations with respect to the different C5ORF42 Ensembl-annotated transcripts that are pre-
dicted to produce proteins. The numbering on top is based on the cDNA positions of ENST00000425232 (identical to RefSeq accession
number NM_023073.3). Mutation c.7957þ288G>A is annotated as part of a coding exon in ENST00000388739 and causes a missense
change (p.Ala1564Thr).
(B) NCBI HomoloGene-generated amino acid alignment of C5ORF42. Its predicted orthologs show the conservation of the Arg1336
residue.
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Figure 8. C5orf42 mutations identified in individuals with Joubert Syndrome. A) 
Sche  showing the positions of the mutations with r spect to the different C5orf42 
ENSEMBLE-annotated trancripts that are predicted to produce proteins. Numbering on 
top i  based on the cDNA positons of ENST00000425232 (identical to NCBI Refseq # 
NM_023073.3). c.7957+288G>A is annotated as part of a coding exon in 
ENST00000388739, causing a missense change (p.Ala1564Thr). B) Homologene-
gen rated (NCBI) amino acid alignment of human C5orf42 with its predicted orthologues 
showi g the conserv tion of the p.Arg1336 residue. 	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allele(70), often accompanied by other alleles that remain at their usual background 
frequency, they can also involve multiple common mutations(73, 74).  
 In summary, after the initial description of JBTS in a French Canadian family 40 years 
ago, we have shown that mutations in C5ORF42 explain this neurodevelopmental disorder in 
many affected individuals from the French Canadian population. We have also found that 
C5ORF42 is associated with a complex founder effect in this population. Although the 
function of C5ORF42 remains unknown, future studies will likely elucidate its role in cilia 
development and/or function. 
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Supplemental Data and Figures 
 
Chromosome 
Size 
(Mb) 
Start 
position 
End 
position 
# of 
patients 
Genes in interval 
12 1.01 38,120,168 39,128,892 5 ALG10B, CPNE8 
8 1.15 48,439,013 49,589,706 4 
KIAA0145, CEBPD, 
PRKDC, MCM4, UBE2V2 
4 0.96 151,184,163 152,147,262 4 
LRBA, MAB21L2, RPS3A, 
SNOD73A, SH3D19 
7 0.57 119,321,200 119,887,000 4 KCND2 
7 0.37 118,773,000 119,239,292 4 none 
2 1.07 135,745,129 136,740,556 3 
YSK4, RAB3GAP1, ZRANB3, 
R3HDM1, MIR128-1, 
UBXN4, LCT, 
LOC100507600, MCM6, 
DARS 
2 0.58 186,303,487 186,895,680 3 FSIP2 
12 0.28 39,288,892 39,566,178 3 CPNE8 
4 0.25 150,854,889 151,103,870 3 DCLK2 
 
Table S1. Regions of identical homozygosity shared by 3 or more patients with Joubert 
syndrome. In each patient, Plink was used to identify regions of homozygosity >30 
consecutive SNPs and >1Mb in size. Thereafter, Excel was used to identify overlapping 
regions of identical homozygosity shared by 3 or more individuals. RefSeq genes from the 
intervals (hg19) are noted in the table. 
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Gene Rank (out of 20870)  
by mutation frequency 
Number of rare 
mutations 
TTN 2 191 
MUC5B 4 130 
FLG 9 88 
PLEC 10 82 
LAMA5 12 73 
FAT3 74 37 
C5ORF42 2248* 9 
* C5ORF42 is tied with 519 other genes. 
Table S2- Frequency of rare mutations in the candidate genes. We have observed that 
certain genes frequently have private mutations in our previous samples. To quantify this, we 
determined the number of “rare” mutations in each of 20870 genes annotated in Ensembl, 
where we defined a rare mutation as one with a 1000 genomes minor allele frequency < 0.005 
and which was seen in two or fewer of our control exomes. The table shows the number of 
such rare mutations in our 261 control exomes for the frequently mutated genes in which 
multiple mutations were found in 3 JBTS families each. 
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Figure S1: Amino acid conservation of the residues affected by the p.D1556V and 
p.E1126K mutations in CC2D2A. Amino acid alignments were generated using homologene 
(NCBI). 
 
 
 
 
Figure S2: Segregation of p.D1556V and p.E1126K CC2D2A mutations. We identified 
compound heterozygous mutations in CC2D2A (c.G3376A/p.D1556V and 
c.A4667T/p.E1126K, numbering according to Refseq NM_001080522.2) in two unrelated 
individuals with JBTS.  These mutations are predicted to be damaging according to SIFT and 
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Figure S1. Amino acid conservation of the residues affected by the p.Asp1556Val and 
p.Glu1126Lys mutations in CC2D2A. Amino acid alignments were generated using homologene 
(NCBI).  
 
 
 
Figure S2. Segregation of p.Asp1556Val and p.Glu1126Lys CC2D2A mutations. We identified 
compound heterozygous mutations in CC2D2A (c.3376G>A/p.Asp1556Val and 
c.4667A>T/p.Glu1126Lys, numbering according to Refseq NM_001080522.2) in two unrelated 
individuals with JBTS.  These mutations are predicted to be damaging according to SIFT and 
Polyphen-2. Both individuals had a mild phenotype with oculomotor apraxia and mild 
developmental delay. 
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Figure S1. Amino acid conservation of the residues affected by the p.Asp1556Val and 
p.Glu1126Lys mutations in CC2D2A. Amino acid alignments were generated using homologene 
(NCBI).  
 
 
 
Figure S2. Segregation of p.Asp1556Val and p.Glu1126Lys CC2D2A mutations. We identified 
compound heterozygous mutations in CC2D2A (c.3376G>A/p.Asp1556Val and 
c.4667A>T/p.Glu1126Lys, numbering according to Refseq NM_001080522.2) in two unrelated 
individuals with JBTS.  These mutations are predicted to be damaging according to SIFT and 
Polyphen-2. Both individuals had a mild phenotype with oculomotor apraxia and mild 
developmental delay. 
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Polyphen-2. Both patients had a mild phenotype with oculomotor apraxia and mild 
developmental delay. 
 
 
Figure S3. Schematic diagram showing shared haplotypes in region surrounding 
C5ORF42 in the JBTS patients. Patient numbers are noted in the left-hand column. 
Chromosome 5 coordinates are noted on the horizontal axis (hg19). Position of C5ORF42 is 
identified by the red arrow. The Homozygosity Haplotype (HH) method 1, 2 was used to 
assess whether patients with identical C5ORF42 mutations shared a common haplotype 
around C5ORF42. Briefly, instead of formally phasing haplotypes, the HH method uses a 
reduced haplotype described only by the homozygous SNPs (the heterozygous SNPs are 
removed) from the high density SNP genotyping data. Patients who inherited the same 
mutation from a common ancestor share a chromosomal segment identical by descent 
around the mutation, and do not have discordant homozygous calls in that region. Analysis 
shows that patients with identical mutations share a common haplotype around C5ORF42 
spanning 5.03Mb (chr5:32,889,034-37,922,612) for the p.A1564T mutation, 4.61Mb 
(chr5:34,742,426-39,357,425) for the c.7400+1G>A mutation and 7.8Mb (chr5:35,054,389-
42,823,549) for the p.R1336W mutation. 
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Figure S4. Coverage histograms of RefSeq unannotated C5ORF42 exon 40a (in red box) 
in different tissues. The vertical grey bars indicate the number of reads from (a) testis, (b) 
brain and (c) a mixture of adipose, adrenal, breast, colon, heart, kidney, liver, lung, lymph, 
ovary, prostate,  skeletal muscle, thyroid, and white blood cell tissues. The proportions of 
reads containing the target exon versus the ones that do not are respectively (a) 21/23, (b) 
13/18 and (c) 44/130. Reads were controlled for quality using FastX tools, assembled with 
TopHat, indexed with SAMtools and displayed with IGV. The tissue mixture (c) was obtained 
by merging the reads from the various tissues using SAMtools. 
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Following the publication of the previous manuscript, we identified 8 additional 
French-Canadian JBTS families from other regions of Quebec.  We performed WES in these 
affected individuals, and analyzed the data by combining the WES datasets of all our 
unexplained JBTS individuals. 
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ABSTRACT 
 
Background: Joubert syndrome (JBTS) is a predominantly autosomal recessive disorder 
characterized by a distinctive mid-hindbrain malformation, ocular-motor apraxia, breathing 
abnormalities and developmental delay. JBTS is genetically heterogeneous, involving genes 
required for formation and function of non-motile cilia. Here we investigate the genetic basis 
of JBTS in 12 French Canadian individuals. Methods and Results: Exome sequencing in all 
subjects showed that six carried rare compound heterozygous mutations in CC2D2A or 
C5ORF42, known JBTS genes. In addition, three individuals (2 families) were compound 
heterozygous for the same rare mutations in TMEM231(c.12T>A[p.Tyr4*]; 
c.625G>A[p.Asp209Asn]). All three subjects showed a severe neurological phenotype and 
variable presence of polydactyly, retinopathy and renal cysts. These mutations were not 
detected among 385 French Canadian controls. TMEM231 has been previously shown to 
localize to the ciliary transition zone and interact with several JBTS gene products in a 
complex involved in the formation of the diffusion barrier between the cilia and plasma 
membrane. siRNA knockdown of TMEM231 was previously shown to affect barrier integrity, 
resulting in a reduction of cilia formation and ciliary localization of signaling receptors. 
Conclusion: Our data suggest that mutations in TMEM231 cause JBTS, reinforcing the 
relationship between this condition and the disruption of the barrier at the ciliary transition 
zone. 
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 Joubert syndrome (JBTS [MIM213300]) is a predominantly autosomal recessive 
disorder characterized by ocumolotor apraxia, abnormal breathing, ataxia, and variable 
developmental delay or intellectual impairment (reviewed in Sattar et al)(75). A cardinal sign 
of JBTS is the presence of a complex mid-hindbrain malformation consisting of hypoplasia of 
the cerebellar vermis, abnormally deepened interpeduncular fossa at the level of the upper 
pons and elongated and thickened superior cerebellar peduncles. This malformation takes the 
appearance of a molar tooth on MRI. Extra-neurological manifestations, including 
retinopathy, renal cysts and polydactyly, are present in a subset of affected individuals. JBTS 
is genetically heterogeneous, with 17 genes described to date (41-44, 47, 50, 53-57, 76, 77),  
all of which appear to play a role in the development and/or function of nonmotile cilia. 
 
There is a high prevalence of JBTS in the French Canadian (FC) population of the 
Lower Saint-Lawrence region of Quebec. We recently performed exome sequencing in 15 
individuals (11 families) with JBTS from that region and found that mutations in C5ORF42 
explain JBTS in 9 individuals (seven families)(77). In addition, we identified pathogenic 
compound heterozygous mutations in CC2D2A, a previously known JBTS gene, in 2 affected 
individuals from 2 different families. The genetic basis of JBTS remained unexplained in 4 
individuals (2 families) from this initial study. Here, we follow up on our previous 
investigation by performing exome sequencing in 8 additional individuals with JBTS (6 
unrelated families) originating from other regions of Quebec. 
 
The 6 probands had a molar tooth sign (MTS) on imaging, and variable expression of 
the classical JBTS features. The two additional individuals are the uncle (II-4) and aunt (II-6) 
of subject IV-1 in family 385/447. These individuals were considered to have a variable 
expression of JBTS as they both had oculomotor apraxia, and II-4 additionally had gait ataxia 
and a history of developmental delay. Brain MRI was normal in II-6 but was not done in II-4. 
Informed consent was obtained from each individual or legal guardian. This study was 
approved by our institutional ethics committee. Genomic DNA from each sample was 
captured with the Agilent SureSelect 50 Mb exome capture oligonucleotide library, and the 
captured DNA was sequenced with paired-end 100 bp reads on Illumina HiSeq 2000 resulting 
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in an average of 12.7 gigabases (Gb) of raw sequence for each sample. Data were analyzed as 
previously described(63). After removing putative PCR-generated duplicate reads using 
Picard (v. 1.48), we aligned reads to human genome assembly hg19 using a Burroughs-
Wheeler algorithm (BWA v. 0.5.9). Median read depth of bases in consensus coding sequence 
(CCDS) exons was 99 (determined with Broad Institute Genome Analysis Toolkit v. 
1.0.4418)(64). On average 87% (±2.0%) of bases in CCDS exons were covered by at least 20 
reads. We called sequence variants using Samtools (v. 0.1.17) mpileup and varFilter, and 
required at least 3 variant reads as well as >=20% variant reads for each called position, with 
Phred-like quality scores of at least 20 for single nucleotide variants (SNVs) and at least 50 
for small insertions or deletions (indels). We used Annovar and custom scripts to annotate 
variants according to the type of mutation, occurrence in dbSNP, SIFT score, 1000 Genomes 
allele frequency, and NHLBI exomes allele frequency(66). To identify potentially pathogenic 
variants we filtered out: 1) synonymous variants or intronic variants other than those affecting 
the consensus splice sites; 2) variants seen in more than two of 416 exomes from patients with 
rare, monogenic diseases unrelated to JBTS that were sequenced at the McGill University and 
Genome Quebec Innovation Centre; and 3) variants with a frequency greater than 0.5% in 
either the 1000 genomes or NHLBI exome datasets. 
 
We first examined the 8 exome datasets to look for rare variants in the 17 known 
JBTS genes (INPP5E[MIM613037], TMEM216[MIM613277], AHI1[MIM608894], 
NPHP1[MIM607100], CEP290[MIM610142], TMEM67[MIM609884], 
RPGRIP1L[MIM610937], ARL13B[MIM608922], CC2D2A[MIM612013], 
CXORF5[MIM300170], KIF7[MIM611254], TCTN1 [MIM609863], TCTN2[MIM613885], 
TMEM237[MIM614424], CEP41[MIM610523], TMEM138[MIM614459], 
C5ORF42[MIM614571](41, 43, 45, 49, 50, 52, 54, 58, 75, 78) as well as in the JBTS 
candidate gene TTC21B(MIM612014)[17]. Five individuals from 3 families (II-1 from family 
379, II-4, II-6 and IV-1 from family 385/447, and II-1 from family 492- Figure S1, p. 58) 
were each found to carry two rare heterozygous variants in CC2D2A(NM_001080522.2). One 
in-frame amino acid deletion (c.3450_3452del[p.Val1151del]) and 4 different missense 
variants (c.3376G>A[p.Glu1126Lys], c.4559A>G[p.Asn1520Ser], 
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c.4667A>T[p.Asp1556Val], c.4702T>C[p.Tyr1568His]) were identified, two of which, 
c.3376G>A(p.Glu1126Lys) and c.4667A>T(p.Asp1556Val), were identified previously in FC 
individuals with JBTS(77). The novel mutations c.4559A>G(p.Asn1520Ser) and 
c.4702T>C(p.Tyr1568His) are predicted to be damaging (by SIFT, Polyphen-2 and Mutation 
Taster) and neither variant has been reported in the Exome Variant Server (EVS; NHLBI GO 
Exome Sequencing Project), dbSNP135 or 1000 Genome datasets. These five CC2D2A 
mutations cluster in either the C2 domain [amino acids 1062-1174] or the C-terminal part of 
the protein, as do most missenses that cause JBTS[18]. Segregation analysis revealed that all 
the affected individuals but none of their unaffected relatives were compound heterozygous 
for the mutations (Figure S1, p. 58). We conclude that these mutations are pathogenic and 
responsible for JBTS in these 5 individuals.  
 
We also identified a frameshift mutation (c.8257_8258insA[p.Lys2753fs]) and a 
splice-site mutation (c.7400+1G>A) in C5ORF42(NM_023073.3) in individual II-2 from 
family 551. Sanger sequencing showed that the proband is compound heterozygous for these 
mutations. The splice site (c.7400+1G>A) mutation has been previously identified in patients 
with JBTS and shown to result in skipping of exon 35 and the creation of a premature stop 
codon while c.8257_8258insA(p.Lys2753fs), which is novel, is predicted to truncate 
C5ORF42 in the middle of its sequence, close to where other truncating mutations have been 
previously identified in JBTS patients(77). Both C5ORF42 mutations are thus considered 
pathogenic in this individual. Table 6 summarizes the genotypes and phenotypes of these 
patients with mutations in CC2D2A and C5ORF42 as well as those of FC patients previously 
described with mutations in these genes. Individuals in our cohort with mutations in CC2D2A 
do not have any extra-neural manifestations, and appear to have a milder phenotype, with all 
affected individuals walking independently before the age of 4 years, and intelligence ranging 
from normal to mild intellectual impairment. Individuals with mutations in C5ORF42 have a 
more variable phenotype. They have borderline to moderate cognitive impairment and age at 
walking ranging between 30 months and 8 years. Some patients also showed limb 
abnormalities, including one individual with combined pre- and post-axial polydactyly, an 
unusual finding in JBTS, which is typically associated with post-axial polydactyly. 
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We then combined the exome data of the 2 remaining individuals with unexplained 
JBTS and the exome data of 4 individuals with unexplained JBTS from our previous 
study[12], making a total of 6 individuals from 4 different families. We analyzed the data by 
looking for protein-coding genes that contained homozygous or multiple heterozygous 
variants in each affected individual. For multiplex families, we only considered genes with 
the same variants in the affected siblings (Supplemental Tables 1 and 2, pages 60-61). Only 
one gene, TMEM231, harbored 
multiple rare mutations in more 
than one family. Three JBTS 
individuals from 2 families (II-1 
and II-2 from family 387, and 
II-1 from family 483) harbored 
the same two variants in 
TMEM231(NM_001077418.1): 
c.12T>A(p.Tyr4*) and 
c.625G>A(p.Asp209Asn). 
Sanger sequencing showed that 
all affected individuals were 
compound heterozygous for 
these variants (Figure 9A). The 
c.12T>A(p.Tyr4*) mutation 
targets exon 1 of the canonical 
isoform of 
TMEM231(NM_001077418.1; 
ENST00000258173), as well as 
the 2 other predicted protein-
coding isoforms reported in the 
Ensemble Genome Browser. In 
ENST00000565067 it leads to 
the same nonsense change 
cohort. They are dependent in all activities of daily living, are
non-verbal, and can take steps only if assisted with a walker.
Both siblings from family 387 had signiﬁcant aggressive and
self-mutilating behaviour consisting of head banging and
biting, requiring treatment with antipsychotic agents, mouth
guard and protective helmet. Individuals II-2 from family 387
and II-1 from family 483 show extraneural manifestations con-
sisting of retinopathy, bilateral macroscopic renal cysts (but
normal renal function), and postaxial polysyndactyly of one
foot (table 1 and see online supplementary ﬁgure S1, D-F).
The presence of rare and potentially deleterious mutations in
TMEM231, which segregate with the disease in two unrelated
FC families, strongly suggests that disruption of this gene
causes JBTS in our subjects. The fact that the three individuals
with the mutations in TMEM231 show a similar form of JBTS
also supports the involvement of this gene. Furthermore,
several observations indicate that TMEM231 plays a key role in
the cilia, and physically interacts with known JBTS genes.
TMEM231 encodes a transmembrane protein that localises at
the base of the ciliary axoneme at the transition zone.19
Recently, TMEM231 was shown to be part of the B9 complex,
which is required for a diffusion barrier between the cilia and
plasma membranes that maintains the integrity of the cilia as a
privileged membrane domain.19 The B9 complex includes at
least 13 proteins (BD91, BD92, TCTN1, TCTN2, TCTN3,
CC2D2A, TMEM216, TMEM67, TMEM237, TMEM231,
MKS1, AHI1, TMEM17), all of which, with two exceptions
(TCTN3, TMEM17), are involved in JBTS and/or Meckel–
Gruber syndrome (MKS), a related ciliopathy.19 20 Proteomic
studies using the MKS proteins BD91 or BD92 as baits have
shown that TMEM231 is in a complex with TCTN1, TCTN2,
MKS1, AHI1 and CC2D2A.19 siRNA knockdown of TMEM231
disrupts the integrity of the ciliary barrier and the localisation
of components of the B9 complex at the transition zone, result-
ing in a reduction of cilia formation and ciliary localisation of
signalling receptors.19 TMEM231 knockout mice die at E15.5
with severe vascular defects, and display typical features of
ciliopathy, namely microphthalmia, polydactyly and
Figure 1 (A) Segregation of mutations in TMEM231 in JBTS families. (B) Brain MRI from individual II-1 from family 387 showing the ‘molar tooth
sign’. (C) Left panel, scheme showing the presence of the mutations with respect to the different TMEM231 Ensemble-annotated transcripts
predicted to produce proteins; right panel, the corresponding TMEM231 proteins are depicted in the right panel. TM, denotes the presence of a
transmembrane domain, as predicted by SMART algorithm. (D) Amino acid conservation of the residues affected by the p.Tyr4* and p.Asp209Asn
mutations in TMEM231. Amino acid alignments were generated using homologene (NCBI).
J Med Genet 2012;49:636–641. doi:10.1136/jmedgenet-2012-101132 639
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Figure 9. TMEM231 mutations identified in JBTS 
individuals. (A) Segregation of mutations in TMEM231 in 
JBTS families. (B) Brain MRI from individual II-1 from family 
387 showing the “molar tooth sign”; (C) Left panel, scheme 
showing the presence of the mutations with respect to the 
different TMEM231 E semble-annotated tra scripts 
predicted to produce proteins; right panel, the 
corresponding TMEM231 protein  are d picted in the right 
panel. TM, denotes the presence of a transmembrane 
d m in, as predicted b  SMART algorithm.  (D) Amino acid 
conservation of the residues affected by the p.Tyr4* and 
p.Asp209Asn mutatio s in TMEM231. Amin  acid 
alignments were generated using homologene (NCBI).  
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(p.Tyr4*), while in the longer isoform ENST00000398114 it abolishes the translation 
initiation methionine (c.2T>A[p.  Met1?]), which would likely prevent translation of this 
isoform due to the absence of any other in-frame methionine in exons 1 and 2. The 
c.625G>A(p.Asp209Asn) causes the same amino acid change in the different TMEM231 
predicted isoforms (Fig.9C). It affects a highly conserved amino acid (Fig.9D), and is 
predicted to be damaging by Polyphen-2 and Mutation Taster but not by SIFT. Both p.Tyr4* 
and p.Asp209N are extremely rare. Amongst the 416 in-house exomes, the c.12T>A(p.Tyr4*) 
was not found, and the c.625G>A(p.Asp209Asn) variant was seen in the heterozygous state in 
one FC individual. No additional TMEM231 coding/splicing variants were present in this 
individual’s exome. To determine the carrier rate of c.625G>A and c.12T>A, we genotyped 
385 healthy FC controls by Sanger sequencing but did not find any carriers of either of these 
mutations, indicating that they are very rare. Only p.Asp209Asn is reported in the 1000 
genomes and EVS, but at a very low frequency (0.01%), while p.Tyr4* is not reported in any 
of these public SNP databases. Furthermore, no truncating mutations in TMEM231 were seen 
in 416 control exomes of patients with other rare diseases, and only one other truncating 
variant (stopgain SNV) is reported in EVS, at a frequency of 0.04%.  For the three individuals 
with compound heterozygous TMEM231 mutations, we examined all SNV genotypes in 
regions surrounding the two mutations. This revealed a region of shared genotypes (two 
shared haplotypes) extending over at least 1.7 Mb, suggesting the existence of founder effects 
(Supplemental Table S1, p.60). 
 
 The three individuals with mutations in TMEM231 are amongst the most severely 
affected in our French-Canadian JBTS cohort. They are dependent in all activities of daily 
living, are non-verbal, and can take steps only if assisted with a walker. Both siblings from 
family 387 had significant aggressive and self-mutilating behavior consisting of head banging 
and biting, requiring treatment with antipsychotic agents, mouth guard and protective helmet. 
Individuals II-2 from family 387 and II-1 from family 483 show extra-neural manifestations 
consisting of retinopathy, bilateral macroscopic renal cysts (but normal renal function), and 
post-axial polysyndactyly of one foot (Table 6).  
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Table 1 Genotypes and phenotypes of French Canadian individuals with JBTS
Genotypes
Srour et al12 This study
406/301 394 474 480 489 479 468 473 484 385/447 379 492 551 387 483
IV-1 IV-2 IV-3 II-1 II-2 II-1 II-1 II-1 II-1 II-1 II-2 II-1 II-4 II-6 IV-1 II-1 II-1 II-2 II-1 II-2 II-1
C5ORF42
c.4006C>T(p.Arg1336Trp) + − − + + + + − + + − − − − − − − − − − −
c.7400+1G>A + + + + + + − − − − − − − − − − + − − −
c.6407del(p.Pro2136Hisfs*31) − − − − − + − − − − − − − − − − − − − − −
c.7477C>T(p.Arg2493*) − − − − − − − + − − − − − − − − − − − − −
c.4804C>T(p.Arg1602*) − − − − − − − − + − − − − − − − − − − − −
c.7957+288G>A; c.4690G>A(p.Ala1564Thr) − + + − − − − + − + − − − − − − − − − − −
c.8257_8258insA(p.K2753fs) − − − − − − − − − − − − − − − − − + − − −
CC2D2A
c.4667A>T(p.Asp1556Val) − − − − − − − − − − + + − − + − + − − − −
c.3376G>A(p.Glu1126Lys) − − − − − − − − − − + + + + + + − − − − -−
c.4559A>G(p.Asn1520Ser) − − − − − − − − − − − − + + − − − − − − −
c.4702T>C(p.Tyr1568His) − − − − − − − − − − − − − − − + − − − − −
c.3450_3452del(p.Val1151del) − − − − − − − − − − − − − − - - + - - - -
TMEM231
c.12T>A(p.Tyr4*) − − − − − − − − − − − − − − − − − − + + +
c.625G>A(p.Asp209Asn) − − − − − − − − − − − − − − − − − − + + +
Age (years) 8 1.5 3 52 45 4 10 7 13 31 3 12 62 53 5 10 5 16 14 9 4
Developmental delay + + + + + + + + + + Mild Mild + − + + + + + + +
Age at walking Walks with aid Not amb NA NA walks 3 Not amb 8 3.5 7 2.5 1.5 1.5 4 1 2 4 2.5 7 Not amb Not amb Not amb
Oculomotor apraxia − + + + + + + + + + + + + + + + + − + + +
Breathing abnormality + + + + + + + + − − − − − − − + − + + + +
Limb abnormality† − + − − − + − − − − − − − − − − − − − + +
Brain MRI MTS MTS MTS ND MTS MTS MTS MTS MTS MTS MTS MTS NA N MTS MTS MTS MTS MTS MTS MTS
Retinal involvement‡ −(f ) −(e) −(e) −(h) −(h) −(f ) −(e) −(e) −(f ) −(h) −(e) −(e) −(f ) −(e) −(e) −(e) −(e) −(f ) −(f ) +(f) +(e)
Renal involvement§ −(us) −(us) −(us) −(h) −(h) −(us) − (us) −(us) −(us) −(h) −(us) −(h) −(h) −(h) −(us) −(us) −(h) −(us) −(us) +(us) +(us)
The nucleotide and amino acid positions for CC2D2A are based on reference sequence #NM_001080522.2, for TMEM231on reference sequence #NM_001077418.1, and for C5ORF42 on reference sequence #NM_023073.3 except for c.G4690A/p.A1564T
that is based on ENSEMBLE transcript ID #ENST00000509849.
†IV-2 from family 406/301 has a 3–4 syndactyly in the left hand, II-1 from family 474 has pre- and postaxial polydactyly of the four limbs, and II-2 from family 387 and II-1 from family 483 have postaxial polydactyly and 4-5-6 syndactyly of the right foot.
‡Retinal involvement was determined by electroretinogram (erg), fundoscopy (f) or history (h).
§Renal involvement was determined by renal ultrasound (us) or history (h). Individuals II-2 from family 387 and II-1 from family 483 have renal cysts with normal renal function.
MTS, Molar tooth sign; N, normal; NA, not available; Not amb, Not ambulatory.
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Table 6: Genotypes and phenotypes of French Canadian individuals with JBTS 
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The presence of rare and potentially deleterious mutations in TMEM231, which 
segregate with the disease in two unrelated FC families, strongly suggests that disruption of 
this gene causes JBTS in our subjects.  The fact that the three individuals with mutations in 
TMEM231 show a similar form of JBTS also supports the involvement of this gene.  
 
 
 Furthermore, several observations indicated that TMEM231 plays a role in the cilia 
and physically interacts with known JBTS genes.  TMEM231 encodes a transmembrane 
protein that localizes at the base of the ciliary axoneme at the transition zone(79). Recently, 
TMEM231 was shown to be part of the B9 complex, which is required for a diffusion barrier 
between the cilia and plasma membranes that maintains the integrity of the cilia as a 
privileged membrane domain[19]. The B9 complex includes at least 13 proteins (BD91, 
BD92, TCTN1, TCTN2, TCTN3, CC2D2A, TMEM216, TMEM67, TMEM237, TMEM231, 
MKS1, AHI1, TMEM17), all of which, with two exceptions (TCTN3, TMEM17), are 
involved in JBTS and/or Meckel-Gruber syndrome (MKS), a related ciliopathy(18, 79). 
Proteomic studies using the MKS proteins BD91 or BD92 as baits have shown that TMEM231 
is in a complex with TCTN1, TCTN2, MKS1, AHI1 and CC2D2A(79). siRNA knockdown of 
TMEM231 disrupts the integrity of the ciliary barrier and the localization of components of 
the B9 complex at the transition zone, resulting in a reduction of cilia formation and ciliary 
localization of signaling receptors[19]. TMEM231 knock-out mice die at E15.5 with severe 
vascular defects and display typical features of ciliopathy, namely microphthalmia, 
polydactyly and abnormalities in patterning of ventral spinal cord(79). All together, these 
observations indicate that autosomal recessive mutations in TMEM231 are a cause of JBTS. 
 
JBTS in French Canadians show both locus and allelic heterogeneity. We identified 
three JBTS genes in this population with a total of 14 different alleles. Three mutations in 
C5ORF42, two mutations in CC2D2A and two mutations in TMEM231 were found in at least 
two unrelated affected individuals (Table 6). Our analysis indicates that each of these 
mutations is located within a distinct haplotype in these individuals, suggesting the existence 
of multiple founder effects(77). Founder effects are typically associated with an increase in the 
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frequency of a specific autosomal recessive allele, which is often accompanied by other alleles 
that remain at their usual background frequency. Interestingly, for each of these three JBTS 
genes, we found at least two founding mutations. It is likely that more of these complex 
founder effects will be unraveled with the use of genomic sequencing.  
 
In summary, combining this study and our previous one, we were able to explain the 
underlying genetic cause of JBTS in 21/24 FC individuals using exome sequencing. In the 
course of this work, we identified TMEM231 as a novel JBTS gene. This discovery gives 
further support to the concept that JBTS results from disruption of the barrier at the ciliary 
transition zone. 
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Supplemental Figures and Tables 
 
Supplemental	  Figure	  1:	  	  Segregation	  studies	  of	  mutations	  in	  CC2D2A	  (NM_001080522.2) in	  families	  385/447,	  379	  and	  492,	  and	  of	  mutations	  in	  C5ORF42	  (NM_023073.3) in	  family	  551.	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Supplemental	  Figure	  2:	  Sagittal	  T1(A)	  	  and	  axial	  T2	  (B)	  brain	  MRI	  of	  individual	  II:6	  from	  family	  385/447	  who	  has	  compound	  heterozygous	  mutations	  in	  CC2D2A,	  and	  ocumolotor	  apraxia	  as	  the	  sole	  manifestation.	  Right	  (C)	  and	  left	  (D)	  renal	  ultrasounds	  from	  individual	  II:2	  from	  family	  387	  with	  compound	  heterozygous	  mutations	  in	  
TMEM231	  showing	  macroscopic	  cysts	  (arrows).	  Post-­‐axial	  polysyndactyly	  in	  individual	  II:1	  from	  family	  483	  (Ei	  and	  ii)	  and	  II:2	  from	  family	  387	  (F	  i	  and	  ii).	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Supplemental Table 1. Analysis of combined exome sequences from the 6 individuals 
(from 4 families) with unexplained JBTS 	  
 
Variant prioritization steps in the combined exomes dataset 
 
Filters applied (sequentially) 
 
Number of variants retained 
 
Non-synonymous/splicing/coding indel variants 
 
19884 
 
After excluding variants present in  
> 2 in-house exomes 
 
1035 
 
After excluding variants reported in 1000 
genomes and EVS datasets (frequency > 0.5%) 
 
987 
 
*Total number of variants identified in the combined 6 exomes; redundant variants were 
counted only once. 
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Supplemental Table 2.  Genes with rare homozygous or multiple heterozygous variants 
in the 6 individuals (from 4 families) with unexplained JBTS 
 
Number of families with 
mutations in the same 
gene 
 
Number of genes Genes 
1 family 19 
 
C14orf135,C9orf174,CLCN1, 
ENTPD3,FBXL22,FCGR3B,FLG,LRR       
K2,MUC12,PDE8A,PPL,PUS10, 
RASIP1,RCC2,SHROOM4,TACC3, 
TMEM231, TRAF5,TTN 
2 families 1 TMEM231 
> 2 families 0 - 
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 We have collected 22 additional FC JBTS patients since the publication of the 
previous 2 manuscripts.  In total, we have identified 43 affected individuals from 35 families.  
We use a stepwise approach, combining screening of recurrent FC mutations and exome 
sequencing to study the genetic basis of JBTS in the newly identified individuals.  This third 
manuscript represents a summary of the genetic landscape of JBTS in French Canadians.  
 
Manuscript 3:  
Genetics of Joubert syndrome in the French Canadian population 
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Jacek Majewski2,4, Jacques L. Michaud1 
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ABSTRACT 
Joubert syndrome (JBTS) is a primarily autosomal recessive disorder characterized by 
a distinctive mid-hindbrain/cerebellum malformation, oculomotor apraxia, irregular breathing, 
developmental delay, and ataxia. JBTS is a genetically heterogeneous ciliopathy with 23 
known genes. We sought to characterize the genetic landscape associated with JBTS in the 
French Canadian (FC) population.  We characterized 43 FC JBTS patients from 35 families 
using a stepwise approach, combining screening of recurrent FC mutations and exome 
sequencing. We identified causal mutations in 32 families (91% of cases). Fourteen families 
had mutations in C5orf42, 9 in CC2D2A, 3 in NPHP1 and 2 in TMEM231 whereas single 
families had mutations in TCTN1, TMEM67 or B9D1. In addition, we report the first JBTS 
individual with mutations in C2CD3, previously associated with the related oral-facial-digital 
syndrome. Interestingly, we documented a complex founder effect with multiple recurrent 
mutations in 4 genes (C5orf42, CC2D2A, TMEM231, NPHP1). In the remaining families, we 
identified potentially pathogenic mutations in known JBTS genes (CEP290, OFD1) and in the 
cilia gene CEP104, which is therefore a strong candidate for JBTS. In conclusion, although 
JBTS shows substantial locus and allelic heterogeneity in the FC population, the great 
majority of cases are explained by mutations in known disease genes.  
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INTRODUCTION 
Joubert syndrome (JBTS, MIM #213300) is a predominantly autosomal recessive 
disorder characterized by oculomotor apraxia, hypotonia, neonatal breathing abnormalities, 
ataxia and variable developmental delay. The hallmark of JBTS is a malformation of the 
brainstem and cerebellum consisting of cerebellar vermis hypoplasia or aplasia, horizontal 
elongated cerebellar peduncles and a deep interpeduncular fossa that take on the 
pathognomonic appearance of a “molar tooth”.  A subset of patients with JBTS have also 
extraneural manifestations such as polydactyly, retinopathy, cystic kidneys and liver fibrosis 
(reviewed by Romani et al, 2013(80)).   
 JBTS is a ciliopathy, as the majority of the 23 known JBTS genes have been shown to 
play a role in the development and/or function of the non-motile cilia. The cilium is a 
compartmentalized extension of the extracellular membrane that functions as an antenna, 
sensing extracellular signals and transducing them intracellularly.  The cilium is composed of 
a microtubule-based cytoskeleton called the axoneme, which nucleates from the basal body, a 
modified centriololar structure.  At the base of the cilium, Y-shaped structures connect the 
basal body to the cell membrane, forming the transition zone, which constitutes a diffusion 
barrier between the cilium and the remainder of the plasma membrane (for review see (19)).  
The majority of JBTS genes encode proteins that localize to the basal body or ciliary transition 
zone.  Many of these proteins physically interact with one another to form large complexes. 
The most important complex in the pathogenesis of JBTS is the B9 complex (also known as 
tectonic complex), in which 9 of its known 15 members are associated with JBTS, Meckel 
syndrome (a related ciliopathy with overlapping features with JBTS including cystic kidneys, 
occipital encephalocele, polydactyly and/or biliary dysgenesis and congenital hepatic fibrosis), 
or both(18, 79, 81).  
 Although JBTS was first described in a French Canadian (FC) family in 1969(1), little 
is known about its molecular etiology in this population. We thus sought to characterize the 
genetic landscape associated with JBTS in the FC population.  We report here on a cohort of 
43 FC JBTS subjects, including 21 cases previously described(77, 82) and 22 new cases. 
Using a stepwise approach of Sanger and exome sequencing, we were able to explain most 
cases and identify a strong candidate gene. 
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METHODS 
Patients 
 All individuals included in the study are of FC ancestry and originated from various 
regions throughout Quebec. These subjects had a diagnosis of JBTS based on the presence of: 
1) at least one JBTS classical neurological manifestation (oculomotor apraxia, ataxia, history 
of breathing abnormalities); and 2) the molar tooth sign (MTS) on brain imaging in at least 
one affected family member (Supplemental figure S1). In addition, four fetuses were included 
in the study. All of these fetal cases showed cerebellar vermis hypoplasia or aplasia on 
prenatal imaging. One fetus had a sibling with JBTS whereas the three other cases showed 
elongated cerebellar peduncles, suggestive of JBTS. 
 
Screening of recurrent FC mutations in C5orf42, CC2D2A and TMEM231 
 We screened, by Sanger sequencing, all unexplained JBTS families in our cohort for 
the seven known recurrent FC mutations in CC2D2A (MIM 6120313, NM_001080522.2, 
c.3376G>A [p.Glu1126Lys] and c.4667A>T [p.Asp1556Val]), C5orf42 (MIM 614571, 
NM_023073.3, c.4006C>T [p.Arg1336Trp], c.7400+1G>A and ENSEMBLE transcript ID# 
ENST00000509849, c.4690G>A [p.Ala1564Thr]) and TMEM231 (MIM 614949, 
NM_001077418.1, c.12T>A [p.Tyr4*]; c.625G>A [p.Asp209Asn])(77, 82).  
 
Whole exome sequencing (WES) and initial variant filtering 
 WES was performed in all individuals in whom Sanger sequencing or clinical testing 
did not identify causal mutations. Genomic DNA from each sample was captured with the 
Agilent SureSelect 50 Mb exome capture oligonucleotide library, and the captured DNA was 
sequenced with paired-end 100 bp reads on Illumina HiSeq 2000 resulting in an average of 
12.8 gigabases (Gb) of raw sequence for each sample. Exome capture and sequencing was 
performed at the McGill University and Genome Quebec Innovation Center (MUGQIC). Data 
were analyzed as previously described(62). We aligned reads to human genome assembly 
hg19 using a Burrows-Wheeler algorithm (BWA v. 0.5.9), then removed putative PCR-
generated duplicate reads using Picard (v. 1.48). Median read depth of bases in consensus 
coding sequence (CCDS) exons was 102 (determined with Broad Institute Genome Analysis 
Toolkit v. 1.6.7)(63). On average 91% (±3%) of bases in CCDS exons were covered by at 
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least 20 reads. We called sequence variants using Samtools (v. 0.1.17) mpileup and  bcftools, 
and required at least 3 variant reads as well as >=20% variant reads for each called position, 
with Phred-like quality scores of at least 20 for single nucleotide variants (SNVs) and at least 
50 for small insertions or deletions (indels). We used Annovar(64) and custom scripts to 
annotate variants according to the type of mutation, occurrence in dbSNP, SIFT score, 1000 
Genomes minor allele frequencies, and NHLBI Exome Sequencing Project (ESP) exomes 
minor allele frequencies, available from the Exome Variant Server (EVS). To identify 
potentially pathogenic variants we filtered out: 1) synonymous variants or intronic variants 
other than those affecting the consensus splice sites; 2) variants seen in more than 5 of 1128 
exomes from patients with rare, monogenic diseases unrelated to JBTS that were sequenced at 
the MUGQIC; and 3) variants with a minor allele frequency greater than 0.5% in either the 
1000 genomes or NHLBI ESP exome datasets. 
 
RESULTS 
 We identified 43 FC cases with JBTS (from 35 families) who met our inclusion 
criteria.  We previously explained JBTS in 21 of these cases who showed pathogenic 
mutations either in C5orf42, TMEM231 or CC2D2A(77, 82) ((see supplemental Table S1). 
Since publication of these cases one family with mutations in C5orf42 had an affected fetus 
(family 474 in Srour et al, 2012(77)). Causal mutations were identified on a clinical basis in 7 
additional individuals.  Two patients (HSJ-JBTS-3 and HSJ-JBTS-4) had a homozygous 
c.4006C>T [p.Arg1336Trp] mutations in C5orf42. Two patients had mutations in NPHP1: 
individual 1712.604 had a 0.152 Mb homozygous deletion on chromosomal microarray on 
chromosome 2q13 (110,826,262-110,978,224, GRCh37/hg19 genome assembly) 
encompassing NPHP1, and individual 1915.669 had a homozygous frameshift c.555delA 
[p.Lys185Asnfs*7] in NPHP1.  Parents were confirmed carriers of the mutations. Individual 
HSJ-JBTS-1 had a homozygous mutation in TMEM67 (NM_153704.5, c.2132A>C 
[p.Asp711Ala]).  This mutation has been previously identified in a French patient with 
JBTS(47). Individual 1123.415 harbored compound heterozygous mutations in CC2D2A 
(NM_001080522.2, c. 4667A>T [Asp1556Val] and c.3544T>C [Trp1182Arg]).  The c. 
4667A>T missense is a recurrent FC mutation, and the c.3544T>C has been previously 
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reported as pathogenic in a patient with nephronophthisis(83). In total, 14 JBTS cases from 12 
families remained unexplained. 
 
Screening of recurrent FC mutations by Sanger sequencing  
 Our previous JBTS WES studies established the presence of a complex founder effect 
in FC JBTS cases with a total of 7 recurrent mutations in C5orf42, CC2D2A and 
TMEM231(77, 82).  We screened all our unexplained JBTS families (n=12) for these known 
recurrent mutations. Two individuals had homozygous or compound heterozygous mutations 
in C5orf42 (1673.590 and 1951.677) and 2 individuals from the same family had compound 
heterozygous mutations in CC2D2A (1342.488 and 1343.488) (Table 7). Screening identified 
a single heterozygous mutation in CC2D2A in one individual (1610.572), and a single 
heterozygous mutation in C5orf42 in a second individual (2049.708). Sequencing the 
remaining exons of C5orf42 in individual 2049.708 revealed a heterozygous truncating 
mutation (NM_023073.3, c.6354dupT [p.Ile2119Tyrfs*2]) whereas sequencing the remaining 
exons of CC2D2A in individual 1610.572 identified a heterozygous canonical splice-site 
mutation (c.2181+G>A) (Table 2).  Both cases were compound heterozygotes for their 
respective mutations. 
 
Identification of mutations in known JBTS genes by exome sequencing 
 Identification of mutations in known JBTS genes by exome sequencing 
 WES was performed in 8 individuals from the remaining 7 families in whom we did 
not identify recurrent FC mutations in C5orf42, CC2D2A and TMEM231. We first looked at 
the exome datasets for rare variants in the 23 genes already associated with JBTS (INPP5E 
[MIM 613037], TMEM216 [MIM 613277], AHI1 [MIM 608894], NPHP1 [MIM 607100], 
CEP290 [MIM 610142], TMEM67 [MIM 609884], RPGRIP1L [MIM 610937], ARL13B 
[MIM 608922], CC2D2A [MIM 612013], CXORF5 (OFD1) [MIM 300170], KIF7 [MIM 
611254], TCTN1 [MIM 609863], TCTN2 [MIM 613885], TMEM237 [MIM 614424], CEP41 
[MIM 610523], TMEM138 [MIM 614459], C5orf42 [MIM 614571] , TMEM231 [MIM 
614949], TCTN3 [MIM 613847], ZNF423 [MIM 604557], CSPP1 [MIM 611654], B9D1 
[MIM 614209](41-53, 55-58, 76, 77, 82, 84-88) as well as the JBTS candidate gene TTC21B 
[MIM 612014](65).  
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In one individual (1310.476), we identified a homozygous frameshift c.555delA 
[p.Lys185Asnfs*7] in NPHP1 (NM_207181.2), the same one that was identified in individual 
1915.669. However, array genomic hybridization showed that the patient is also heterozygous 
for a 116 kb deletion on chromosome 2q13 (110,862,369-110,978,000, GRCh37/hg19 genome 
assembly) encompassing NPHP1.  This deletion is similar to that found in patient 1712.604.  
The mother was heterozygous for the frameshift mutation, but paternal DNA was unavailable. 
It is thus appears that the proband in this family is a compound heterozygous for mutations in 
NPHP1.  
 
In one fetus (HSJ-JBTS-2), we identified compound heterozygous mutations in TCTN1 
(NM_001082538.2; c.342-2A>C and c.898C>T [p.Arg300*]).  The splicing mutation c.342-
2A>C had previously been reported to be causative for JBTS(54). This fetus came to medical 
attention because of the presence of a small vermis, large cerebellomedullary cistern, 
elongated cerebellar peduncles, and post-axial polydactyly of the hands on the ultrasound and 
MRI (supplemental figure 
S2, p. 53). It should be 
noted that 
neuropathological 
examination showed 
severe hypoplasia of the 
posterior vermis and 
dysmorphism of the 
dentate and olivary nuclei 
without elongation of the 
cerebellar peduncles.   
In one individual 
(1639.581), we identified 
a nonsense 
(c.493C>T[p.Gln165*], 
NM_001243473.1) and a 
2 3 
c.151T>C  
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1 
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2 I 
II 
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H.sapiens 47   EEGISQITSK  57 140   RRPEYTDPKVVA   151 
M.mulatta     47   EEGISQITSK  57 140   RRPEYTDPKVVA   151 
C.lupus  47   EEGISQITSK  57 140   RRPEYTDPKVVA   151 
M.musculus 47   EEGISQIASK  57 140   RRPEYTDPKVVA  151 
R.norvegicus   47   EEGISQIASK  57 140   RRPEYTDPKVVA   151 
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Figure 10: Segregation of mutations in candidate JBTS 
genes. (A, B, C) Segregation of mutations within families in 
B9D1 (A), C2CD3 (B) and CEP104 (C). The panels on the 
right show conservation of the affected amino acids in B9D1 
and C2CD3. Amino acid alignments were generated using 
homologene (NCBI). 
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missense (c.151T>C [p.Ser51Pro], NM_015681.3) variant in B9D1 (Table 7).  These variants 
are both extremely rare as they are absent in EVS.  The c.151T>C [p.Ser51Pro] missense 
mutation is predicted to be damaging on Polyphen-2 and SIFT (score=0.989 and =0.0 
respectively).  Sanger sequencing showed that the proband is compound heterozygous for 
these mutations (Figure 10A). Similarly to the previously-described JBTS individuals with 
mutations in B9D1, our patient has a mild phenotype. He had congenital clubfeet and mild 
developmental delay. He walked at 18 months and benefited from speech therapy for a 
language delay. He has normal intelligence and attended college.  He has mild gait ataxia, 
dysarthria and oculomotor apraxia, but no retinal, renal or liver involvement.  Brain imaging 
showed the presence of the MTS.	  	  
 
Case 1767.621 is a fetus in whom prenatal ultrasound showed findings consistent with 
the MTS. In addition, the fetus showed occipital encephalocele, olfactory bulb agenesis, 
polydactyly and renal cysts. This case thus has some features of both JBTS and Meckel 
syndromes.  We identified 2 rare compound heterozygous variants in CEP290: a missense 
c.6401T>C [p.Ile2134Thr] and a canonical splice-site mutation, c.4195-1G>A 
(NM_025114.3). This acceptor splice-site mutation has been previously reported in a patient 
with a JBTS-related ciliopathy, Senior-Lorken syndrome (nephrophthiasis and congenital 
leber amaurosis)(89). The c.6401T>C missense is predicted damaging by Polyphen-2 
(score=0.99) and Mutation Taster but tolerated by SIFT (score=0.51).  It affects an aminoacid 
that is perfectly conserved down to the lower vertebrates.  However, it is found at a minor 
allele frequency of 0.55% in EVS (64/11600), and at a relatively high frequency of 2.2% in in-
house FC samples, suggesting that it is unlikely to be pathogenic. Sanger sequencing did not 
show any other rare variant in CEP290 or in the other known JBTS genes. Moreover, search 
for a deletion or duplication in CEP290 using multiplex ligation-dependent probe 
amplification was negative. Subsequently, the mother became pregnant of a second fetus, 
which showed the same phenotype and genotype as the proband. It is unclear whether the 
c.6401T>C missense is pathogenic, whether these fetuses carry another yet unidentified 
mutation in CEP290, or whether JBTS in this family is explained by mutations in another 
gene. 
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 In a fourth case (1686.595), we identified a hemizygous c.920T>A [p.Val307Asp] 
missense in OFD1 (NM_003611.2), on chromosome X. This missense, which is located in a 
coiled-coil domain, is predicted damaging on Polyphen-2 (score=0.995) but tolerated on SIFT 
(score= 0.60) and Mutation Taster.  It is absent in EVS.  Segregation studies were not 
performed as parental DNA was unavailable. It remains unclear whether this mutation is 
pathogenic.  
 
Mutations in C2CD3 in a case with JBTS 
 We then focused our attention on the 3 remaining cases without mutations in known 
JTBS genes. We searched the exome dataset for rare variants in the genes associated with 
other ciliopathies with overlapping features with JBTS.  We first sought to determine whether 
any patient harbored rare variants in the MKS genes not yet associated with JBTS (MKS1, 
NPHP3 and B9D2) but none were found. The oral-facial-digital syndromes (OFD, MIM 
311200) are also displaying features of JBTS, including the MTS, as well as distinctive 
patterns of malformations of the face, oral cavity and digits (PMID:17963220).  Several genes, 
namely OFD1, TMEM216, C5orf42 and TCTN3, are responsible for both OFD and JBTS 
phenotypes (87, 90-92).  We searched for rare variants in the OFD genes not previously 
associated with JBTS: C2CD3(87) and TBC1D32 (93) and DDX59 (94).  In the two affected 
siblings of family 472, we identified compound heterozygous mutations in C2CD3: a 
nonsense mutation (c.5929C>T[.p.Arg1977*], NM_001286577.1) and a missense mutation 
(c.5227G>T [p.Gly1743Cys]) (Table 7). The c.5227G>T [p.Gly1743Cys] missense is 
predicted to be highly damaging by SIFT (score=0.0), Polyphen-2 (score=1.00) and Mutation 
Taster.  It affects a conserved aminoacid (including in zebrafish), located in the 5th C2 domain 
(Figure 10B).  The two siblings with C2CD3 mutations have severe global developmental 
delay, though one is more severely affected than the other.  Individual 1299.472 walked at 3 
years and 2 months.  At the age of 6 years, he could write his name, but could not recognize 
letters nor numbers. He had an ataxic gait, but did not have oculomotor apraxia, retinopathy, 
breathing irregularities nor extraneural manifestations.  Individual 1294.472 is more severely 
affected.  At the age of 2.5 years, he was unable to sit, could grab and transfer objects and say 
3 words. He had significant respiratory difficulties with central sleep apneas. He also had 
significant swallowing difficulties and gastroesophageal reflux necessitating a gastrostomy 
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Table 2: Clinical characteristics of new additional patients to this study 
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Fetus 474 C5ORF42 c.4006C>T [p.Arg1336Trp] 
c.6407del [p.Pro2136Hisfs*31]a 
F 22 
wks 
+ NA - - - NA NA NA NA NA  
HSJ-JBTS-
3 
C5ORF42 c.4006C>T [p.Arg1336Trp] 
c.4006C>T [p.Arg1336Trp] 
F 28 + + -(f) -(h) - - Borderline - + + Strabismus 
HSJ-JBTS-
4 
C5ORF42 c.4006C>T [p.Arg1336Trp] 
c.4006C>T [p.Arg1336Trp] 
F 3 + + +(f) -(u) + + NA - NA NA Bifid epiglottis, strabismus, right 
had central polydactyly, bilateral 
preaxial poldaytyly in feet 
1712.604 NPHP1 NPHP1 Del 
NPHP1 Del 
F 2 + + -(e) - (u) - - NA - - +  
1915.669 NPHP1 c.555delA [p.Lys185Asnfs*7] 
c.555delA [p.Lys185Asnfs*7] 
F 3 + + -(f) - (u) - + NA - + NA  
HSJ-JBTS-
1 
TMEM67 c.2132A>C [p.Asp711Ala] 
c.2132A>C [p.Asp711Ala] 
F 3.5 + + - (f) - (u) - + Mild ID - + +  
1123.415 CC2D2A c.3544T>C [Trp1182Arg] 
c. 4667A>T [Asp1556Val] 
F 4 + + -(f) - (u) - + NA - + +  
1673.590 C5ORF42 c.4006C>T [p.Arg1336Trp] 
c.4006C>T [p.Arg1336Trp] 
F 12 + + - (f) - (u) - + Mild ID - + + ADHD, motor apraxia 
1951.677 C5ORF42 c.4006C>T [p.Arg1336Trp] 
c.7400+1G>A 
F 1  + + + (e) - (u) - + NA + + NA Swallowing difficulties 
1342.488 CC2D2A c.4667A>T [p.Asp1556Val] 
c.3376G>A [p.Glu1126Lys] 
M 28 + + - (f) - (h) - + Moderate ID - + + Autism, ADHD 
1343.488 CC2D2A c.4667A>T [p.Asp1556Val] 
c.3376G>A [p.Glu1126Lys] 
M 31 + + - (f) - (h) - + Normal 
(university) 
- + +  
2049.708 C5ORF42 c.4690G>A [p.Ala1564Thr] 
p.Ile2119Tyrfs*2 
F 1.5 + - - (f) - (u) + + NA + + + Oromotor apraxia, swallowing 
difficulties, tongue and 
hypothalamic hamartomas, 
neonatal seizures 
1610.572 CC2D2A c.4667A>T [p.Asp1556Val]  
c.2181 +G>A 
F 2 + + - (e) - (u) - + NA - + +  
1310.476 NPHP1 c.555delA [p.Lys185Asnfs*7] 
NPHP1 Del 
M 18 + + -(f) + (u) - + 
 
Mild ID + + + Severe dysphasia 
HSJ-JBTS-
2 
TCTN1 c.342-2A>C 
c.898C>T [p.Arg300*]  
 27w
ks 
+ NA NA - 
(us) 
+ NA NA NA NA NA Abnormal gyration of the frontal 
lobes 
1639.581 B9D1 c.493C>T[p.Gln165*],  
c.151T>C [p.Ser51Pro],  
M 22 + + - (f) - (h) - - 
 
normal - + + Congenital club feet, dysphasia 
1767.621  CEP290 c.6401T>C [p.Ile2134Thr]  
c.4195-1G>A 
F 21 
wks 
+ NA NA + (u) +  NA NA NA NA NA Occipital encephalocele, olfactory 
bulb agenesis, bifid uterus 
Fetus2 621 CEP290 c.6401T>C [p.Ile2134Thr]  
c.4195-1G>A 
F 20 
wks 
+ NA NA + (u) - NA NA NA NA NA  
1686.595 OFD1 
 
c.920T>A [p.Val307Asp] M 15 + + + (f)b + (u) - + Severe ID + + + Autism, end-stage renal failure, 
swallowing difficulties, abdominal 
situs inversus 
1299.472 C2CD3 c.5929C>T [.p.Arg1977*] 
c.5227G>T [p.Gly1743Cys] 
M 7 + - - (f) - (u) - + NA - + +  
1294.472 C2CD3 c.5929C>T [.p.Arg1977*] 
c.5227G>T [p.Gly1743Cys] 
M 4 + + -(e) - (u) - + 
 
NA + + + Swallowing difficulties, oromotor 
apraxia, gastrostomoy, 
fundoplication 
1763.618 CEP104 c.735+2T>C 
c.735+2T>C 
F 2 + + + (e) - (u) - + NA + + +  
The following abbreviations are used: ADHD, attention deficit and hyperactivity disorder; F, female; e, electroretinogram; f, fundoscopy; h, history ID, intellectual disability; M, male; MTS, molar tooth 
sign; NA, not available/not applicable and us, ultrasound.a Genotype of fetus not tested but assumed based on genotype of similarly affected sibling 1304.474 (supplemental table 1), bhypertensive 
retinopathy 
Table 7: Clinical characteristics of new additional JBTS patients to this study 
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and a NIssen fundoplication  He had oculomotor apraxia and growth retardation but no 
retinopathy, polydactyly, renal or liver dysfunction.  Both brothers showed the MTS. 
 
CEP104, a novel candidate JBTS gene 
We were now left with only one individual (1763.618) without any candidate variants. 
We examined the patient’s exome dataset for genes that contained homozygous or multiple 
rare heterozygous variants. Thereafter, for each of these genes, we searched Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed/) to see whether the gene product localized to or had a 
role in cilia function (by using the search-term “cilia” and the name of the gene of interest).  
Individual 1763.618 had 18 genes that contained homozygous or multiple rare variants. Only 
one of these, CEP104, is known to be implicated in cilia function(95-97). CEP104 has 22 
exons and encodes a centrosomal protein containing 2 coiled-coil domains. CEP104 harbored 
a homozygous splice-site mutation (c.735+2T>C, NM_014704.3) affecting the canonical 
donor splice site following exon 8, likely causing its skipping. Exon 8 encodes part of the 
coiled-coil domain. Sanger sequencing confirmed that this mutation was homozygous in the 
patient and heterozygous in the unaffected parents (Figure 10C). At the current age of 2.5 
years, this individual is not yet sitting independently, nor is she saying any words (Table 7). 
She has oculomotor apraxia, significant hypotonia and ataxia. She does not have breathing 
irregularities, polydactyly, neither retinal, renal nor kidney involvement. Brain imaging 
showed the MTS. 
 
DISCUSSION 
 In this study, we surveyed the genetic landscape associated with JBTS in the FC 
population. We found that JBTS is characterized by great genetic heterogeneity within this 
population, with possibly as many as 11 genes involved. Of a total of 35 families, 14 had 
causal mutations in C5orf42, 9 in CC2D2A, 3 in NPHP1 and 2 in TMEM231, with individual 
families explained by mutations in TCTN1, TMEM67, B9D1 or C2CD3 (Fig. 11). We 
identified possible pathogenic mutations in CEP290 in one family and OFD1 in another. In 
addition, we identified CEP104 as a strong candidate JBTS gene. There is also significant 
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allelic heterogeneity with a total of 8 different mutations identified in C5orf42 and 7 in 
CC2D2A (Fig. 11).   
 
  
Overall, we were able to identify the definite causal gene in 32 of 35 families (91.4%), 
possible causal genes in 2 families and a strong candidate gene in the remaining family.  Thus, 
the genetics of JBTS in the FC population appears to be relatively well elucidated.  This is in 
contrast to the estimation that mutations in known JBTS genes account for only half of 
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Figure 11: Locus and allelic heterogeneity of JBTS in French Canadians. Graph showing the 
number of the different alleles associated with JBTS in FC cases. The total number of JBTS families 
for each of the genes is shown beneath the gene name. Deletion1 refers to chr2:  110,826,262-
110,978,224 and deletion 2 refers to chr2: 110,862,369-110,978,000 (GRCh37/hg19 genome 
assembly). 
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patients(80). The high yield in our study is partially related to the use of WES in this 
extremely genetically heterogeneous condition. 
 
  
JBTS in French Canadians: a complex founder effect 
We identified 3 recurrent mutations in C5orf42, 2 recurrent mutations in CC2D2A, and 
2 recurrent mutations in TMEM231, each of which were previously shown to be present on a 
common haplotype indicating the presence of a complex founder effect(77). In addition, we 
documented the presence of the same nonsense mutation in NPHP1 in two unrelated cases. 
For C5orf42 and CC2D2A, all known FC cases carried at least one of the recurrent mutations. 
There is a clear cluster of families with mutations in C5orf42 in the lower Saint Lawrence 
region of Quebec, especially in the Matapedia Valley (population: 20,000) where the 3 
recurrent mutations can be found (Fig. 12). The distribution of patients with mutations in 
CC2D2A is more widespread, with a crowding of affected families around the Montreal region  
but with also the presence of two recurrent mutations in the Matapedia Valley (Fig. 12). There 
is no obvious geographical clustering of cases with mutations in TMEM231 and NPHP1. 
 
Founder effects are typically characterized by the introduction of a major “driver” 
mutation that explains the disease in the majority of the patients. For recessive conditions, 
distinct low frequency variants can be found in the compound heterozygotes and with the 
increasing number of patients analyzed.  As illustrative examples, a single founder mutation is 
responsible for 95% of FC mutant alleles in tyrosinemia type 1 (MIM 276700), and another 
single mutation represents 98% of FC mutant alleles in Leigh syndrome (MIM 220111)(36). 
Yet, accumulation of more than one frequent variant, underlying a clinically recognized 
founder effect, is increasingly observed challenging the “one (major) mutation, one disease” 
model. For instance, in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS, 
MIM 270550), one founder mutation is responsible for 94% of mutant FC alleles, though there 
are also 5 other recurrent mutations identified, albeit at a low frequency(36, 98). In hereditary 
sensory autonomic neuropathy type 2 (HSAN2, MIM 201300)(74), two mutations are 
responsible for 60% and 40% of mutant alleles in FC patients, and in autosomal recessive 
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cerebellar ataxia (ARCA1, MIM 610743), 3 mutations each account for 50, 13 and 10% of 
mutant FC alleles(99). 
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Figure 12. Map of Quebec showing the geographic distribution and the 
genetic heterogeneity of FC families with JBTS. *Note that this individual is of 
FC ancestry, but born and living in the Unites States of America. 
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 The complexity of the founder effect in Quebec is partly explained by (1) an initial 
settlement of a small number French pioneers in the 17th century (approximately 8,500 
including 1,600 women) mainly originating from North-Western France who gave rise to the 
FC population, (2) relative isolation of the population with little intermarriage with the British 
who had a differing language and religion, and (3) later waves of pioneering fronts in the mid-
19th century along the eastern area of the Lower Saint-Lawrence region, creating a series of 
genetic bottle necks and a regionalization of the gene pool(36, 100).  
 
 
C2CD3 is a novel JBTS gene 
 We identified compound heterozygous nonsense and missense mutations in C2CD3 in 
two JBTS siblings. This is the first report of mutations in C2CD3 resulting in JBTS. Thavin-
Robinet et al recently reported two families with an unclassified form of OFD with recessive 
mutations in C2CD3.  In one family with a homozygous truncating mutation (NM_015531.5, 
c.184C>T, p.Arg62*), two siblings had orofacial dysmorphism, severe microcephaly, bilateral 
hand post-axial polydactyly and broad hallux, micropenis, severe intellectual disability, MTS, 
subarachnoid cyst and corpus callosum hypoplasia.  The affected fetus from the second 
reported family had compound heterozygous mutations in C2CD3 (c.3085TG, p.Cys1029Gly 
and c.3911_3914delCAAG, p.Ala1304Valfs*3). The fetus also had severe microcephaly, 
micropenis, bilateral hand post-axial polydactyly, broad hallux, MTS, subarachnoid cysts and 
abnormalities of the corpus callosum. The patients we describe in our study have a pure form 
of JBTS without any extraneural manifestations, highlighting the broad and overlapping 
clinical spectrum associated with mutations in cilia genes. The reason for the milder 
phenotype in our patients is unclear, but may be related to the fact that the nonsense mutation 
results in a more distally truncated protein in our family (c.5929C>T[.p.Arg1977*] than the 
previously reported OFD patients.   
 
CEP104, Novel JBTS candidate gene 
We have identified a homozygous canonical splice-site mutation affecting the donor 
splice site following exon 8 in CEP104, which is predicted to result in skipping of that exon. 
CEP104, which contains 21 exons, encodes a 925 amino-acid centrosomal protein that 
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localizes to the centriole(95) and the distal end of the growing cilium (96, 97).  It has been 
shown to be critical for ciliogenesis as Retinal Pigment Epithelial cells treated with siRNA 
against CEP104 had severe defects in ciliogenesis: cells were either unable to form cilia under 
starvation, or if they did, the cilia were short and abnormal(96). CEP104 is known to interact 
with CEP97 and CP110, two proteins that are required for centrosome and primary cilia 
function (101). Both CEP97 and CP110 suppress ciliogenesis as depletion of either protein 
promotes primary cilia formation. Interestingly, CP110 mediates ciliary formation by 
suppressing the ability of CEP290, a JBTS gene product, to cooperate with Rab8a to enable 
cilia assembly(102, 103). The identification of other JBTS patients with mutations in CEP104 
will be needed to confirm that it is a bona fide JBTS gene. 
 
Genotype-phenotype correlations 
A summary of the clinical features of all 43 FC JBTS individuals is presented in table 
8. We have reviewed the clinical information on our 17 FC cases with mutations in C5orf42, 
as well as all additional cases reported by other groups (91, 104-106). None of these cases 
showed renal or liver involvement. Retinal involvement, though rare, can be associated with 
mutations in C5orf42 as one of our cases (1951.677) and a previously reported affected 
individual had abnormal electroretinograms(104). Features absent in our patients, but reported 
in others include left ventricular outflow tract obstruction (coarctation of the aorta or left 
hypoplastic ventricle in 3 cases) and occipital meningocele (in 3 cases)(91, 104, 105). 
Recently, C5orf42 has been shown to be the major gene responsible for OFD type VI (MIM 
277170), explaining 9 of 11 OFD-VI families (91). Criteria for OFD-VI include the presence 
of a MTS and at least one of the following: (1) tongue hamartoma and/or additional frenula 
and/or upper lip notch, (2) mesoaxial polydactyly, (3) hypothalamic hamartoma(90). Another 
group however noted that C5orf42 mutations only explained 11.7% (2 of 17) of their OFDVI 
patient cohort.  Comparison of the phenotypes of the two groups revealed that C5orf42 was 
mainly associated with preaxial and/or mesoaxial polydactyly, and hypothalamic hamartomas.  
OFDVI patients without mutations in C5orf42 were more likely to have tongue hamartomas or 
multiple lingual frenulae (107). Three cases from our cohort showed a phenotype that is 
consistent with OFD-VI, including individual 2049.708 who had a tongue hamartoma, an 
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upper lip notch and a hypothalamic hamartoma, individual 1304.474 who had mesoaxial 
polydactyly, and HSJ-JBTS-4 who had a bifid epiglottis and mesoaxial polydactyly.  
  
The majority of the cases in our cohort (13/17) with mutations in C5orf42 carried at 
least one truncating mutation. The 4 individuals with compound missense mutations 
(1281.468, 1673.590, HSJ-JBTS-3 and HSJ-JBTS-4) had a mild neurologic phenotype, with 
only mild developmental delay, borderline intelligence, and minimal gait ataxia. Five cases 
with homozygous truncating mutations in C5orf42 have been previously reported in the 
literature, one fetus with the MKS phenotype, and 4 cases with the JBTS phenotype (including 
one with occipital encephalocele and retinopathy(104, 106). Although it is possible that cases 
with homozygous truncating mutations overall show a more severe phenotype, more patients 
carrying such mutations need to be characterized before concluding that this is the case. 
 Though mutations in CC2D2A may be associated with retinal and renal findings(108), 
no one from our cohort had any extraneural manifestations.  Because there are 2 missense 
founder mutations in CC2D2A in the FC population, the majority of our patients (10/11) had 
missense mutations.  Overall, patients seemed to have a mild phenotype with mild-moderate 
developmental delay, and intelligence in the normal to mild intellectual disability (ID) range.  
Nevertheless, there was intrafamilial variability. For example, in family 385, one sibling had 
oculomotor apraxia without ataxia nor MTS, whereas the second sibling had all the classic 
features of JBTS. In another family (family 488), one sibling had autism and moderate ID, 
whereas the second sibling completed regular high school and attended college. Both brothers 
carried the recurrent FC mutations in CC2D2A.  It is not known whether modifying alleles in 
Table 6: Summary of the clinical features of 43 FC patients with JBTS 
Gene C5ORF42 CC2D2A TMEM231 NPHP1 OFD1 CEP290 B9D1 C2CD3 TCTN1 TMEM67 CEP104 
No. of patients 17 11 3 3 1 2 1 2 1 1 1 
MTS 16/17 10/11 
 
3/3 3/3 1/1 2 1/1 2/2 1/1 1/1 1/1 
OMA 15/16 11/11 3/3 3/3 1/1 2/2 1/1 1/2 NA 1/1 1/1 
Respiratory 
abnormalities 
11/16 
 
1/11 3/3 1/3 1/1 NA 0/1 1/2 NA 1/1 1/1 
Developmental 
Delay 
14/14 
 
10/11 3/3 2/3 1/1 NA 1/1 2/2 NA 1/1 1/1 
Renal 0/17 0/11 2/3 1/3 1/1 2/2 0/1 0/2 0/1 0/1 0/1 
Liver 0/17 0/11 0/3 0/3 0/1 0/2 0/1 0/2 0/1 0/1 0/1 
Retinal 1/17 0/11 2/3 0/3 0/1 NA 0/1 0/2 NA 0/1 1/1 
Limb abnormalities 4/17 0/11 2/3 0/3 0/1 0/2 0/1 0/2 1/1 0/1 0/1 
 
 
  Table 8. Summary of the clinical features of 43 FC patients with JBTS 
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other cilia genes may contribute to the variable phenotype in this family, a mechanism that has 
been previously described in ciliopathies(65).  
 
 The most severely affected individuals in our cohort were those with mutations in 
TMEM231.  The three patients had severe developmental delay. Indeed, they could not stand 
independently, ambulate, nor say any words. They had severe behavioural issues with 
automutilation and head banging. The 3 individuals had extraneural manifestations with 2/3 
having renal cysts but no renal dysfunction, 2/3 pre-axial polydactyly and 2/3 retinopathy. 
Mutations in TMEM231 are also responsible for MKS(109). 
 
  Finally, we report on a patient with a homozygous splice-site mutation in B9D1. To 
date, there have only been reports of 3 other individuals harboring mutations in B9D1. Hopp et 
al reported one newborn with MKS, who died after a few hours of life with posterior 
encephalocele, multicystic dysplastic kidneys, clubbed feet and ambiguous genitalia(110). He 
carried an inherited splice-site mutation (c.505+2T>C) in B9D1 as well as a de-novo 1.7Mb 
deletion encompassing B9D1. Romani et al reported 2 individuals with JBTS with mutations 
in B9D1, both of whom had a mild phenotype without extraneural manifestations: a 9 year old 
boy carrying a homozygous c.G467A (p.R156Q) with mild intellectual disability, and a 7 year 
old girl carrying c.A95G (p.Y32C) and c.520_522delGTG (p.V174del) with normal 
intelligence.  Interestingly, our patient also has a mild phenotype with no extraneural 
manifestations and normal intelligence. 
In summary, we have identified the definitive causal mutations in 32 out of 35 FC 
families with JBTS. We expand the phenotype associated with mutations to include JBTS.  In 
addition, we implicate CEP104 as strong JBTS candidate gene. Though the genetic landscape 
of JBTS is greatly heterogeneous, even within the FC population, it is becoming well 
understood in great part due to WES.  
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Chapter 5: 
General Discussion 
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We have used a combination of Sanger sequencing and whole exome sequencing to 
study the genetic basis of Joubert syndrome in 43 affected individuals from 35 unrelated 
French-Canadian families. Our work has resulted in the identification of 2 novel JBTS genes 
(C5orf42 and TMEM231) and 1 strong candidate JBTS gene (CEP104)(77, 82). It has also 
enabled the deciphering of the genetic landscape of JBTS in French-Canadians.  Prior to the 
start of this research endeavor, the underlying genetic etiology was unknown in all 35 families.  
Now, a definite molecular diagnosis has been identified in 32 families, and a probable 
molecular diagnosis in the remaining 3.  
 
Mutations in C5orf42 are the most common cause of JBTS in French-Canadians and 
worldwide 
 
Mutations in C5orf42 explain JBTS in 14 of our 35 FC families. There is a presence of 
a complex founder effect with 3 recurrent mutations (c.4006C>T [p.Arg1336Trp], 
c.7400+1G>A and, c.4690G>A [p.Ala1564Thr]) of which c.4006C>T [p.Arg1336Trp] is the 
most common being present in 9 of 14 families.  Each of these mutations was found to be on a 
common haplotype indicating the presence of 3 separate founder mutations. As previously 
discussed in manuscript 1, the large size of the C5orf42 and the complicated population 
migration patterns partly explain this phenomenon. In addition, the c.4006C>T corresponds to 
a CpG site, thus it has a higher susceptibility to spontaneous mutation.  
 
 Since our original publication in 2012 (77), further insight into the function and 
localization of C5orf42 is available thanks to a JBTS17 mouse model harbouring a 
homozygous missense mutation in the mouse homologue of C5orf42, 2410089E03Rik 
(c.757T>C, pS235P)(111).  This mouse mutant, named Heart Under Glass (Hug), was 
recovered from a forward genetic screen with ENU mutagenesis using fetal ultrasound 
imaging to identify congenital heart defects. The Hug mouse exhibits a number of defects 
characteristic of ciliopathies, including polydactyly, craniofacial anomalies, cystic kidneys and 
central nervous system abnormalities. In addition, this mutant mouse has congenital heart 
defects comprising of outflow tract abnormalities associated with pulmonary atresia. Detailed 
analysis of the brain shows abnormal cerebellar development with reduction in the number 
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and size of the cerebellar lobules.  This parallels the cerebellar defects observed in JBTS in 
humans.  In addition, Shh signalling is disrupted in Hug mutant fibroblasts, but stereocilia 
patterning is not perturbed, suggesting that cochlear planar cell polarity regulation is 
unaffected.  Given that PCP defects underlie the cystic kidneys associated in ciliopathies, this 
observation may explain in part the lack of renal involvement in C5orf42 patients. C5orf42 
localizes to the ciliary transition zone in normal fibroblasts.  Fibroblasts derived from Hug 
mutant mice and from a patient C5orf42 mutations (patient 1320-480)(77) exhibited 
ciliogenesis defects, and showed loss of not only C5orf42, but also NPHP1 and CEP290 from 
the cilia transition zone.  
 
Mutations in C5orf42 are not only responsible for JBTS in the French-Canadian 
population. Mutations in C5orf42 have now been identified in JBTS patients outside of 
Quebec, and are in fact one of the most common cause of JBTS worldwide.  Very shortly after 
the publication of our manuscript, Alazami et al. reported homozygous truncating mutations in 
C5orf42 in 3 out 12 Saudi Arabian families with JBTS.  More recently, C5orf42 was screened 
in a cohort of 313 patients with JBTS (107).  Causal mutations were identified in 28 (8.9%), 
making C5orf42 one of the most frequently mutated genes in this cohort.  In another study, 
causal mutations in C5orf42 were identified in 12% of a cohort of 51 Northern European 
JBTS patients (106). Furthermore, mutations in C5orf42 have been identified in patients with 
Orofacial digital syndrome 6 (OFDVI), a related ciliopathy.  The diagnostic criteria of OFDVI 
are defined as presence of the molar tooth sign and one or more of the following: (1) tongue 
hamartoma and/or additional frenula and/or upper lip notch; (2) mesoaxial polydactyly of one 
or more hands or feet and (3) hypothalamic hamartoma (90). Lopez et al reported that C5orf42 
mutations accounted for 82% of their OFDVI patients, although a second group found that 
C5orf42 mutations only explained 11.7% (2 of 17) of their OFDVI patient cohort (107).  
Comparison of the phenotypes of the two groups revealed that C5orf42 was mainly associated 
with preaxial and/or mesoaxial polydactyly and hypothalamic hamartomas.  OFDVI patients 
without mutations in C5orf42 were more likely to have tongue hamartomas or multiple lingual 
frenulae.  
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Mutations in C5orf42 have never been associated with renal or liver abnormalities.  
Retinal abnormalities have been reported, though rarely (in 2 patients only, one from 
manuscript 3 and one from a separate publication (104)).  Thus, C5orf42-related JBTS is 
either associated with a pure neurologic phenotype or an OFDVI phenotype, usually sparing 
the kidneys, liver and retina. Neurodevelopmental outcomes are variable and difficult to 
predict, as reviewed in manuscript 3. 
Finally, mutations in C5orf42 have been reported in one Saudi Arabian fetus with 
Meckel syndrome, a JBTS-related ciliopathy considered on the more severe end of the 
spectrum of JBTS, that is characterized by dysplastic kidneys, polydactyly, occipital 
encephalocele and early lethality(109). It is important to note however, that the fetus did not 
have the classic findings of Meckel syndrome, as it had neither polycystic kidneys nor 
polydactyly. This fetus had a cleft lip and palate, and an occipital encephalocele, suggesting 
that a diagnosis of OFDVI may have been more accurate.  
 
Mutations in TMEM231 cause JBTS 
 
Our work has resulted in the identification of TMEM231 as a novel JBTS gene.  It is a 
rare cause of JBTS, as only one other JBTS patient has been reported to date (107). However, 
following our publication, mutations in TMEM231 were identified in patients with Meckel 
syndrome and OFD type 3 (112, 113). In fact, mutations in TMEM231 were found to be a 
relatively common cause of Meckel syndrome, as homozygous or compound heterozygous 
mutations were identified in 9 out of 95 Meckel syndrome families.  Both missense and 
truncating TMEM231 mutations have been described.  Interestingly, our JBTS patients were 
the most severely affected patients from our cohort, having polydactyly, retinal involvement, 
renal cysts and the most severe neurodevelopmental impairment.  Our 3 patients were 
nonverbal and nonambulatory. 
 
TMEM231 is a transmembrane protein that localizes to the ciliary transition zone.  It is 
a member of the B9/tectonic complex, one of four transition zone complexes..  Mutations in 
all 15 members of the B9/tectonic complex have been found to underlie human disease and are 
responsible for overlapping JBTS / Meckel syndrome and orofacial digital phenotypes.  
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Tandem affinity purification and mass spectroscopy experiments have determined that 
TMEM231 interacts with multiple other components of the MKS complex(79, 113).  
TMEM231 knock-out or mutant mice (lacking exons 2 and 3) have a ciliary phenotype with 
polydactyly, central nervous system abnormalities and Shh signaling defects, cystic kidneys 
and hepatic ductal plate malformations(79, 113). Tmem231 mutant mouse embryonic 
fibroblasts (MEFs) fail to localize ciliary proteins such as Adcy3, Arl13b and other transition 
zone proteins such as B9D1, TMEM67 and MKS1. Robertson et al show that the TMEM231 
mutations identified in MKS and OFD3 patients are hypomorphic.  The localization of Arl13b 
and B9D1 in Tmem231-/- MEFs is fully rescued by transient transfection with wild-type 
Tmem231, but is only partially rescued with the mutant forms of Tmem231. siRNA 
knockdown of TMEM231 disrupts both the integrity of the ciliary barrier and the localization 
of B9 complex components to the transition zone, resulting in reduced cilia formation and 
ciliary localization of signaling receptors[19]. Furthermore, loss of Tmem231 in C. elegans 
sensory neurons results in the inappropriate leak of nonciliary proteins into the cilia. This 
suggests that the MKS complex serves either as an entry barrier, excluding entry of nonciliary 
proteins into the cilia, or as an exit barrier, retaining certain membrane-associated proteins 
within the cilia while allowing the exit of nonciliary proteins.  
 
JBTS- a ciliary transition zone-opathy 
 
 Dysfunction of the transition zone in TMEM231 mutants provides additional support 
to the mounting evidence suggesting that dysfunction of the transition zone is central to the 
pathophysiology underlying JBTS. In vitro or in vivo knock-down of the other individual 
components of the transition zone B9 complex results in reduced cilia formation, reduction of 
the expression of receptors in the ciliary membranes, and defective Shh signaling.  Multiple 
lines of evidence demonstrate that the B9 complex prevents the rapid diffusion of unselected 
proteins across the transition zone, while at the same time promoting the access of selected 
proteins and receptors to the cilium. For example, the membrane‐associated GPI–GFP and 
GFP‐tagged CEACAM1 accumulate at higher levels in cilia with dysfunctional transition 
zones (79); in C. elegans, abrogation of six different transition zone‐localized proteins causes 
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abnormal ciliary entry of the TRAM protein and membrane‐associated RP2 homologues.  
Ciliary proteins, such as AC3 and PKD2, no longer localize to the cilia in cells with transition 
zone disruption(114).  
 
Recent data have shown that ciliary proteins interact within functional networks that 
largely relate to specific ciliopathy phenotypes. For example, two motor complexes of proteins 
(intraflagellary transport complex B and A) mediate the anterograde and retrograde 
intraflagellary transport systems that bidirectionally move ciliary proteins along the axoneme  
These use the microtubule motor proteins kinesins and dyneins,.  Mutations in the 
intraflagellary transport proteins are a major cause of skeletal ciliopathies, including 
Sensenbrenner syndrome, Jeune syndrome, and other short rib polydactyly syndromes. The 
correct assembly of intraflagellary transport complexes at the ciliary base, and the turnaround 
from anterograde to retrograde transport at the ciliary tip, are mediated by another protein 
complex, the BBSome, that consists of several proteins that are mutated in Bardet-Biedl 
syndrome. 
 
Variability of JBTS phenotype 
 
There is large phenotypic variability associated with mutations in JBTS genes.  As 
mentioned previously, mutations in the same JBTS gene can be associated with differing 
severity of neurodevelopmental deficits, and extra-neural involvement.  Substantial variability 
can also occur within the same family.  Furthermore, mutations in the same gene can result in 
different, though related diagnoses, such as JBTS, Meckel syndrome, nephronophthesis or 
isolated retinopathy.  
 
A possible explanation for this wide variability is the oligogenic model of 
transmission, whereby inherited recessive mutations in one gene are not sufficient to fully 
explain the clinical phenotype: concurrent presence of additional mutations, rare allelic 
variants or even common polymorphisms in other ciliary genes contribute to the mutational 
load, which modulates the phenotype of the patient(115).  This mechanism has been 
demonstrated in Bardet-Biedl syndrome (BBS), another ciliopathy, where affected individuals 
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with non-fully penetrant mutations also carried heterozygous mutations on other BBS loci. 
This mechanism has also been documented in JBTS patients: individuals with mutations in 
NPHP1 have muticystic renal dysfunction either in isolation (in the form of 
nephronophthiasis), or combined with neurologic abnormalities (such as MTS) to give a JBTS 
phenotype. JBTS individuals harboring homozygous NPHP1 deletions had an enriched 
incidence of pathogenic lesions in trans in CEP290 or AHI1, other known JBTS genes, likely 
explaining the presence extra-renal manifestations [31]. 
 
The landscape of JBTS in French-Canadians is largely unraveled 
 
Prior to the start of this study, the genetic etiology of JBTS was largely unknown in the 
French-Canadian population.  Now, however, it is well characterized.  There is the presence of 
significant genetic and allelic heterogeneity, with the involvement of at least 10 separate 
genes.  Of these, C5orf42 and CC2D2A explain the largest proportion of affected families, and 
are responsible for 14 of 35 (40%) and 9 of 35 (26%) families respectively.  We have 
uncovered the presence of a complex founder effect.   
 
The reason for the presence of multiple founder mutations is several-fold. Although 
JBTS it is unified by a relatively specific phenotype reflecting ciliary dysfunction, it is 
nonetheless a markedly genetically heterogeneous disorder. Since founder effects are capable 
of increasing disease prevalence associated with any mutation, a genetically heterogenous 
disorder is more prone to have multiple founder effects. Furthermore, both CC2D2A and 
C5orf42 are very large genes thus are more likely to accumulate mutations, explaining the 
presence of multiple founder mutations.  The migration and population history of Quebec 
provided favorable conditions for the development of such complex founder effect given the 
initial small number French pioneers in the 17th century who gave rise to the French-Canadian 
population, the relative isolation of the population, and later waves of pioneering fronts in the 
mid-19th century along the eastern area of the Lower Saint-Lawrence region, creating a series 
of genetic bottle necks and a regionalization of the gene pool(36, 100).   
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The deciphering of the genetic etiology of JBTS in the French-Canadian population 
has made an important impact on the affected children and their families.  Carrier parents can 
now be offered pre-implantation genetic testing and early screening of pregnancies.  Carrier 
status of the siblings, spouses and the extended family can be tested in order to facilitate 
genetic counseling. For the children affected with JBTS, knowledge of the molecular 
diagnosis can help tailor management, though caution is used, given the imprecise genotype-
phenotype correlations.  These generalizations are very helpful to the clinician and informative 
to the affected families.  For example, individuals with mutations in NPHP1 will need to be 
followed extremely closely for renal dysfunction with renal imaging and function testing; 
patients with mutations in C5orf42 will likely have a pure neurologic phenotype and thus very 
close monitoring of renal and liver function will not be necessary; patients with TMEM231 
mutations are likely to be have more severe neurodevelopmental disabilities with extraneural 
complications including renal, skeletal and retinal involvement requiring close monitoring; 
however,  though mutations in CC2D2A can be associated with a broad clinical phenotype 
with extra-neurologic complications,  French-Canadian patients with the recurrent FC 
CC2D2A mutations are more likely to have a mild neurologic phenotype with no extra-
neurologic manifestations.   
 
Role of WES in JBTS gene discovery 
 
Next generation sequencing technologies such as WES have revolutionized the study 
of genetically and clinically heterogeneous diseases such as JBTS.  Classic genetic strategies 
such as linkage analysis and homozygosity mapping rely heavily on consanguineous families 
or multiple large families with multiple affected individuals. Given the extreme allelic and 
genetic heterogeneity that we uncovered in the French-Canadian JBTS population, this 
doctoral project would not have been possible without Next Generation sequencing 
technologies.  Indeed, our initial approach of using homozygosity mapping failed. WES has 
been instrumental in the deciphering of the genetics and pathophysiology of JBTS in the past 
decade. The first JBTS gene, AHI1, was identified in 2004. In 2010, when this project started, 
only 8 causal genes were known. This number has exploded since, with at least 24 known 
genes.  It is important to note that the exploration of JBTS genes is dramatically facilitated by 
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the known unifying underlying pathogenesis of ciliary dysfunction, particularly with analysis 
of candidate genes from WES.   
 
The use of Next Generation sequencing technologies is also very important in the 
clinical setting. Despite some general phenotype-genotype correlations, it is very difficult to 
predict the causal gene in a given patient. Next Generation sequencing gene panels are 
affordable and time efficient.  Even for French-Canadian patients, in which 65% of mutations 
are in two genes, next generation sequencing is still more efficient than Sanger sequencing of 
targeted genes.  Thus, in the diagnostic exploration of a patient with the clinical diagnosis of 
JBTS, a clinician would order forst a chromosomal microarray (to look for large deletions 
involving JBTS genes such as NPHP1) followed by a Next Generation JBTS gene panel. 
 
In summary, starting from a cohort of 35 French-Canadian families with JBTS in 
which none had identified causative mutations, we identified the definitive causal mutations in 
32, and the possible causal mutation in the remaining 3. Our work has resulted in the 
identification of two novel JBTS genes- C5orf42 and TMEM231, and implicated CEP104 as 
strong JBTS candidate gene. Though the genetic landscape of JBTS is greatly heterogeneous, 
even within the French-Canadian population, it has now become largely mapped. 
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ABSTRACT 
 Anophthalmia and/or microphthalmia, Pulmonary hypoplasia, Diaphragmatic 
hernia and Cardiac defects are the main features of PDAC syndrome. Recessive 
mutations in STRA6, a membrane-receptor for the retinol-binding protein, have been 
identified in some cases with PDAC syndrome, though many cases remained 
unexplained.  Using whole-exome sequencing, we found that 2 siblings with PDAC 
syndrome, but not their unaffected sibling, were compound heterozygous for nonsense 
(c.355C>T, p.Arg119*) and framefhift (c.1201_1202insCT, p.Ile403Serfs*15) mutations 
in the retinoic acid receptor beta gene (RARB). Transfection studies showed that the 
p.Arg119* and p.Ile403Serfs*15 RARB mutants had no transcriptional activity in 
response to ligands confirming that the mutations induced a loss of function. We then 
sequenced RARB in 15 subjects with microphthalmia and/or anophthamia and at least one 
other feature of PDAC syndrome. Surprisingly, we identified 3 unrelated subjects with 
microphthalmia and diaphragmatic hernia who showed de novo missense mutations 
affecting the same codon; two of the subjects had the mutation c.1159C >T (Arg387Cys) 
whereas the other one carried the mutation c.1159C >A (p.Arg387Ser).  We found that 
the p.Arg387Ser and p.Arg387Cys RARB mutants induced a 2 to 3-fold increase in 
transcriptional activity compared to wild-type receptor in response to retinoic acid 
ligands, suggesting a gain-of-function mechanism. Our study thus suggests that both 
recessive and dominant mutations in RARB cause microphthalmia and/or anophthalmia 
and diaphragmatic hernia, providing further evidence of the crucial role of the retinoic 
acid pathway during eye development and organogenesis. 
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 Anophthalmia and microphthalmia (A/M) refer to the absence or reduced size of 
the axial diameter of the globe in the ocular orbit, respectively.  In over 50% of cases, 
A/M is associated with other congenital abnormalities1,2. The combination of, Pulmonary 
hypoplasia or agenesis, Diaphragmatic hernia or eventration, A/M and Cardiac defects 
are the features of the acronym PDAC syndrome, which is also known as Matthew-Wood 
or Spear syndrome [MCOPS9, MIM 601186]3. In some individuals, PDAC syndrome is 
caused by autosomal recessive mutations in STRA6 (MIM 610745), a membrane receptor 
for the retinol-binding protein4, 5. Many cases of PDAC syndrome, however, remain 
unexplained.  
 In this study, we performed whole-exome sequencing in a non-consanguineous 
family with PDAC syndrome to uncover the genetic cause (Figure 1A). The couple has 2 
healthy daughters and four progenies of whom 2 had all the features of PDAC, and 2 
others with at least 2 features of PDAC (family A, individuals II-1, 4, 5 and 6, see table 1 
for clinical details). This family was previously described (family A in Chitayat et al, 
20073; Case 1A is individual II-4, case 2A is II-5 and case 3A is II-6). STRA6 was 
previously sequenced in one affected individual of this family and no mutation was 
identified.  
 This study was approved by our institutional ethics committee and informed 
consent was obtained from each participant or legal guardian. Blood genomic DNA from 
the affected individuals II-4 and II-5 and the non-affected sister (II-2) from family A was 
captured with the Agilent SureSelect Human All Exon Capture V4 Kit (Mississauga, 
ON), and sequenced (paired-end, 2x100bp, 3 exomes/lane format) using the Illumina 
HiSeq2000 at the McGill University Genome Quebec Innovation Center (Montreal, 
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Canada). Sequence processing, alignment (using a Burroughs-Wheeler algorithm, BWA), 
and variant calling were done according to the Broad Institute Genome Analysis Tool Kit 
(GATK v4) best practices, and variant annotation was done using Annovar6. The exome 
target base average coverage was 111-114X, with 95% of the target bases being covered 
by at least 20 reads. Only the variants whose positions were covered at ≥ 8x and 
supported by ≥ 3 variant reads that constitute at least 20% of the total reads for each 
called position were retained. To identify potentially pathogenic variants we filtered out: 
1) synonymous variants or intronic variants other than those affecting the consensus 
splice sites; 2) variants seen in more than 2% of our in-house exomes dataset (n = 1000) 
from unrelated projects; and 3) variants with a minor allele frequency greater than 0.5% 
in either the 1000 genomes or NHLBI exome sequencing project (ESP) datasets (Exome 
Variant Server, EVS). There were no rare coding or splicing variants that were shared 
between the affected individuals in STRA6 or in ALDH1A3 (MIM 600463), another gene 
involved in A/M and retinoic acid signaling 7. 
 Since transmission of the phenotype in this family was consistent with an 
autosomal recessive inheritance, we searched the whole-exome datasets for genes that 
harboured homozygous or multiple rare variants in both affected probands but not in their 
unaffected sibling. There were no such genes with rare homozygous variants.  We 
identified only 3 genes containing multiple rare variants in both affected individuals, not 
shared by the unaffected sister: PRPF39 (MIM 614907), RARB (MIM 180220) and 
GAPVD1 (MIM 611714).  Sanger sequencing in the parents and the siblings revealed that 
the variants in PRPF39 were inherited in cis, thus excluding this gene as a candidate. The 
affected probands, but not the unaffected sister, were compound heterozygous and the 
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parents were singly heterozygous for the variants in RARB and GAPVD1 (Figure 1A). 
RARB (NM_000965.3), which encodes Retinoic acid receptor beta, harboured two 
protein-truncating mutations: a nonsense c.355C>T (p.Arg119*) and a frameshift 
c.1201_1202insCT (p.Ile403Serfs*15). These variants are absent from all public SNP 
databases (1000 Genomes, EVS, dbSNP138) and from our in-house exome data sets 
(n>1000). RARB has 2 major isoforms noted as reference sequences (Refseq) in the 
UCSC Genome Browser, as well as 3 additional isoforms noted in the Ensembl Genome 
Browser. The major Refseq isoform (NM_000965.3) has 8 exons and encodes a 448 
amino acid protein. Both identified mutations affect all known RARB isoforms (Figure 
2A). GAPVD1 (NM_015635), which encodes GTPase activating protein and VPS9 
domain 1, harboured two rare missense variants, c.2809C>T (p.Arg937Trp) and 
c.3266G>T (p.Gly1089Val) in the probands.  The p.Arg937Trp substitution is predicted 
damaging in both SIFT and Polyphen-2 (score=0.0 and 1.0 respectively), however the 
p.Gly1089Val substitution is predicted benign in both SIFT and Polyphen-2 (score=0.2, 
and 0.145 respectively). GAPVD1 is involved in endocytosis8, phagosome maturation9 
and regulation of the epidermal growth factor receptor10 but is not known to have a role 
in eye development or embryogenesis. Because of the importance of the retinoic acid 
pathway for eye and diaphragm development (discussed below), mutations in RARB were 
deemed more likely to be pathogenic than those in GAPVD1. 
 
 Retinoic acid receptors bind to DNA motifs known as Retinoic Acid Response 
Elements (RAREs) to modulate transcription of target genes by interacting with 
transcriptional co-repressors and co-activators. Upon binding to retinoic acid (RA), the 
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position were retained. To identify potentially pathogenic
variants, we filtered out (1) synonymous variants or in-
tronic variants other than those affecting the consensus
splice sites, (2) variants seen in more than 2% of our in-
house exomes (n ¼ 1,000) from unrelated projects, and
(3) variants with a minor allele frequency greater than
0.5% in either the 1000 Genomes Project or the National
Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server (EVS). The
affected individuals did not share any rare coding or
splicing variants in STRA6 or ALDH1A3 (MIM 600463),
another gene involved in A/M and retinoic acid (RA)
signaling.7
Given that transmission of the phenotype in this family
was consistent with autosomal-recessive inheritance, we
searched the whole-exome data sets for genes harboring
homozygous or multiple rare variants in both affected
probands, but not in their unaffected sibling. There were
no such genes with rare homozygous variants. Only three
genes containing multiple rare variants in both affected
individuals were not shared by the unaffected sister:
PRPF39 (MIM 614907), RARB (MIM 180220), and GAPVD1
(MIM 611714). Sanger sequencing in the parents and the
siblings revealed that the variants in PRPF39 were in-
herited in cis, thus excluding this gene as a candidate.
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Figure 1. Mutations in RARB in Individ-
uals with PDAC Syndrome
Sanger sequencing confirmed segregation
of the recessive mutations in RARB in fam-
ily A (A) and revealed that the mutations
were de novo in families B (B), C (C), and
D (D).
The affected probands, but not the
unaffected sister, were compound
heterozygous and the parents were
singly heterozygous for the variants
in RARB and GAPVD1 (Figure 1A).
RARB (RefSeq accession number
NM_000965.3), which encodes RA
receptor beta (RARB), was found
to harbor two protein-truncating
mutations: nonsense c.355C>T
(p.Arg119*) and frameshift
c.1201_1202insCT (p.Ile403Serfs*
15). These variants are absent from
all public SNP databases (1000 Ge-
nomes, EVS, and dbSNP138) and
from our in-house exomes (n >
1,000). RARB has two major isoforms
noted in the UCSC Genome Browser
and three additional isoforms noted
in the Ensembl Genome Browser.
The major RefSeq isoform (RefSeq
NM_000965.3) has eight exons and
encodes a 448 aa protein. Both iden-
tified mutations affect all known RARB isoforms
(Figure 2A).GAPVD1 (RefSeq NM_015635), which encodes
GTPase-activating protein and VPS9 domain 1, was found
to harbor two rare missense variants, c.2809C>T
(p.Arg937Trp) and c.3266G>T (p.Gly1089Val), in the pro-
bands. The p.Arg937Trp substitution is predicted to be
damaging by both SIFT (score 0.0) and PolyPhen-2 (score
1.0), but the p.Gly1089Val substitution is predicted to be
benign by both SIFT (score 0.2) and PolyPhen-2 (score
0.145). GAPVD1 is involved in endocytosis,8 phagosome
maturation,9 and regulation of the epidermal growth fac-
tor receptor10 but is not known to have a role in eye devel-
opment or embryogenesis. Because of the importance of
the RA pathway for eye and diaphragm development (dis-
cussed below), mutations in RARB were deemed more
likely to be pathogenic than those in GAPVD1.
RA receptors bind to DNA motifs known as RA response
elements (RAREs) to modulate transcription of target genes
by interacting with transcriptional corepressors and coacti-
vators. Upon binding to RA, the corepressor docking site
becomes hindered by helix 12 positioning, resulting in
the recruitment of coactivators and an increase in tran-
scription of target genes.11 The c.355C>T (p.Arg119*)
nonsense mutation is predicted to result in an inactive
truncated receptor lacking the second zinc finger of the
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Figure 1.  Mutations in RARB in individuals with PDAC syndrome.  Sanger sequencing 
confirmed segregation of the recessive mutations in RARB in family A (A), and revealed that 
the mutations were de novo in family B, C and D (B-D).	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 co-repressor docking site becomes hindered by helix-12 positioning, resulting in the 
recruitment of co-activators and an increase in transcription of target genes 11. The 
c.355C>T (p.Arg119*) nonsense mutation is predicted to result in an inactive truncated 
receptor, lacking the second zinc finger of the DNA-binding domain as well as the entire 
ligand-binding domain (Fig. 2B). Moreover, this mutation has the potential of activating 
the non-sense mediated mRNA decay pathway, resulting in the degradation of the 
corresponding transcript. The c.1201_1202insCT (p.Ile403Serfs*15) mutation results in 
the substitution of a hydrophobic isoleucine by serine, a polar residue, as well as the 
replacement of the last 52 amino acids by an aberrant extension of 15 amino acids (Fig. 
2B).  As part of helix 12, residue Ile403 is thus predicted to play a key role in the 
recruitment of transcriptional cofactors and response to ligand. As such, in vitro studies 
have shown that Ile403 substitution with serine in RARB conferred an increased binding 
to co-repressor SMRT in absence of ligand, resulting in reduced transcriptional activity12.  
Both mutations found in family A are thus predicted to disrupt RARB function.  
 We tested the impact of these truncating mutations on RARB activity using a 
cellular one-hybrid luciferase reporter transcriptional assay as described13. Expression 
plasmids encoding transcription factor Gal4 DNA-binding domain fusions to wild-type 
RARB or truncated variants p.Arg119* and p.Ile403Serfs*15 were generated and used to 
transfect human embryonic kidney (HEK) 293 cells in the presence of a luciferase 
reporter gene construct under the control of a Gal4-binding DNA upstream-activating 
sequence (UAStkLuc). This assay allows direct determination of transcriptional activity 
and response to ligand of variants compared to wild-type receptor, avoiding any 
background effect of endogenously-expressed RARB in cells. Transfected HEK293 cells 
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were treated with the natural ligands all-trans retinoic acid (atRA) and its stereoisomer 9-
cis retinoic acid (9-cis RA), 
which both act as pan-RAR 
agonists. As expected, the 
transcriptional response of 
the p.Arg119* mutant to the 
two RA ligands was 
completely abolished 
compared to wild-type 
RARB, correlating with its 
lack of ligand-binding 
domain (Fig. 3). Similarly, 
the transcriptional response 
to retinoids was impaired in 
the p.Ile403Serfs*15 mutant 
compared to wild-type 
RARB. The disruption, in 
the p.Ile403Serfs*15 
mutant, of helix-12 and 
its replacement by an 
aberrant extension likely 
interferes with its ability 
DNA-binding domain and the entire ligand-binding
domain (Figure 2B). Moreover, this mutation has the po-
tential to activate the nonsense-mediated mRNA decay
pathway, resulting in the degradation of the corresponding
transcript. The c.1201_1202insCT (p.Ile403Serfs*15) muta-
tion results in the substitution of a hydrophobic isoleucine
with serine, a polar residue, and the replacement of the last
52 amino acids with an aberrant extension of 15 amino
acids (Figure 2B). As part of helix 12, residue Ile403 is
thus predicted to play a key role in the recruitment of tran-
scriptional cofactors and response to ligand. As such,
in vitro studies have shown that Ile403 substitution with
serine in RARB confers an increased binding to corepressor
SMRT in the absence of ligand and thus results in reduced
transcriptional activity.12 Both mutations found in family
A are thus predicted to disrupt RARB function.
We tested the impact of these truncating mutations on
RARB activity by using a cellular one-hybrid luciferase-
A
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C
D
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DNA-Binding Hormone-Binding
Figure 2. Localization and Impact of the
Mutations in RARB
(A) Shown are the positions of the muta-
tions with respect to the different RARB
Ensembl-annotated transcripts that are
predicted to produce proteins. Numbering
on top is based on the cDNA positions of
Ensembl ENST00000330688 (identical to
RefSeq NM_000965.3).
(B) A schematic of RARB shows the DNA-
binding and hormone-binding domains.
Arrowheads above the protein show the
positions of the variants.
(C) The HomoloGene-generated amino
acid alignment of human RARB and its pre-
dicted orthologs shows the conservation of
the p.Arg387 residue.
(D) The three-dimensional structure of
RARB (Protein Data Bank ID 4DM8) in
the presence of the RA ligand (purple)
shows the proximity of the Arg387 residue
in helix 11 to the RA ligand.
reporter transcriptional assay as pre-
viously described.13 Expression plas-
mids encoding transcription factor
Gal4 DNA-binding domain fusions
to wild-type RARB or truncated vari-
ants p.Arg119* and p.Ile403Serfs*15
were generated and used for transfect-
ing human embryonic kidney 293
(HEK293) cells in the presence of a
luciferase reporter gene construct un-
der the control of a Gal4-binding
DNA upstream-activating sequence
(UAStkLuc). This assay allowed tran-
scriptional activity and response to
ligand to be directly compared be-
tween variants and the wild-type
receptor, avoiding any background
effect of endogenously expressed
RARB in cells. Transfected HEK293 cells were treated
with the natural ligands all-trans RA (atRA) and its stereo-
isomer, 9-cis RA, which both act as pan-RAR agonists. As
expected, compared to that of wild-type RARB, the
transcriptional response of the p.Arg119* variant to the
two RA ligands was completely abolished, correlating
with its lack of ligand-binding domain (Figure 3). Similarly,
compared to wild-type RARB, the p.Ile403Serfs*15 variant
showed an impaired transcriptional response to retinoids.
In the p.Ile403Serfs*15 variant, the disruption of helix
12 and its replacement with an aberrant extension most
likely interfered with its ability to occlude the corepressor
docking site. All together, these results strongly suggest
that these truncating variants confer a loss of RARB func-
tion and explain the occurrence of PDAC syndrome in
family A.
We next sequenced all the coding exons and intron-
exon boundaries of RARB and the alternate exon 1
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Figure 2. Localization and impact of the mutations in RARB. (A) Shown 
are the positions of the mutations with respect to the different RARB 
ENSEMBLE-annotated transcripts that are predicted to produce proteins. 
Numbering on top is based on the cDNA positions of ENST00000330688 
(identical to NCBI Refseq # NM_000965.3). (B) Schematic of the RARB 
protein, showing the DNA-binding and hormone-binding domains. 
Arrowheads above the protein show the positions of the mutations. (C) 
Homologene-generated (NCBI) amino acid alignment of human RARB with 
its predicted orthologues showing the conservation of the p.Arg387 residue. 
(D) 3-dimensional structure of RARB (PDB ID: 4DM8) in the presence of the 
retinoic acid (RA) ligand (purple) showing the proximity of the Arg387 
residue in helix 11 to the RA ligand. 	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to occlude the corepressor docking site. All together, these results strongly suggest that 
these truncating mutations confer a loss of RARB function and explain the occurrence of 
PDAC syndrome in family A.  
 We next sequenced all the coding exons and intron/exon boundaries of RARB 
(NM_000965.3) as well as the alternate exon 1 (ENST00000404969) in 15 additional 
individuals with bilateral or unilateral M/A and at least one additional feature of PDAC 
(diaphragmatic hernia, cardiac defect or lung hypoplasia) who were previously screened 
for mutations in STRA6 14.  In three unrelated subjects, who were all simplex cases, we 
identified single heterozygous RARB missense mutations affecting the same nucleotide.  
Of these, two subjects (II-1 from family C and II-1 from family D) harboured the 
c.1159C >T (p.Arg387Cys) missense, and one individual (II-3 from family B) harboured 
the  c.1159C >A (p.Arg387Ser) missense (Fig. 1B-C).  These mutations were absent from 
the genomic DNA of the parents, indicating that they occurred de novo. Using 6 
informative unlinked microsatellite markers (D3S1754, D4S3351, D8S1179, D15S659, 
D14S587, and D19S215), we confirmed the paternity and maternity in these families, as 
previously described15. Both c.1159C >T (p.Arg387Cys) and  c.1159C >A (p.Arg387Ser) 
are absent from public SNP databases (EVS, 1000 Genomes, and dbSNP138) and from 
our entire collection of in-house exomes (>1000). They are both predicted damaging by 
SIFT and Polyphen-2 (scores= 0.0 and 1.0 for both, respectively) and affect a highly 
conserved amino acid in helix 11 of the ligand binding domain (Figure 2C). Subject II-1 
from family C is a fetus for whom pregnancy was terminated because of unilateral 
microphthalmia and left diaphragmatic hernia on prenatal ultrasound (Table 1). Autopsy 
also showed hypoplasia of a pulmonary lobe of the left side. Subject II-1 from family D 
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is a newborn who passed away within a few hours after birth because of a left 
diaphragmatic hernia. This subject also showed bilateral microphthalmia and pulmonary 
hypoplasia. Subject II-3 from family B is currently a 14-year-old male with bilateral 
microphthalmia, corrected diaphragmatic hernia, and abnormal cognitive development 
with spasticity (for clinical details, see case # 6 in Chitayat et al., 20073). We also 
sequenced RARB in 11 cases with isolated bilateral A/M but we did not find any mutation 
in this gene.   
 The fact that the de novo mutations involved the same residue (Arg387) suggests 
that they confer a specific property to the protein. These mutations could induce a 
dominant-negative effect or act through a gain-of-function mechanism. In order to 
distinguish between these possibilities,  we sought to study the impact of these mutations 
using our one-hybrid functional assay. The p.Arg387Ser and p.Arg387Cys RARB 
mutants exhibited a significant increase in their transcriptional response to all-trans 
retinoic acid (atRA), reaching respectively 23- and 28-fold induction compared to 9-fold 
for wild-type RARB (Fig. 3). Similar activation levels were also obtained using 9-cis RA 
ligand. These results suggest that the two mutations at Arg387 provide an increased 
transcriptional potential to respond to retinoid ligands through a gain-of-function 
mechanism. A more detailed mechanistic analysis remains to be done to explain such 
increase in activity. 
 We have identified compound heterozygous truncating mutations as well as de 
novo mutations affecting the same nucleotide in the RARB gene of individuals with 
PDAC syndrome. The occurrence of such mutations in individuals with a similar and rare 
phenotype strongly suggests that they cause PDAC syndrome. Indeed, several 
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observations indicate that the retinoic acid (RA) pathway plays a major role in the 
development of the eyes, diaphragm and lungs. RA is a metabolite of retinol, a derivative 
of vitamin A. The importance of the RA pathway in embryogenesis has been recognized 
for decades, as rats deficient in vitamin A give birth to progeny with multiple congenital 
malformations, including ocular abnormalities and diaphragmatic hernia16. Circulating 
retinol is bound to retinol binding protein 4 (RBP4).  The transmembrane protein STRA6 
(Stimulated by Retinoic acid) facilitates the intracellular uptake of the retinol-RBP 
complex 4. Mutations in STRA6 have been identified in at least 24 individuals with M/A5, 
14, 17-19. Most of these subjects showed other features of the PDAC syndrome but some of 
them had isolated M/A. Once transported into the cell, retinol is successively oxidized to 
retinaldehyde and retinoic acid. Mutations in ALDH1A3, which encodes a retinaldehyde 
dehydrogenase that is responsible for the oxidation of retinaldehyde into RA, have been 
found to be responsible for M/A with variable neurodevelopmental and cardiac features7.  
 In target cells, RA acts as a ligand for nuclear RA receptors. Several observations 
in mice suggest that these receptors play a major role in eye, diaphragm and lung 
development. Mice lacking all Rarb isoforms display microphthalmia20,21. RA is 
generated in the epithelial ocular compartment and diffuses in the neural crest-cell 
derived periocular mesenchyme to activate RARB and RARG. In turn, these receptors 
regulate the remodeling of the periocular mesenchyme, the growth of the ventral retina as 
well as the expression of Foxc1 and Pitx2, which play central roles in anterior eye 
segment development22. Studies of RA receptor double null-mutant mice, lacking both 
Rara and Rarb subtypes, have also demonstrated the presence of diaphragmatic hernias 
in a subset of offsprings23. Moreover, administration of nitrofen to pregnant rodents is 
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thought to cause diaphragmatic 
hernias, in part through down-
regulation of RA receptor 
signaling (reviewed in Greer et 
al24). Recent studies indicate that 
Rarb functions along a pathway 
that directs development of the 
central tendon of the 
diaphragm25. Finally, Rarb-/- 
knock-out mice have smaller and 
more numerous alveoli in their 
lungs26. Rarb has been shown to 
have a critical role in lung 
morphogenesis by inducing 
Fgf10 expression in bud fields27. 
Overall, these studies support our 
conclusion that loss of RARB 
function causes PDAC syndrome in family A.  Our transfection experiments suggest 
that the de novo mutations affecting Arg387 result in enhanced activity of RARB in 
response to retinoic acid ligands, suggesting a gain-of-function mechanism. Whether 
these two substitutions induce a conformational change that enhances protein stability, 
favors co-activator recruitment and/or increases RA binding affinity remains to be 
determined. Consistent with this latter possibility, crystallographic studies have 
(Ensembl accession number ENST00000404969) in 15
additional individuals who had bilateral or unilateral A/
M and at least one additional feature of PDAC (diaphrag-
matic hernia, cardiac defect, or lung hypoplasia) and
who had been previously screened for mutations in
STRA6.14 In three unrelated subjects, who were all simplex
cases, we identified single heterozygous RARB missense
mutations affecting the same nucleotide. Of these, two
subjects (II-1 from family C and II-1 from family D)
harbored missense mutation c.1159C>T (p.Arg387Cys)
and one individual (II-3 from family B) harbored missense
mutation c.1159C>A (p.Arg387Ser) (Figures 1B and 1C).
These mutations were absent from the genomic DNA of
the parents, indicating that they occurred de novo. Using
six informative unlinked microsatellite markers
(D3S1754, D4S3351, D8S1179, D15S659, D14S587, and
D19S215), we confirmed the paternity and maternity in
these families, as previously described.15 Both c.1159C>T
(p.Arg387Cys) and c.1159C>A (p.Arg387Ser) are absent
from public SNP databases (EVS, 1000 Genomes, and
dbSNP138) and from our entire collection of in-house
exomes (n >1,000). They are both predicted to be
damaging by SIFT (score 0.0) and PolyPhen-2 (score 1.0)
and affect a highly conserved amino acid in helix 11 of
the ligand-binding domain (Figure 2C). Subject II-1 from
family C was a fetus for whom pregnancy was terminated
because of unilateral microphthalmia and left diaphrag-
matic hernia on prenatal ultrasound (Table 1). Autopsy
also showed hypoplasia of a pulmonary lobe on the left
side. Subject II-1 from family D was a newborn who passed
away within a few hours after birth because of a left dia-
phragmatic hernia. This subject also showed bilateral mi-
crophthalmia and pulmonary hypoplasia. Subject II-3
from family B is currently a 14-year-old male with bilateral
microphthalmia, corrected diaphragmatic hernia, and
abnormal cognitive development with spasticity (for clin-
ical details, see case 6 in Chitayat et al.3). We also
sequenced RARB in 11 cases with isolated bilateral A/M,
but we did not find any mutation in this gene.
The fact that the de novo mutations involved the same
residue (Arg387) suggests that they confer a specific prop-
erty to the protein. These mutations could induce a domi-
nant-negative effect or act through a gain-of-function
mechanism. In order to distinguish between these possibil-
ities, we sought to study the impact of these mutations by
using our one-hybrid functional assay. The p.Arg387Ser
and p.Arg387Cys altered RARB exhibited a significant
increase in their transcriptional response to atRA; they
reached 23- and 28-fold induction, respectively, compared
to 9-fold induction for wild-type RARB (Figure 3). Similar
activation levels were also obtained with the 9-cis RA
ligand. These results suggest that the two variants at
Arg387 provide increased transcriptional potential to
respond to retinoid ligands through a gain-of-function
mechanism. Explaining such an increase in activity will
require a more detailed mechanistic analysis.
We have identified compound-heterozygous truncating
mutations and de novo mutations affecting the same
RARB nucleotide in individuals with PDAC syndrome.
The occurrence of such mutations in individuals with a
similar and rare phenotype strongly suggests that they
cause PDAC syndrome. Indeed, several observations indi-
cate that the RA pathway plays a major role in the develop-
ment of the eyes, diaphragm, and lungs. RA is a metabolite
of retinol, a derivative of vitamin A. The importance of the
RA pathway in embryogenesis has been recognized for
decades, given that rats deficient in vitamin A give birth
to progeny with multiple congenital malformations,
including ocular abnormalities and diaphragmatic her-
nia.16 Circulating retinol is bound to retinol-binding
protein 4 (RBP4). The transmembrane protein STRA6
(stimulated by RA) facilitates the intracellular uptake of
the retinol-RBP complex.4 Mutations in STRA6 have been
identified in at least 24 individuals with A/M.5,14,17–19
Most of these subjects showed other features of PDAC
syndrome, but some of them had isolated A/M. Once
transported into the cell, retinol is successively oxidized
to retinaldehyde and RA. Mutations in ALDH1A3, which
encodes a retinaldehyde dehydrogenase that is responsible
for the oxidation of retinaldehyde into RA, have been
found to be responsible for A/M with variable neurodeve-
lopmental and cardiac features.7
In target cells, RA acts as a ligand for nuclear RA re-
ceptors. Several observations in mice suggest that these
receptors play a major role in eye, diaphragm, and lung
9-cis RA
Figure 3. Transcriptional Response of Human RARB Variants to
RA Ligands
HEK293 cells were seeded in 24-well plates and transfected with
100 ng per well of expression plasmid encoding either Gal4 fusion
of wild-type human RARB or p.Arg119*, p.Ile403Serfs*15,
p.Arg387Ser, or p.Arg387Cys RARB variants in the presence of
500 ng of UAStkLuc reporter-gene construct. All variant con-
structs, including p.Ile403Serfs*15 (carrying the additional out-
of-frame amino acid extension), were generated by site-directed
mutagenesis. Cells were treated with 1 mM atRA, 1 mM 9-cis RA,
or vehicle (DMSO; 1/1,000, v/v) for 16 hr. Luciferase values were
ormalized to b-galactosidase activity and expressed as a fold
response compared to those of empty Gal4-transfected control
cells. Data were derived from three independent experiments per-
formed in triplicate. *p < 0.005 versus wild-type RARB response to
the respective RA ligand. Values represent means, and error bars
represent SEs.
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treated with 1µM all-trans retinoic acid (atRA), 1µM 9-cis 
retinoic acid (9-cis RA), or with vehicle (DMSO; 1/1000, 
v/v) for 16hrs. Luciferase values were normalized to β-
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compared to empty Gal4-transfected control cells. Data are 
derived from three indep nd nt experi ents performed in 
triplicates. *, P<0.005 vs wild-type RARB response to 
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established that Arg387 residue is facing inward of the ligand-binding pocket, in close 
proximity of the retinoid ligand (Fig. 2D). Our model of gain-of-function mutations thus 
suggests that an increase in RARB response to retinoids might represent a primary cause 
of PDAC syndrome.  Indeed, excess of vitamin A or RA during development in mice 
cause various malformations, including microphthalmia and diaphragmatic hernia28-32.	  
Moreover, expression of a constitutively active RAR transgene in the developing eye 
resulted in animals that exhibited microphthalmia33.	    Similarly, Zebrafish embryos 
exposed to 9-cis-RA develop multiple developmental abnormalities including 
microphthalmia34. RA is also teratogenic in humans35. Interestingly, microphthalmia and 
diaphragmatic hernia have been reported in some babies from women exposed to RA 
during pregnancy 35, 36. 
 All together, our findings and the previous work described above therefore 
suggest that both decreased and increased RARB activity can result in PDAC syndrome. 
A recent study showed that RA exposure during embryonic development in mice was 
followed by decreased levels of Raldh transcripts encoding retinoic acid-synthesizing 
enzymes and increased levels of Cyp26a1 and Cyp26b1, mRNAs encoding enzymes that 
catabolize retinoic acid32. Overall, these changes resulted in a decrease of RA levels. 
Restoration of RA levels by maternal supplementation with low doses of RA following 
the teratogenic insult rescued several developmental defects. Paradoxically, increased 
RARB signaling could thus result in a secondary state of RA deficiency, which could 
impact on this pathway at specific stages of development.  Alternatively, it is possible 
that some developmental processes require a tight regulation of RARB targets, too little 
or too much signaling having the same consequence on these pathways. 
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 In summary, we found that both recessive and dominant mutations affect RARB 
function in the context of PDAC syndrome, opening a new window on the structural and 
mechanistic basis of retinoic acid receptor activity with relation to human disease. 
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Table 1: Clinical characteristics of subjects with mutations in RARB 
Family A B C D 
Individual II-1 II-4 II-5 II-6 II-3 II-1 II-1 
Ethnicity French Canadian/English French 
Africa (Angola 
[father] and Congo 
[mother]) 
French 
Consanguinity - - - - 
Mutation NA 
c.355C>T 
(p.Arg119*), 
c.1201_1202insCT(p
.Ile403Serfs*15) 
c.355C>T  
(p. Arg119*), 
c.1201_1202insCT(p
.Ile403Serfs*15) 
NA c.1159>A (p.Arg387Ser)c 
c.1159C>T 
(p.Arg387Cys)c 
c.1159C>T 
(p.Arg387Cys)c 
Gender M F M M M M F 
Age 
(age at death) 
(Few hours, 34 wks 
gestation)a 
(Few hours, 38 wks 
gestation) (21 wks fetus)
b (few hours, term) 16 years (34 wks fetus)b (Few hours, 39 wks gestation)b 
Bilateral 
Microphthalmia/ 
Anophthalmia 
+ + + + + 
Unilateral (left) 
microphthalmia 
Right eye normal 
Bilateral 
microphthalmia 
Pulmonary 
hypoplasia NA + + NA - 
Left lung with  one 
hypoplastic lobe;  
Right lung normal 
Bilateral 
(predominant on the 
left side) 
Diaphragmatic 
hernia NA + + + + 
+ 
(Left) 
+ 
(Left) 
Cardiac 
abnormality NA + - NA - - - 
Intellectual 
disability NA NA NA NA 
+ 
 NA NA 
Other - 
Cleft palate, 
dysmorphisms, small 
spleen, bicornate and 
small uterus 
Dysmorphisms, 
unfixed malrotated 
bowel 
Dysmorphisms - 
Malrotated bowel 
right cryptorchydy 
mild IUGR (W, L 
and OFC at the 5e 
percentile 
 
Bicornate uterus 
aDied shortly after birth at 34 weeks due to presumed tangled cord, though a diagnosis of PDAC is strongly suspected.bTerminated pregnancy.cDe novo mutation. NA=Not available, 
wks: weeks, M:male; F:female; ; W-weight;L-length;OFC-occipitofrontal circumference. 
 
